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Abstract 
Diabetic retinopathy (DR) is one of the leading causes of blindness in the 
developed world. Characteristic features of DR are retinal neurodegeneration, 
pathological angiogenesis and breakdown of both the inner and outer retinal barriers of 
the retinal vasculature and RPE-choroid respectively. Vascular endothelial growth factor-
A (VEGF), a key regulator of angiogenesis and permeability, is the target of most 
pharmacological interventions of DR. VEGF can be alternatively spliced at exon 8 to 
form 2 families of isoforms, pro- and anti-angiogenic. VEGF165 is the most abundant pro-
angiogenic isoform, is pro-inflammatory and a potent inducer of permeability. VEGF165b 
is anti-angiogenic, anti-inflammatory, cytoprotective and neuroprotective. In the diabetic 
eye, pro-angiogenic VEGF isoforms are up-regulated such that they overpower 
VEGF165b. I hypothesised this imbalance contributed to increased breakdown of the 
retinal barriers and by redressing this imbalance, the pathological angiogenesis, fluid 
extravasation and retinal neurodegeneration could be ameliorated. 
VEGF165b prevented VEGF165 and hyperglycaemia-induced tight junction 
breakdown and subsequent increase in solute flux in retinal pigmented epithelial (RPE) 
cells. In streptozotocin-induced diabetes, there was an increase in Evans’ blue 
extravasation after both 1 and 8 weeks of diabetes, which was reduced upon intravitreal 
and systemic delivery of rhVEGF165b. 8-weeks diabetic rats also showed an increase in 
retinal vessel density, which was prevented by VEGF165b. To try to ensure sustained 
delivery of VEGF165b in the diabetic eye an adeno-associated virus, AAV.VEGF165b was 
developed and delivered subretinally. Although injection of AAV.VEGF165b resulted in 
effective expression of VEGF165b in the eye, this caused a detrimental effect on retinal 
function. 
These results show rhVEGF165b reduce DR-associated BRB dysfunction and 
angiogenesis. Although the neuroprotective effects of VEGF165b in DR are unclear, 
evidence from other retinopathies, neuropathy and data presented in this thesis suggest 
that, if the delivery systems can be optimised, VEGF165b may be a suitable therapeutic in 
treating DR.  
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1.1 Diabetes 
Diabetes mellitus is a metabolic disorder that is characterised by hyperglycaemia 
as a result of poor insulin secretion, detection, actions or a combination of these actions 
(National Diabetes Data Group 1979). Currently it is estimated that 387 million people 
are diagnosed with diabetes and it is predicted that this number will rise to 592 million by 
the year 2035 (Key findings 2014 | International Diabetes Federation). Diabetes mellitus 
can be divided into type 1 and type 2 diabetes. Type 1 diabetes is typically an immune or 
autoimmune-mediated disorder (Atkinson et al. 2014) resulting from an autoimmune T 
cell-mediated destruction of pancreatic β-cells and the remaining β-cells are incapable of 
regeneration, resulting in a rapid decline in insulin production (Devendra et al. 2004) and 
persistent hyperglycaemia. Type 2 diabetes, typically associated with obesity and ageing, 
is a result of both a lack of insulin secretion and diminished insulin sensitivity (Donath & 
Shoelson 2011). A β-cell compensatory mechanism involves enhancement of β-cell mass 
and increased insulin secretion, eventually this mechanism is no longer adequate resulting 
in a long-term decrease in insulin-mediated glucose uptake and persistent hyperglycaemia 
(Rydén et al. 2007; Donath & Shoelson 2011). As both types of diabetes progress, 
patients show a high incidence of macro- and microvascular complications associated 
with diabetes including atherosclerosis, stroke, neuropathy, nephropathy and retinopathy 
(Stratton 2000). Type 1 diabetes is treated with insulin supplementation therapy 
(Atkinson et al. 2014) and type 2 diabetes has multiple treatment strategies aimed at 
either increasing insulin sensitivity, stimulating insulin secretion or limiting glucose 
uptake or a combination of the 3, some of which are shown in table 1.1.  
 
Drug Mechanism of action Reference 
Metformin • Increases insulin sensitisation of the liver 
and decreases hepatic glucose production 
through AMPK activation 
• Encourages glucose uptake in skeletal 
myocytes  
• (Dardano et al. 
2014) 
 
• (Zhou et al. 
2001) 
Thiazolidinediones • Peroxisome proliferation activated 
receptor-gamma (PPARγ) agonist 
• Improves peripheral insulin sensitivity 
• (Yki-Järvinen 
2004) 
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• Reduces hepatic gluconeogenesis 
Incretins • Dipeptidyl peptidase-4 inhibitors (DPP4-
I). 
• Stimulate insulin secretion 
• Suppress glucagon secretion 
• (Dardano et al. 
2014) 
• (Ahrén 2003) 
• (Baggio & 
Drucker 2007) 
 
 Patients with long-term elevated HbA1C, glycated haemoglobin – a marker for 
average plasma glucose concentration, are more at risk of developing diabetic 
microvascular complications than diabetics with good glycaemic control (Stratton 2000). 
Of the many microvascular complications associated with diabetes, the most common are 
nephropathy, neuropathy and retinopathy.  
 Diabetic nephropathy is one of the leading cause of kidney disease in the working 
population of the western world (Gross et al. 2004) and clinically manifests as increased 
proteinuria, high blood pressure and a decrease in glomerular filtration rate and can 
eventually lead to end stage renal failure (Fioretto & Mauer 2007). These outcomes are 
caused by structural changes in the kidney that are initially characterised by mesangial 
expansion, due to an increase in extra cellular matrix deposition, potentially contributing 
to the reduced glomerular filtration rate (Mauer et al. 1984). Glomerular endothelial cells, 
part of the glomerular filtration barrier, show a reduced endothelial glycocalyx in 
glomerular endothelial cells and in retinal arteries of diabetic patients (Nieuwdorp et al. 
2006), contributing to increased albumin clearance (Jeansson & Haraldsson 2006). 
Albuminuria also correlates with podocyte loss in glomeruli of diabetic patients (Fioretto 
& Mauer 2007). Eventually these, and other events progress, resulting in gradual decline 
in kidney function. 
 Diabetic peripheral neuropathy involves peripheral nerve dysfunction and its 
occurrence is proportional to magnitude and length of hyperglycaemia (Fowler 2008). 
Symptoms include tingling, increased allodynia, hyerpalgesia and eventually numbness 
(Dobretsov et al. 2007). As neurones have a persistently high glucose uptake, 
hyperglycaemia encourages further, up to fourfold, glucose uptake (Tomlinson & 
Gardiner 2008b). Prolonged excessive glucose uptake results in glucose neurotoxicity, 
affecting: sensory afferents, myelinated and unmyelinated nerve fibres (Tomlinson & 
Gardiner 2008a; Hulse et al. 2015). Nociceptors are more susceptible to activation, 
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particularly by non-painful stimuli, due to inadequate vascular perfusion, neuronal 
interference or a combination of both (Hulse et al. 2015). Diabetic rodents also show 
increased demyelination centrally and peripherally, further leaving the neurones 
vulnerable to degeneration (Hulse et al. 2015).  
   
1.2 Diabetic retinopathy 
1.2.1. Clinical manifestations 
Diabetic retinopathy (DR), a condition culminating in a gradual decline in vision, 
affects both type 1 and type 2 diabetic patients (Klein 1984) and is the leading cause of 
blindness in the working population of the western world. DR is the most common 
microvascular complication associated with diabetes (Hammes 2013). As with other 
complications, prevalence of DR increases with increasing duration of diabetes. Diabetic 
macular oedema (DME) and proliferative diabetic retinopathy (PDR) are the main causes 
of vision loss. The risk of developing PDR is greater in type 1 diabetics than type 2, with 
the converse true for DME (Nentwich & Ulbig 2015).  
Presence and grading of DR are initially assessed by fundus examinations, as 
shown by figure 1.1. Diagnosis and grading of DR can be divided according to PDR and 
DME. DR is initially characterised by the appearance of microaneurysms and intraretinal 
haemorrhage (figure 1.1A). As the disease progresses to PDR there is an increase in the 
number of microvessels in the retina that are prone to rupture and leakage (figure 1.1B). 
As the vessels continue to grow, PDR can result in retinal detachment (figure 1.1C) As 
these vessels are compromised, fluid and plasma proteins leak from the microvasculature 
and accumulate in the macula, resulting in DME (figure 1.1D).  DME is often 
characterised by the appearance of hard exudates, are protein deposits that have 
accumulated due to increased vessel permeability, and “cotton wool spots”, regions of 
nerve fibre layer (NFL) infarct (Antonetti et al. 2012). If left untreated, the nascent blood 
vessels can grow into the vitreous, haemorrhage and result in vision loss. Of these clinical 
features, macular oedema is most closely correlated with the degree of vision loss (Moss 
et al., 1988).  
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Figure 1.1. Stages of diabetic retinopathy by fundus examination (Adapted from 
Nentwich & Ulbig 2015). 
There are two main types of DR, a non-proliferative stage and a proliferative 
stage. For diagnostic purposes, the non-proliferative stage can be further sub-divided into 
mild/background, moderate and severe. Mild/background non-proliferative retinopathy 
shows presence of microaneurysms in the retinal microvasculature (A). As the retina 
become progressively ischaemic, there is increased angiogenesis in the retina resulting in 
PDR (B). leaving them prone to rupture and leakage. As well as leaking blood, these 
vessels also leak plasma proteins that aggregate to form hard exudates. With this increase 
in blood vessel growth, also increases the rate at which hard exudates are formed and 
microaneurysms occur, resulting in tractional retinal detachment (C). The fluid that has 
leaked from these vessels then accumulates in the macula, resulting in its thickening, 
which eventually results in DME (D). 
1.2.2. Proliferative diabetic retinopathy 
 
PDR, like many other retinal neovascular retinopathies, occurs as a result of an 
ischaemic retina.  Persistent hyperglycaemia in diabetic patients causes structural, 
functional and haemodynamic changes in the retinal vasculature (Nentwich & Ulbig 
2015; McGahon et al. 2007) . Changes in blood flow can occur early on in diabetes 
before any noticeable signs of retinopathy, potentially contributing to the ischaemic retina 
typically observed in DR (Bursell et al. 1996). This is likely due to improper activity of 
large-conductance calcium (Ca2+)-activated ion channels, located on vascular smooth 
muscle cells (VSMCs) that enable contraction of retinal arterioles. In the early stages of 
(A) (B) 
(C) (D) 
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DR, rather than eliciting arteriolar vasodilatation, an influx of intracellular Ca2+ results in 
vasoconstriction (McGahon et al. 2007). The earliest detectable sign of diabetes-induced 
structural changes is loss of pericytes (Cai & Boulton 2002), also contributing to retinal 
ischaemia. Pericytes, located within the basement membrane of vessels, are associated 
with maintaining appropriate vessel contractility (Rucker et al. 2000) and with 
angiogenesis (Hammes et al. 2002). They remain in close contact with endothelial cells, 
and are highly expressed in the CNS and the retina, in a 1:1 ratio, and it is hypothesised 
that it is this close relationship that ensures the “tightness” of the BBB and the BRB 
(Bergers & Song 2005).  
Hyperglycaemia induces significant pericyte loss (Hammes et al. 1995), however 
the mechanisms behind diabetic pericyte dropout are not fully understood. It is 
hypothesised that this is likely due to an accumulation of hyperglycaemia-induced waste 
products, such as advanced glycacation end-products (AGEs) that trigger apoptosis within 
the pericyte (Stitt et al. 1997). It is also suggested that pericyte dropout is an active 
diabetes-induced angiopoietin-2 mediated process (Hammes et al. 2004). The relationship 
between pericytes and endothelial cells is so tightly coupled that a loss in pericytes results 
in a loss of endothelial cells, resulting in acellular capillaries that are inadequately 
perfused (Kohner & Henkind 1970). These non-perfused regions of the retina result in 
focal ischaemia and a consequent increase in vascular endothelial growth factor (VEGF-
A) expression, amongst other pro-angiogenic factors, in an attempt to redress the hypoxia 
by triggering angiogenesis (Aiello 1994). This is usually in the form of sprouting 
angiogenesis, forming from proliferating endothelial cells where there is pericyte loss 
(Hirschi & D’Amore 1996). As there is persistent hyperglycaemia, the region of non-
perfused areas may increase over time, resulting in increased pathological angiogenesis in 
the retina and into the vitreous. As these newly formed vessels rarely recruit pericytes, 
they lack vessel integrity and therefore are prone to rupture, as detectable by presence of 
microaneurysms and haemorrhage.  
Whilst the best treatment for PDR is tight glucose control, it merely halts the 
progression of the condition, but does not necessarily stop it. In the early stages of PDR, 
pan-retinal laser photocoagulation (PRP) is used to halt progression of PDR and prevent 
vision loss (Grunwald et al. 1986). Typically, an argon laser is used to create multiple 
burns approximately 200µm in diameter (Frank 2004). This method aims to ablate the 
ischaemic retina, therefore reducing the metabolic demand of the outer retina. This results 
in a reduced oxygen consumption and VEGF production of the RPE layer and 
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photoreceptors (Wolbarsht & Landers 1980). By burning the outer BRB, more oxygen 
from the choroidal circulation can be can be made available to the inner retina. This 
method therefore attempts to halt the progression of DR by preventing angiogenesis and 
reducing hypoxia. The Diabetic Retinopathy study showed that PRP reduced the risk of 
blindness by at least 50%. (The Diabetic Retinopathy Research Group, 1981). However 
PRP is associated with side effects such difficulty with light-dark adapatation, decreased 
visual acuity and loss of peripheral vision (Cheung et al. 2010) In the later stages of PDR, 
where there is excessive neovascularisation into the vitreous and/or tractional retinal 
detachment, surgical interventions are necessary. A pars-plana vitrectomy aims to remove 
the opacities formed by microaneuryms, from the vitreous (Flynn et al. 1992).  
1.2.3. Diabetic macular oedema 
 
 DME is a major cause of sight loss in diabetic patients and can occur in patients 
with non-proliferative DR as well as those with PDR (Wilkinson et al. 2003). DME 
occurs due to the accumulation of fluid from microaneurysms and haemorrhages and 
accumulation of plasma proteins that have escaped from leaky blood vessels, within 2 
disc diameters of the macula, with vision loss occurring when the macula is involed 
(Cheung et al. 2010). Clinically significant macular oedema (CSME) is diagnosed when 
there is thickening 500µm from the macula or thickening of the macula itself (Early 
Treatment Diabetic Retinopathy Research Group 1985). It is also characterised when 
there is exudate formation within 500µm of the macula plus adjacent retinal thickening or 
when there is any retinal thickening within one disc diameter of the macula (Early 
Treatment Diabetic Retinopathy Research Group 1985). DME can be further subdivided 
into mild, moderate and severe according to proximity of exudate formation and retinal 
thickening to the macula (Ciulla et al. 2003).  Fluid accumulation in the diabetic retina, 
monitored using optical coherence tomography (OCT), can occur as a result of vessel 
rupture from regions where there is pericyte dropout, and from BRB breakdown. Both of 
these factors worsen with persistent hyperglycaemia and retinal ischaemia-mediated 
VEGF upregulation.  
 Treatments for DME can involve both surgical and pharmacological intervention. 
Again, the best way to assist the prevention of DME is by tight control of HbA1C as well 
as blood pressure. In patients with CSME without foveal involvement, focal laser 
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photocoagulation is performed using laser burns 50-100µm in diameter targeting 
microaneurysms and areas of leakage with the aim of reducing the risk of vision loss by 
50% (Early Treatment Diabetic Retinopathy Research Group 1985). Like PRP, focal laser 
photocoagulation aims to increase the amount of oxygen that diffuses from the choroid 
and into the retina (Nentwich & Ulbig 2015). It is also hypothesised that focal laser 
treatment is restorative to the inner and outer BRB by thermally stimulating the RPE and 
retinal endothelial cell (RECs) respectively as regions of fluid leakage appear to be 
reduced (Bhagat et al. 2009). Grid laser photocoagulation is prescribed when there is 
diffuse DME and foveal involvement (Bhagat et al. 2009). However, this method has 
varying prognoses, usually poor, and so it has since been replaced with the advent of anti-
VEGF drugs or carried out in conjunction with anti-VEGF therapy (Nentwich & Ulbig 
2015).  
1.2.4. Retinal neurodegeneration  
 
Largely associated with disorders of the central nervous system, 
neurodegeneration is also observed in the retina in conditions such as glaucoma (Kerrigan 
1997), retinitis pigmentosa (Baumgartner 2000) and mitochondrial retinopathies (La 
Morgia et al. 2010). Retinal neurodegeneration is also a key feature of DR and is involved 
in vision loss.  
The changes that typically occur in the diabetic neural retina include neural 
apoptosis, increased glial fibrillary acidic protein (GFAP) in glial cells and microglia 
activation (Barber, 2003). These changes are similarly seen in many neurodegenerative 
disorders of the CNS including Alzheimer’s and Parkinson’s disease (Cordeiro et al. 
2004), further illuminating that DR is also a neurodegenerative disorder.  Functional 
changes that represent some neurodegeneration can often be seen before the characteristic 
vascular pathology develops, indicating that the neuronal dysfunction may in fact be a 
primary effect of the diabetes rather than as a result of BRB break down and macular 
dysfunction (Barber, 2003; Lieth et al., 2000). Whilst clinical diagnosis of DR requires 
detection of vascular pathology, functional changes in vision can be detected using the 
electroretinogram (ERG) and contrast sensitivity, indicating that the pathway that allows 
vision acquisition or processing is compromised (Kern & Barber, 2008).  
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ERG has been used in the clinic to establish changes in oscillatory potentials in 
diabetic patients, and in patients diagnosed with diabetes for 7 years or less, it was 
noticed that the amplitude and latency of oscillatory potentials were reduced before any 
noticeable changes in vasculature had developed (Frost-Larsen et al., 1990; Juen & 
Keiselbach, 1990). Whilst the exact origin of the functional changes seen in DR are 
widely debated, it seems the most likely candidate cells that are compromised are 
amacrine neurones, bipolar or retinal ganglion cells. In animal models of diabetes, 
changes in ERG are also used to assess progression of DR. It has been reported that 
diabetic rats show prolonged peak latencies and a reduced B–wave, indicating 
dysfunction in bipolar cells, (Segawa et al. 1988; Robinson et al. 2012a). It has been 
observed that diabetic Lewis and Sprague-Dawley rats showed a reduced scotopic B-
wave latency (Kern et al. 2010), a feature similarly seen in the clinic.  
DR is often termed as a “neurovascular” disorder, and it is believed that diabetic 
retinal dysfunction is due to a change in the “neurovascular unit”. The neurovascular unit 
refers to the close physiological and biochemical relationship between the retinal 
vasculature and retinal neurones. The neurovascular unit in healthy retinae involves close 
relationship between glial cells, neurones and the pericyte-endothelial cell complex 
(Antonetti et al. 2012). In diabetic retinae the number of ganglion and bipolar cells 
decrease, as do the number of pericytes. The numbers of synapses formed between the 
neurones are decreased as the numbers of dendritic and axonal processes decrease, 
contributing to the diminished the neural activity in the diabetic retina. There is also 
decreased interaction between the vascular retina and the neural retina (Lieth et al. 2000; 
Antonetti et al. 2012). 
The relationship between the neurones, glia and microvasculature ensures 
appropriate energy homeostasis and neurotransmitter regulation. Pericytes surrounding 
capillaries in particular are essential in this region, as the pericyte – glial – neuronal axis 
promotes formulation of the blood – retina – barrier (BRB) (Antonetti et al. 2012), which 
tightly controls the movement of fluids and metabolites. The coupling between these 
types of cells is so tight that dysfunction in one cell type may affect the whole unit. 
Conditional VEGF deletion in Müller cells in the diabetic retina showed a marked 
reduction in leukostasis, tight junction breakdown and vascular leakage compared to 
untreated diabetic retinae (Wang et al., 2010); again underlying the pivotal role VEGF 
plays in DR. 
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Whilst many cell types are implicated in DR, retinal neural dysfunction is likely to 
be due to loss of retinal ganglion cells (RGC) in the ganglion cell layer (GCL) of the 
retina. Histological analysis of the human retina and scanning laser polarimetry indicated 
a thinning of the NFL in diabetic patients (Kerrigan 1997; Takahashi et al. 2006), 
indicating a loss of RGCs and their axons. Histological analysis indicates that RGCs 
show an increased expression of apoptotic markers such as: Bax, caspase-3 and caspase-8 
in diabetes (Oshitari et al. 2008). Other studies have shown that these cells become 
TUNEL positive or caspase-3 positive (Kern & Barber, 2008), however this does not 
correlate with number of cells dying, which could indicate that neurodegeneration, while 
it may precede neovascularisation, is a slow process.   
In the hypoxic retina, there is overproduction of TNF-α from the RPE (Chen et al. 
2011). Hyperglycaemia results in less PEDF secretion in vitro (Ablonczy et al. 2009), 
which may translate to reduced neuroprotection in vivo. Furthermore, hyperglycaemia 
results in increased AGE accumulation in the RPE resulting in overproduction of VEGF 
(Simó et al. 2010), TJ breakdown in the RPE and neurodegeneration. A compromised 
RPE layer not only means a compromised outer BRB, but also impinges upon its other 
functions in the retina. Most treatments, pharmacological and surgical, are not targeted 
towards treating retinal neural dysfunction, likely due to patients seeing an improvement 
in vision after anti-VEGF treatment. However, considering DR is a neurovascular 
disorder, and changes in the retinal neurones occurs early on in diabetes, it is important to 
consider the neural architecture when developing new treatment strategies.  
 
1.3. The blood-retina barrier 
 
The blood-retina barrier (BRB) describes the selectively permeable region formed 
by TJs on RECs (Shakib & Cunha-Vaz 1966) and RPE (Cunha-Vaz 1976), which form 
the inner and outer BRB respectively, as shown by figure 1.3. The BRB protects the 
neural retina from contents of the retinal and choroidal circulation. The BRB also has a 
vital role in homeostatic maintenance of the neural retina. Much like the blood-brain 
barrier (BBB), the BRB controls fluid and molecular flux between cells.  
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Figure 1.2. Schematic diagram of a cross section of the eye 
The neural retina is comprised of many layers the ganglion cell layer (GCL), the inner 
nuclear layer (INL), the outer nuclear layer (ONL), and is separated from the choroid by 
the retinal pigment epithelium (RPE). The retina has two regions of blood-retina barrier 
(BRB); an inner BRB and an outer BRB to protect the neural retina from the retinal and 
choroidal circulation respectively.  
1.3.1. The inner BRB 
 
 There are two plexuses of retinal vasculature, an inner plexus located near the 
GCL and an outer plexus near the OPL, as shown by figure 1.3 (Kaur et al. 2008), the 
endothelial cells that line form these vessels are the inner BRB. The TJs between these 
RECs are located on the basal lamina, and provides a selectively permeable barrier to the 
capillaries. These barrier properties are enhanced by the neurovascular unit that RECs are 
so closely associated with. Pericytes contribute to TJ integrity by inducing occludin and 
ZO1 mRNA and protein expression in the REC that they are associated with under 
normoxic conditions. Furthermore, pericytes partially prevent loss of TJs under hypoxic 
conditions (Wang et al. 2007). Müller glia are also closely associated with the inner BRB 
and are involved in nutrient uptake and removal of metabolites (Kaur et al. 2008). Under 
normal conditions, Müller glia have been shown to secrete pigment epithelium derived 
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growth factor (PEDF), an anti-angiogenic growth factor (Yafai et al. 2004) perhaps as 
part of maintenance of the inner BRB. Under diabetic conditions, Müller glia secrete 
VEGF, which induces retinal vascular leakage and inflammation (Wang et al. 2010). 
1.3.2. The outer BRB  
  
 The outer BRB is formed by TJs between the RPE cells separates the choroidal 
circulation from the inner retina (Cunha-Vaz 1976). The apical surface of the RPE 
contain villi-like structures that are in close contact with rod and cone outer segments for 
the phagocytosis of photoreceptor outer segment discs (Steinberg et al. 1977), and for 
vitamin A transport (Kaur et al. 2008). The RPE layer is highly involved in the visual 
cycle, as mutations of the RPE65, a protein responsible for isomerisation of trans-
retinaldehyde to 11-cis-retinaldehyde, results development of Leber congenital amaurosis 
and severe vision loss (Acland et al. 2001).  
Unlike the retinal vasculature, the choroidal plexus is fenestrated, to allow 
diffusion of nutrients such as glucose and fatty acids from the systemic circulation to the 
RPE, which in turn transports them to the outer retina. This transcellular movement is 
also utilised to transport outer retinal waste products back to the choroidal circulation 
(Weinberger et al. 1995). Due to its close proximity to and association with the chorioidal 
circulation, TJ integrity of the RPE layer is important. Moreover, the fenestrae of the 
choroidal plexus may allow macromolecular leakage from the choroid that may otherwise 
be deleterious in the retina, further reiterating the importance of outer BRB integrity.  
 As well as providing a barrier function and a transporter of nutrients and waste, 
the RPE layer also provides a protective mechanism. There is high generation of ROS in 
the retina, due to its vast oxygen consumption. The RPE contains large amounts of 
superoxide dismutase, and anti-oxidant to protect the retina against oxidative stress (Simó 
et al. 2010). In addition to this the RPE protects against oxidative stress using pigments 
such as lipofuscin and melanin, to filter out light at different wavelengths and contribute 
to anti-oxidant defence.  
  As part of maintaining outer retinal and choroidal homeostasis, the RPE produce 
and secrete many growth factors. The RPE basolaterally secretes VEGF to maintain the 
choroidal endothelium and to stabilise choroidal fenestrae (Saint-Geniez et al. 2009a). 
The RPE also secretes PEDF, an anti-angiogenic and neuroprotective growth factor, from 
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the apical side (Ablonczy et al. 2009). PEDF is also involved in the maintenance of the 
choroid as well as the retinal vasculature, perhaps by curtailing VEGF-mediated 
endothelial proliferation.  
 
1.4. Mechanisms associated with DR 
 
Diabetes is a complex metabolic disease and as a result complications associated 
with diabetes involve multiple pathways. Pathological pathways associated with 
hyperglycaemia-induced damage specific to this thesis are further discussed below.  
1.4.1. Oxidative stress 
 
 Generation of reactive oxygen species (ROS) such as superoxide and hydrogen 
peroxide, is a common by product of the electron transport chain, as well as from 
NADPH oxidases and nitric oxide synthases (Dröge 2002). Under normal physiological 
conditions, ROS are produced to support basic cell function, and are then cleared. 
Overproduction of ROS can result in oxidative stress can be deleterious and result in 
damage of DNA, proteins, lipids and other cellular mechanisms (Giugliano et al. 1996).  
 As the retina is one of the most metabolically active tissues in the body, it has a 
high oxygen and glucose uptake, making it vulnerable to hyperglycaemia-induced 
oxidative stress (Anderson et al. 1984). Cells in the retina are unable to adequately adapt 
glucose transport rates when the extracellular environment is hyperglycaemic, resulting in 
an increased intracellular glucose (Kaiser et al. 1993). Increased intracellular glucose 
results in increased glucose metabolism through the tricarboxylic acid (TCA) cycle and 
increased electron transport chain activation, resulting in a ROS production greater than 
can be scavenged (Giugliano et al. 1996). Not only does elevated ROS result in 
intracellular damage and apoptosis, that it triggers many other pathogenic pathways 
involved with diabetes and complications associated with diabetes (Brownlee 2001).  
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1.4.2. Polyol pathway 
 
 Elevated intracellular glucose in the diabetic eye results in increased activation of 
the polyol pathway. Aldose-reductase, reduces excess glucose to sorbitol, and as it does 
so converts NADPH to NADP+ (Brownlee 2001). Sorbitol is then oxidised to fructose by 
sorbitol dehydrogenase, resulting in NADH production. This process results in decreased 
intracellular NADPH, which is detrimental to the retina as NADPH is involved in the 
production of glutathione, a ROS scavenger (Kowluru & Chan 2007). This means that 
there will be a build-up of ROS production as it is unable to be cleared appropriately, 
triggering further oxidative stress. Furthermore, NADPH is involved in nitric oxide (NO) 
production (Kowluru & Chan 2007). NO is critically involved in vasomotor tone, 
therefore a reduction in NADPH results in decreased NO. Any reduction in NO 
production could result in alterations in vascular perfusion in the already inadequately 
perfused diabetic retina (Ho et al. 2012). This may further exacerbate tortuosity of the 
microvasculature. Increased intracellular NADH/NAD+ also results in glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) inhibition, resulting in activation of the AGE and 
PKC pathways (Brownlee 2001).  
1.4.3. Advanced glycation end-products (AGEs) 
 
 AGEs are formed by reducing sugars, such as glucose, reacting non-enzymatically 
with amino groups found in proteins, nucleic acids and lipids, which become glycated or 
glycoxidated (Singh et al. 2001). AGE accumulation takes many weeks, and as it does so 
it causes the dysfunction of many long-lived proteins and targets regions such as the 
basement membrane of blood vessels and can cause tubulin dysfunction, both of which 
are involved in BRB breakdown. AGE also interacts with collagen, and initiates cross-
links across these fibres, which can affect vasomotor tone and haemodynamics in the 
diabetic retina (Brownlee 2001). 
 AGE formation occurs with increasing age, and forms at an accelerated rate in 
diabetes and correlates with the progression of retinopathy (Stitt et al. 1997). AGEs bind 
to their cognate receptors with high affinity, with the most well characterised receptor 
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being the receptor for AGE (RAGE). They activate inflammatory mediators such as 
NFKB and TNFα (Brownlee 2001), and elevates ROS, causing further retinal 
degeneration. RAGE is found in various cells in the retina including pericytes, RPE and 
RECs and its activation is associated with increased retinal vascular permeability 
(Hammes 2005). RAGE activation also upregulates cytokines such as VEGF, a key factor 
involved in diabetic retinal pathology (Hammes et al. 1999). Interestingly, RAGE-
induced VEGF upregulation has been found in the RPE and the RGC layer (Hammes et 
al. 1999) and may participate in outer BRB breakdown and retinal neurodegeneration 
respectively. Exogeneously applied AGE induces BRB breakdown in normoglycaemic 
retinae (Stitt et al. 2000) and RAGE inhibition results in a prevention of diabetes-induced 
vascular leakage (Wautier et al. 1996).  
1.4.4. Protein kinase C (PKC) activation 
 
 PKC consists of a family of 11 isoforms, divided into typical (α, βI, βII and γ) 
activated by diacyglycerol (DAG) and Ca2+, novel (δ, ε, η and θ) activated by DAG and 
atypical isoforms (ζ and λ) activated by neither DAG nor Ca2+ (Parekh et al. 2000) . PKC 
phosphorylate intracellular proteins using kinases, this is a critical factor in enzyme 
activation, receptor pathways and gene expression (Donnelly et al. 2004)  and can be 
deleterious if over-activated. Elevated intracellular glucose results in increased DAG 
expression in the retina (Koya & King 1998), hypothesised to be formed de novo 
(Brownlee 2001). Increased hyperglycaemia-induced ROS production results in increased 
triose phosphate expression, a precursor to DAG (Inoguchi et al. 2000). This will 
stimulate the production of DAG upon hyperglycaemia, and increase typical and novel 
PKC activation. Furthermore, increased PKC activation further increases ROS production 
and oxidative stress through increased NADPH oxidase activity (Inoguchi et al. 2000). 
PKC upregulation has been shown to reduce endothelial nitric oxide synthase and NO 
production, which would impair an already compromised vasomotor tone in the retinal 
microvessels (Wu et al. 2014). PKC activation triggers activation of many other pathways 
including increasing expression of transforming growth factor β (TGFβ), which in turn 
increases collagen and fibronectin activity (Brownlee 2001). This is particularly 
detrimental in the diabetic eye, as it will help further compromise blood flow, and result 
in a greater onset of capillary occlusion. PKC activation also increases NFKB expression, 
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resulting in increased transcription of pro-inflammatory genes and cytokines (Tang & 
Kern 2011).  
 PKC phosphorylates intracellular proteins at the serine or threonine residue, which 
can be pathological if this occurs too frequently, for example in the diabetic retina. Serine 
and threonine residues are also phosphorylated in the BRB by PKC on tight junction 
proteins, resulting in barrier dysfunction and permeability in the retina (Harhaj et al. 
2006) as well as pericyte dropout (Pomero et al. 2003). The role of PKC βI and βII have 
been the most extensively characterised in DR as it is hypothesised that they are the most 
activated isoforms in response to hyperglycaemia (Donnelly et al. 2004). 
Hyperglycaemia-mediated VEGF upregulation also increases PKC activation (α, β and δ), 
however VEGF-induced mitogenic activity appears to be mediated largely by PKCβ, 
making PKCβ an attractive therapeutic target in treating DR. Interestingly, PKC also 
increases hyperglycaemia-mediated VEGF expression in the RPE (Poulaki et al. 2002). 
VEGF-mediated endothelial cell activation (Xia et al. 1996) and retinal permeability 
(Aiello 2002) were both reduced upon treatment with a PKCβ inhibitor, LY33531 or 
ruboxistaurin. Ruboxistaurin treatment in diabetic patients has shown a gain in vision and 
a prevention in DME progression, however it is still awaiting FDA approval (Javey et al. 
2012).  
 Hyperglycaemia also upregulates PKCδ in the retina and induces ROS and 
NFKB-mediated pericyte apoptosis and formation of acellular capillaries (Geraldes et al. 
2009), possibly resulting in VEGF upregulation and PKCβ activation. In hypoxic RPE in 
vitro, VEGF secretion appeared to be PKCδ mediated (Young et al. 2005). PKCζ, an 
atypical PKC isoform, has been shown to be necessary in hyperglycaemia-mediated 
VEGF expression (Young et al. 2005). However, when inhibited, PKCζ showed no effect 
on VEGF secretion, indicating that different PKCs are involved in the expression and 
secretion of VEGF upon different hyperglycaemic and/or hypoxic stimuli (Young et al. 
2005).   
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1.5. Vascular endothelial growth 
factor  
 
VEGF-A, or VEGF, is a gene that is a mitogenic factor (Leung et al. 1989), potent 
inducer of permeability (Adamis et al. 1993) and a neuroprotective agent (Foxton et al. 
2013). VEGF exists as multiple isoforms of varying amino acid length, (e.g. VEGF121, 
VEGF145, VEGF165, VEGF189 are examples of human VEGF isoforms and murine 
isoforms contain one amino acid less). The most widely studied, understood and the most 
predominant VEGF isoform is VEGF165 / VEGF164. The biological effects of VEGF are 
mediated by their cognate receptors, VEGFR1 (Flt-1) and the more biologically active, 
VEGFR2 (KDR or Flk-1) (Ferrara 2004). Furthermore, neuropilin-1 also binds VEGF165 
and is crucial in endothelial cell migration (Soker et al. 1998). VEGFR1 and VEGFR2 are 
expressed by multiple cell types including endothelial cells (Shibuya et al. 1999) and 
epithelial cells (I Kim et al. 1999), and is ubiquitously expressed in the eye.  
1.5.1. Angiogenesis  
 
Angiogenesis is the formation of new blood vessels from pre-existing vasculature 
and is critical in embryonic development (Carmeliet et al. 1996), wound healing (Nissen 
et al. 1998) and fertility (Ferrara et al. 1998). There are many angiogenic factors 
including placental growth factor (PlGF; Maglione et al. 1993) and angiopoeitin-1 
(Koblizek et al. 1998). However, VEGF is deemed to be the key regulator of 
physiological and pathological angiogenesis.  
VEGF-mediated angiogenesis in the eye is often driven by hypoxia (Shima et al. 
1995). HIF-1α is stabilised and translocated to the nucleus in hypoxic conditions. This 
interacts with hypoxia response element (HRE) to activate transcription of VEGF (Pe’er 
et al. 1995). In diseased states where there is persistent hypoxia, oxidative stress or 
inflammatory response such as DR, there is overexpression of VEGF, VEGR2 and 
subsequent angiogenesis (Aiello 1994). Blocking VEGF activity results in a reduction of 
pathological retinal neovascularisation (Aiello 1995).  
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1.5.2. Vascular leakage  
 
 Vascular leakage refers to the movement of fluid or solutes across a capillary wall 
and is increased upon VEGF stimulation and inflammatory mediators. Vascular leakage 
is a broad term that includes transcellular leakage and paracellular leakage, the latter 
being the most deleterious aspect of DR. Paracellular leakage in DME is hypothesised to 
occur when junctional proteins located on endothelial cells, such as occludin, zonula 
occludens 1 (ZO1) and VE-cadherin, amongst others, are disrupted (Wallow & Engerman 
1977). This disruption allows the contents of the microvasculature, such as plasma 
proteins, to leak through between the cells, and becomes pathological when this fluid 
build up exceeds fluid clearance, and accumulates.  
 Addition of VEGF165 to bovine retinal endothelial cells reduced their occludin 
expression and increased extraction of occludin (Antonetti 1999a). Furthermore, 
intravitreal addition of VEGF increases vascular permeability (Xu et al. 2001), which 
reflects what is observed in models of diabetic retinopathy in vivo (Qaum et al. 2001). 
VEGF-mediated PKC activation phosphorylates occludin and ZO1 at the serine and/or 
threonine residue, resulting in ubiquitination, endocytosis and subsequent degradation of 
TJs in endothelial cells(Murakami et al. 2009). Interestingly, in the RPE, the actin 
cytoskeleton anchors TJs, and undergoes a conformational change due to increased PKC 
activation, resulting in disassembly of TJs and their internalisation in a soluble pool, 
where they are recycled back to the membrane (Harhaj & Antonetti 2004) . Both of these 
instances result in increases in paracellular flux, and fluid accumulation.  
1.5.3. Anti-VEGF therapy and DR 
 
Since the discovery of VEGF in the pathogenesis of DR (Aiello 1994), the use of 
anti-VEGF therapy in treating DR has been a widely investigated area of research. The 
main anti-VEGF treatment strategies are administered intravitreally and mainly targeted 
at the inner BRB. This aims to neutralise VEGF through soluble VEGF dimer 
neutralisation or inhibition of VEGFR1 and VEGFR2 dimerization. Anti-VEGF therapy 
has limited effectiveness in treating DR, with approximately 50% of patients responding 
to therapy (Stitt et al. 2015). Conversely, anti-VEGF therapy in treating wet AMD is 
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much more effective with 87% of patients responding positively (Falavarjani & Nguyen 
2013).  
Ranibizumab (Lucentis, Genentech, San Francisco), a pan-VEGF-A 40kDa 
fragment antibody, reduces VEGF-A expression by preventing VEGF110, VEGF121 and 
VEGF165 from interacting with VEGFR1 and VEGFR2 (Ferrara et al. 2006). By doing so, 
cell proliferation, migration and permeability were reduced. Various multicentre trials 
have shown that ranibizumab not only prevents vision loss, but also showed a meaningful 
gain in vision in many patients (Ferrara et al., 2006; da Cruz, 2008). Ranibizumab also 
shows a reduction in central retinal thickness (CRT) and fluorescein leakage in AMD 
patients and is now widely used to treat AMD. Data from the READ clinical trial testing 
the use of ranibizumab in treating DME showed that there was a decrease in oedema and 
an increase in BCVA, relative to focal or grid laser therapy alone, and is currently being 
further investigating as a treatment for DME (Nguyen et al. 2010).  
Bevacizumab (Avastin, Genentech, San Francisco) a humanised, recombinant 
monoclonal pan-VEGF-A antibody, binds to the binding domain of all VEGF isoforms, 
and therefore neutralises the activity of VEGF-A. Bevacizumab has been FDA approved 
for the treatment of metatstatic colon cancer, metatstatic breast cancer and non-small cell 
lung cancer. However, it is used off label to treat AMD (Javey et al. 2012). Studies 
showed that there was a significant improvement in BVCA when compared to laser 
therapy alone in patients with DME, although further trials are still taking place (Avery et 
al. 2006).  
Whilst ranibizumab and bevacizumab are typically administered intravitreally 
every 4-6 weeks, aflibercept (Eyelea, Regeneron, NY, USA) is administered every 2 
months in AMD patients (Heier et al. 2012). Aflibercept acts as a soluble decoy receptor 
and inhibits VEGFR1 and VEGFR2 activation, and binds all isoforms of VEGF-A with 
greater affinity than ranibizumab or bevacizumab and also inhibits VEGFR1 and 
VEGFR2 more potently than both pan-VEGF-A antibodies in vitro (Papadopoulos et al. 
2012). Interestingly, aflibercept also possesses a high affinity for VEGF165 as well as 
VEGF121, VEGF-B and PIGF (Heier et al. 2012), and it is these qualities that have now 
many aflibercept increasingly popular.  
Whilst shown to be a promising therapeutic intervention in treating wet AMD, 
ocular anti-VEGF therapy is still in its infancy. Neutralising or inhibiting an endogenous 
cytokine like VEGF could prove to be deleterious. Considering diabetic retinae are prone 
to BRB breakdown, the privileged immunity that the eye obtains is now compromised. As 
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a result, these anti-VEGF drugs may end up in the systemic circulation, and may prevent 
the necessary actions of VEGF, systemically. An example would be interfering with 
wound healing and maintenance and regulation of the systemic vasculature may be 
harmful, especially in elderly or diabetic patients (Gillies 2006). VEGF is neurogenic and 
neuroprotective (Jin et al. 2000; Jin et al. 2002). Situations where anti-VEGF agents have 
leaked into the systemic circulation from compromised BRBs may affect other 
neurovascular units within the body. Diabetic patients are prone to neurodegeneration, 
particularly in the peripheral nervous system, to administer anti-VEGF agents and risk its 
entry into the circulation, may exacerbate the condition further.  
Within the eye itself, suppression of VEGF may lead to widespread geographic 
atrophy (GA). A study looking at the effect of bevacizumab on the development of 
chorioretinal atrophy (CRA) in patients suffering from CNV, showed that in fact whilst 
the patients’ vision improved, there was often a development and enlargement of CRA as 
time progressed. CRA has been shown to worsen vision improvement, when compared to 
patients that did not develop CRA (Oishi et al. 2013). This indicates that either a strategy 
needs to be put in place to manage this atrophy, or another treatment route needs to be 
adopted.  
 Endophthalmitis, inflammation of the intraocular cavities, is usually caused by 
infection from ocular surgery or intravitreal injections, and can result in permanent vision 
loss. Whilst its incidence is rare, between 0.019%-1.6% (Falavarjani & Nguyen 2013), it 
is still one of the greater adverse events associated with intravitreal therapy. Although 
anti-VEGF therapy is successful in managing and treating DME, all treatments require 
frequent injections. Therefore although the risk of developing endophthalmitis is low, that 
risk is still there during every injection. Unfortunately, all current anti-VEGF therapies 
present this risk, again reiterating the importance of an alternative treatment strategy, one 
that requires fewer intravitreal injections.  
1.5.4. Alternative splicing of VEGF-A  
 
As well as having multiple isoforms of varying amino acid length, VEGF pre-
mRNA can be alternatively spliced at exon 8 (Bates et al. 2002a) to generate two families 
of isoforms, as shown by figure 1.3. There are two different splice sites on exon 8, a 
proximal splice site (PSS) at exon 8a and a distal splice site (DSS) at exon 8b, and 
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selection of which results in a pro-angiogenic and anti-angiogenic family of isoforms 
respectively (Bates et al. 2002a). The anti-angiogenic family, VEGFxxxb (x=amino acid 
number) has a different terminal six amino acid sequence (Ser-Leu-Thr-Arg-Lys-Asp, 
SLTRKD) to the by pro-angiogenic family, VEGFxxx (Cys-Arg-Lys-Pro-Arg-Arg, 
CDKPRR) (Woolard et al. 2004). VEGF165b has since been the most characterised of the 
VEGFxxxb family, and has unique properties that differ to VEGF165, its pro-angiogenic 
sister isoform, due to this difference in C’ terminal sequence. VEGF165b binds to 
VEGFR2, however unlike VEGF165, it does not bind neuropilin 1, and only weakly 
phosphorylates VEGFR2 due to insufficient rotation of the VEGF165b-VEGFR2 complex 
(Kawamura et al. 2008). This reduced autophosphorylation, relative to VEGF165, results 
in a weakened internal receptor phosphorylation and weakened downstream signalling to 
that elicited by VEGF165.  
VEGF165 and VEGF165b competitively bind to VEGFR2, therefore binding of 
VEGF165b to VEGFR2 prevents VEGF165 interaction with VEGFR2, thereby preventing 
pro-angiogenic activity and eliciting anti-angiogenic activity (Woolard et al. 2004). It is 
hypothesised that the prevalence of one isoform over the other can result in pathology. In 
diseases characterised by pathological angiogenesis, there is increased VEGFxxx 
expression, predominantly VEGF165 (Bates et al. 2002a; Woolard et al. 2004; M. V. R. 
Gammons et al. 2013), and in systemic sclerosis, a disease characterised by insufficient 
angiogenesis, there is systemic upregulation VEGF165b (Manetti et al. 2011).  
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Figure 1.3. Splice variants of the VEGF-A gene 
VEGF-A is alternatively spliced at exon 8 to generate two families of isoforms, a pro-
angiogenic VEGFxxx family and an anti-angiogenic VEGFxxxb family of isoforms 
according to proximal or distal splice site selection respectively.  
1.5.5. VEGFxxxb in the eye 
 
 Since 2002, the expression and use of VEGFxxxb isoforms in various diseases has 
been studied extensively. It has been identified in many healthy tissues including the 
kidney (Bevan et al. 2008), the central nervous system (Beazley-Long et al. 2013), the 
peripheral nervous system (Hulse et al. 2014a) and the eye (Perrin et al. 2005),. 
VEGF165b has been shown to inhibit endothelial permeability (Bevan et al. 2008), prevent 
endothelial migration (Woolard et al. 2004) and is neuroprotective (Hulse et al. 2014a).  
It is hypothesised that both families of isoforms are required for development and 
maintenance of tissue, for example foetal eye development requires both families of 
isoforms (Baba et al. 2012). Over the course of gestation, there are spatial and temporal 
differences in VEGF165 and VEGF165b, most notably in the RPE layer and putative NFL, 
with VEGF165b being most abundant towards the end of the gestation period (Baba et al. 
2012). It is well known that pro-angiogenic VEGF is crucial for embryonic development 
(Carmeliet et al. 1996), however in the very early stages of eye development, VEGF165b  
is detected at much lower levels than VEGF165. It is possible that at this time splicing is in 
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favour of pro-angiogenic isoforms and switches in favour of VEGFxxxb when necessary 
later on. It also suggests that the spatial differences in isoform expression are due to their 
competition in binding to VEGFR2.  
VEGFxxxb isoforms are also found in the adult human vitreous, as almost half of 
the total VEGF expressed in the eye, indicating that both families of isoforms are required 
for adequate ocular function (Perrin et al. 2005). However, in diabetic patients, this 
balance shifts in favour of VEGFxxx, with the percentage of VEGF in the vitreous that is 
anti-angiogenic decreasing (12.5±3%) compared to that of normal eyes (65.3±7.2%) 
(Perrin et al. 2005). This study inferred that DR is governed by a switch in splicing from 
the anti-angiogenic isoform being the dominant form of VEGF, to the pro-angiogenic 
isoform in diabetes.  
A switch in splicing can also govern the extent of pathological neovascularization 
in a model of retinopathy of prematurity (ROP). The 50/10 oxygen-induced retinopathy 
model was subject to new-born rats that received an intravitreal injection of DMSO or 
SRPIN340, a serine-arginine protein kinase inhibitor that can influence VEGF pre-mRNA 
splicing (Gammons et al., 2013). OIR causes an increase in VEGF165–mediated pre-retinal 
neovascularization (PRNV) and intravitreal neovascularization (IVNV) in DMSO-treated 
control eyes. Conversely, eyes treated with SRPIN340, show less PRNV and IVNV. It is 
likely that this reduction in pathological neovascularization is due to SRPIN340-induced 
switch in splicing favouring the anti-angiogenic, VEGF165b, isoform, therefore inhibiting 
binding of any excessive VEGF165. This strategy as also been used to treat neuropathic 
pain in diabetic rats. Rats subjected to diabetic peripheral neuropathy show elevated 
levels of VEGF165 and increased mechanical and thermal hyperalgesia (Hulse et al. 
2014a). Conversely, rats treated with SRPIN340 show a reduction in pain markers and 
pain sensitivity and increased levels of VEGF165b (Hulse et al. 2014a). 
Direct application of VEGF165b also shows similarly promising results. 
Intravitreal administration of VEGF165b has shown both a reduction in neovascularization 
and increased cytoprotection in oxygen-induced retinopathy (Konopatskaya et al. 2006; 
Magnussen et al. 2010). As well as reducing pathological neovascularization, VEGF165b 
shows neuroprotectivity. Rats subjected to OIR show a significant reduction in retrograde 
transport of fluorogold to the RGC layer in untreated retinae relative to VEGF165b–treated 
eyes (Beazley-Long et al. 2013). This indicates that VEGF165b is able to protect RGCs 
against ischaemic insult, and when compared to control ischaemic eyes and contralateral 
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eyes, there is a reduction in activated caspase-3 staining suggesting that this 
neuroprotection is mediated through inhibition of apoptosis in the retina.  
It therefore seems likely that VEGF165b can be used to treat the various 
pathological aspects of PDR, as the diabetic retina is so severely deficient in anti-
angiogenic isoforms. The unique neuroprotective, anti–angiogenic and anti-permeability 
properties that VEGF165b possesses makes it an ideal candidate in targeting the three 
hallmark pathologies in DR.  
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1.6. Gene therapy  
Retinal gene therapy for the treatment of blindness has shown great progress, 
particularly with inherited retinal degenerations such as Leber congenital amaurosis 
(LCA) (Bainbridge et al. 2015) and achromatopsia (Pang et al. 2010). The success of 
retinal gene therapy, plus the immune privilege nature of the eye have made it an 
attractive candidate for targeting increased VEGF in AMD and DR for long periods of 
time. The benefit of a long-lasting treatment strategy such as anti-angiogenic gene 
therapy removes risks associated with intravitreal injections, such as endophthalmitis, as 
it reduces the number of injections required relative to standard anti-VEGF therapy.  
Adenoviral and AAV-mediated soluble VEGFR1 (sFlt1) gene transfer show a 
reduction in ischaemia-induced retinal neovascularisation in mice (Bainbridge et al. 2002) 
and in monkeys (Lai et al. 2005). Endostatin is hypothesised to be anti-angiogenic in the 
retina (Takahashi et al. 2003). Several groups using endostatin gene therapy have shown a 
reduction in retinal (Auricchio et al. 2002) and choroidal (Balaggan et al. 2006) 
neovascularisation. PEDF, also hypothesised to be anti-agiogenic in the eye (Dawson et 
al. 1999), has shown to cause a reduction in ischaemia-induced neovascularisation 
(Auricchio et al. 2002) and adenoviral PEDF has been shown to reduce lesion size in 
patients with AMD (Campochiaro et al. 2006). These are just some examples of the 
research conducted in anti-angiogenic gene therapy for ocular neovascular diseases, 
however none are yet to make it past clinical trial stages.  
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1.7. Hypothesis and Aims 
It is clear that VEGF is critical in the progression of DR and that VEGF165b is able to 
inhibit VEGF-induced pathology. Gene therapy is a potential mechanism for long-term 
expression. I therefore set out to test the hypothesis that VEGF165b gene therapy would be 
a novel approach to treating diabetic retinopathy as it targets neovascularisation, oedema 
and neurodegeneration. Furthermore, it reduces the number of ocular injections required, 
therefore reducing the incidence of injection-related side effects. I also hypothesised that 
outer BRB dysfunction is involved in the pathogenesis of DR, and RPE-targeted 
treatment would be a novel way of treating DR. Specifically, I designed a series of 
experiments that tested the hypotheses to determine: -  
 
I. Whether rhVEGF165b could prevent VEGF165-induced changes in TJ expression 
and function in 1˚ human RPE in vitro, to test the hypothesis that VEGF165b could 
prevent VEGF165-induced pathology in an in vitro model of the outer retinal 
barrier. 
 
II. Whether an in vitro model of diabetic retinopathy, specifically diabetic outer BRB 
dysfunction, could be created, and whether rhVEGF165b could prevent any 
potential changes in TJ function and expression. This tested the hypothesis to see 
whether VEGF165b would be suitable in treating hyperglycaemia-induced outer 
BRB breakdown.  
 
III. Whether intravitreal administration of rhVEGF165b can prevent a diabetes-induced 
increase in fluid extravasation in acute, type 1 diabetic rats in vivo. This tested the 
hypothesis that locally administered VEGF165b would prevent BRB breakdown in 
the diabetic retina.  
 
IV. Whether 8-week diabetic rats showed an increase in retinal fluid extravasation, 
and if so, could this be prevented by systemic administration of VEGF165b; to test 
the hypothesis that VEGF165b could be tolerated long-term and prevent diabetes 
induced-BRB breakdown in vivo. 
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V. If 8-week diabetic rats showed changes in barrier properties, they may also show a 
difference in vascular density, which may be ameliorated by systemic rhVEGF165b 
treatment. This tested the hypothesis that VEGF165b would be able to prevent 
neovascularization in a potential model of PDR, in vivo.  
 
VI. Whether long-term diabetes could induce a decrease in A- and B-wave ERG 
amplitude and a change in retinal thickness, which may be prevented upon 
subretinal delivery of AAV.VEGF165b, to test the hypothesis that VEGF165b gene 
therapy can prevent diabetes-induced retinal neurodegeneration and thinning of 
the rat retina.  
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Chapter 2: Materials and 
Methods 
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2.1. Cell culture 
 
 2.1.1. Isolation and culture of primary human RPE cells. 
 
 All cell extractions were carried out under cell culture hoods in class II facilities 
using sterile and autoclaved instruments and solutions, approved by the HTA ethics 
guidelines. Primary human RPE were extracted from human donor globes obtained 
within 24 hours post-mortem (Bristol Eye bank, Bristol Eye Hospital). Retinae were 
excised with choroid-RPE sheets intact, finely chopped and digested in a petri dish with 
5ml Dulbecco’s Modified Eagle Medium (DMEM):F12 (1:1) + GlutaMAX (Invitrogen) 
with added collagenase (0.3mg/ml) for 15 minutes at 37˚C. Following digestion, 30ml 
DMEM:F12+GlutaMAX was added to the choroid:RPE sheets, supplemented with 10% 
foetal bovine serum (FBS, Invitrogen), 0.5% penicillin / streptomycin (Invitrogen). The 
samples were spun at 1500 rotations per minute (rpm) for 10 minutes at room temperature 
to pellet cells. The supernatant was discarded and the pellet resuspended in 4ml 
DMEM:F12+GlutaMAX supplemented with 25% FBS and transferred to a T25 flask 
(Greiner). Upon reaching 80% confluence, cells were split and either transferred to a T75 
flask (Greiner) or used for experimental purposes. RPE were used until passage 8 and 
cultured in DMEM:F12 + GlutaMAX supplemented with 10% FBS and 1% penicillin / 
streptomycin. 
 
 2.1.2. HEK293T cells  
 
 Cells were maintained in in DMEM (Invitrogen) + 10% foetal calf serum (FCS, 
Invitrogen). Media was supplemented with 1% penicillin G and streptomycin and 
0.25µg/ml amphotericin B (all Invitrogen). This medium will henceforth be referred to as 
“D10”. Cells were cultured on 150cm2 plates (Nunclon Surface, Nunc) and split when 
reaching 80% confluence and were transfected with plasmids between passages 10 and 
24. 
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2.2. Treatments with growth factors  
 
 2.2.1. Vascular endothelial growth factor (VEGF-A). 
  
 RPE were treated with both isoforms of VEGF-A, proangiogenic VEGF165 and 
anti-angiogenic VEGF165b, both at varying doses (0nM, 0.1nM, 0.2nM, 0.5nM, 1.0nM, 
2.5nM, 5.0nM), to assess the effects of both isoforms on tight junction integrity. 24 hours 
prior to treatment, cells were subject to serum starvation by replacing culture medium 
with serum–free medium. 24 hours following treatment, cells were stained for tight–
junctions, and protein lysate was extracted for further analysis or immediately post-
treatment cells were subject to trans-epthelial electrode resistance (TEER, section 2.3). 
 
 2.2.2. Glucose 
  
 RPE were treated with D-glucose (Sigma) at 5mM and 35mM to test the effect of 
normoglycaemia and hyperglycaemia on tight-junctions respectively. RPE were 
simultaneously treated with mannitol (30mM mannitol + 5mM glucose, Sigma), as an 
osmotic control for 35mM glucose. Cells were also subject to co-treatment of glucose 
with 2.5nM VEGF165, 2.5nM VEGF165b and 1µM anti-VEGF165b (56/8) 24 hours prior to 
treatment, cells were subject to serum starvation by replacing culture medium with serum 
– free medium. 24 hours following treatment, cells were stained for tight – junctions, and 
protein lysate and conditioned media was also extracted for further analysis; or 
immediately post-treatment cells were subject to trans-epthelial electrode resistance 
(TEER, section 2.3). 
2.3. Trans–epithelial electrode resistance  
 
Trans-epithelial electrode resistance (TEER) was measured using electric cell-
substrate impedance sensing (ECIS, Applied Biophysics, Troy, NY, USA) using a 1600R 
ECIS model. Human primary RPE cells were plated on 8 well plates (8W10E+ plates, 
Applied Biophysics). Wells were pretreated with 10mM L-cysteine (Sigma) for 30 
minutes at 37˚ to neutralise the electrodes and enable to cells to adhere to the wells. After 
the 30-minute period the L-cysteine was aspirated, and the wells were washed with 
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distiller water at room temperature. Following this wash, the wells were filled with 400ul 
medium (DMEM: F12+GlutaMAX, Gibco) and the electrodes were stabilised on the 
machine.  
The wells were plated with 60,000 cells per well in 400ul medium. Cells are 
deemed confluent when the resistance is greater than 1000Ω. Measurements were 
collected at multiple frequencies (125Hz, 250Hz, 500Hz, 1000Hz, 2000Hz, 4000Hz, 
8000Hz and 16000Hz) for one hour, to establish baseline data. Once baseline was 
established, the programme was paused and plates were taken to a laminar flow hood, and 
growth factor treatment (see section 2.2) was prepared in 50µl medium. 50µl of medium 
was carefully aspirated from each well of the plate and replaced with 50µl of growth 
factor treatment, and was allowed to equilibrate for 30 minutes before reattaching the 
plates to the ECIS and recommencing TEER evaluation, so as to prevent any convection–
induced detachment of cells from a change in solutions. Plates were then assayed for 
changes in TEER for at least 15 hours. Data was analysed at 500Hz to give an indication 
of tight-junction integrity and paracellular flux.  
2.4. Protein work 
 
 2.4.1. Protein extraction 
 
 Protein was collected from freshly excised retinae or choroids by homogenising 
them in 200µl ice-cold radioimmunoprecipitation buffer (RIPA, Sigma) containing 
protease inhibitor (Sigma) on ice. Protein lysate was extracted from cells when cells 
reached 80% confluence in 6–well (Greiner). Cells were washed twice in ice-cold 1xPBS, 
followed by 50µl RIPA buffer plus cocktail inhibitor. Cells were incubated on ice for 5 
minutes, scraped from the wells and transferred to a 0.5ml eppendorf. All samples were 
kept on ice for a further 15 minutes, followed by sonication for 15 minutes and 
centrifugation at 10,000 x g at 4˚C for 15 minutes. Supernatants were collected in fresh 
eppendorfs and stored at -20˚C. 
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 2.4.2. Protein quantification 
 
 Total protein was quantified using the Bradford method with protein assay dye 
reagent (BioRad). The dye was diluted 1:5 in distilled water, and 200µl added to 10µl of 
each sample in triplicate on a 96-well plate. Protein samples were assayed against protein 
standards made from BSA serial dilutions. Colorimetric analysis was performed on a 
microplate reader at 595nm (OpsysMR; Dynex Technology). 
 
 2.4.3. Immunoblotting 
 
50µg protein was denatured for 5 minutes at 95˚C in sodium dodecyl sulphate 
polyacrylamide (SDS) loading buffer (100mM Tris-HCl, 4% SDS, 20% glycerol, 0.2% 
(w/v) bromophenol blue, 5% 2-mercaptoethanol, pH 6.8, all from Sigma). Samples were 
separated using SDS poly-acrylamide gel electrophoresis (SDS PAGE), either in 
homemade gels or pre-cast gels (4-20%, BioRad) for homemade gel percentages, see 
table 2.1. Homemade gels were run at 90V in ice-cold running buffer (25mM Tris-HCl, 
250mM glycine, 0.1% SDS, pH8.3) for 90 minutes. Precast gels were run at 150V for 40 
minutes. All gels were then wet – transferred onto a polyvinylidene fluoride (PVDF) 
membrane (BioRad) in cold transfer buffer (50mM Tris-HCl, 38mM glycine, 20% 
methanol, pH8.3) for 2 hours at 90V. For high MW proteins such as VEGFR2 and 
pVEGFR2, membranes were transferred at 4˚C for 15 hours at 0.15A.  
 
Resolving Gel 10% 12% Stacking Gel 4% (for 2 
gels) 
MilliQ water  3.3ml MilliQ water 7.3ml 
30% Acryl/Bis  4ml 30% Acryl/Bis 1.3ml 
1.5M Tris HCl 
pH8.8 
 2.5ml 1M Tris HCl 
pH6.8 
1.25ml 
20% SDS  50µl 20% SDS 50µl 
10% AMPS  50µl 10% AMPS 50µl 
TEMED  5µl TEMED 10µl 
 
Table 2.1. Homemade stacking and resolving gel recipes. 
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Membranes were blocked using 3% bovine serum albumin (BSA, Sigma) for an 
hour at room temperature with agitation, and then washed in solution of PBS and 0.01% 
TWEEN®20 (Sigma), PBS-T, 3 times for 5-minute intervals. This was followed by 
incubation with a primary antibody, also diluted in 3% BSA, at 4˚C overnight, with gentle 
agitation, dilutions of primary antibodies used are shown in table 2.2. The primary 
antibody is then poured off, and is followed by 3 consecutive 5-minute washes in PBS-T. 
The horseradish peroxidase (HRP) conjugated secondary antibody is either diluted in 3% 
BSA, and is added to the membrane and allowed to incubate at room temperature for 1 
hour. Following this incubation period, the antibody is again poured off, and washed 3 
times in PBS-T. Protein bands are then detected using Amersham ECL Prime Western 
Blotting Detection Reagent (GE Life sciences, USA), and chemiluminescence is detected 
using a Fujifilm LAS-1000. Western blots were also detected using fluorescent-labelled 
secondary antibodies (1:7000, Licor Odyssey) and incubated at room temperature for 1 
hour, followed by detection using Licor software. 
Antibody Dilution Supplier 
Rabbit anti-pan VEGF 
(A20) 
1:500 Santa Cruz 
Rabbit anti-ZO1  1:500 Invitrogen 
Mouse anti-occludin 1:500 Invitrogen 
Mouse anti – VE cadherin 1:500 BD Biosciences 
Mouse anti – HIF-1α 1:250 BD Bioscience 
Mouse anti – ERK 1:1000 Cell Signalling 
Mouse anti – pERK 1:1000 Cell Signalling 
Rabbit anti – VEGFR2 
(Ty1175) 
1:500 Cell Signalling 
Rabbit anti – pVEGFR2 
(Ty1175) 
1:500 Cell Signalling 
Rabbit anti – cleaved 
caspase 
1:500 Cell Signalling 
Mouse anti- α tubulin 1:1000 Santa Cruz 
Goat anti – β actin 1:200 Santa Cruz 
Goat anti-rabbit HRP 
conjugated secondary 
1:10000 Pierce Biotech 
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Goat anti-mouse HRP 
conjugated secondary 
1:10000 Pierce Biotech 
Donkey–anti mouse IRdye 
2˚ anti-body 
1:7000 Licor 
Donkey–anti rabbit IRdye 
2˚ anti-body 
1:7000 Licor 
 
Table 2.2. List of antibodies and concentrations at which they were used for 
immunoblotting 
 
2.4.4. Enzyme-Linked Immunosorbent Assay (ELISA) 
 
96 well cell culture plates (Fischer), were coated with the capture antibody (Pan 
VEGF AF293, and VEGF165b, MAB3405 R&D Systems) and we left overnight at room 
temperature with gentle agitation. The antibody was then discarded, and washed with 
0.05% PBS-T, three times. The pan VEGF plate and the VEGFxxxb plate was blocked 
with 1% BSA and 5% BSA respectively, for a maximum of two hours at room 
temperature, with gentle agitation. Following this period, the blocking solution was 
discarded from both plates, and then each plate was washed 3 times in PBS-T. A 
minimum volume of 50µl of whole eye, retinal or cellular protein was added to the plates 
in duplicate, as well as pan VEGF and VEGFxxxb standards (4000pg/ml, 2000pg/ml, 
1000pg/ml, 500pg/ml, 250pg/ml 125pg/ml, 62.5pg/ml, 31.25pg/ml and 15.625pg/ml). 
Samples were left to incubate at 37˚C for 1 hour, and discarded and the wells were 
washed with PBS-T three times. Following this wash, 100µl of detection antibody was 
added to each well(Pan VEGF, 840163, VEGF165b, BAF293, R&D systems), and allowed 
to incubate at room temperature for an hour, followed by 3 washes with PBS-T. 100µl 
Streptavidin-HRP (1:200) was added to each well, and the plates were wrapped in foil 
and allowed to incubate at room temperature for 20 minutes followed by the wash steps. 
Substrate solutions A and B were added (1:1, 100µl) to each well, and allowed to 
incubate for 20 minutes, wrapped in foil. To stop the reaction, 50µl Stop solution was 
added to each well and gently tapped to enable thorough mixing and the optical density 
was measured immediately at 450nm.  
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2.5. Immunfluorescence 
  
2.5.1. Cell Immunofluorence 
 
Cells grown on glass coverslips (13mm, Fischer Scientific), were treated with 
either VEGF165, VEGF165b or glucose and then 24 hours post–treatment, media was 
aspirated off and cells washed with PBS, 3 times. They were fixed at room temperature 
with 4% paraformaldehyde, permeabalised in 0.05% Triton-X (Sigma) in PBS and then 
blocked in 5% normal goat serum (Sigma) in PBS, all for 30 minutes at room temperature 
respectively. All cells were incubated in primary antibody in PBS, at 4˚C overnight 
(Mouse anti – occludin and rabbit – anti ZO1, both at 4µg/ml and both Invitrogen). 
Coverslips were then incubated with Alexa-Fluor 488 conjugated secondary antibody 
(1:500 Invitrogen) in PBS, for 45 minutes at room temperature. Cells were then incubated 
with Hoescht (1:5000, Sigma), for ten minutes at room temperature. Coverslips were then 
mounted on glass slides (Fischer) and mounted with Vectasheild (Fischer). 
 
2.5.2. Retina flat mount immunofluorescence  
 
 Rats were culled using a lethal dose of Euthatal (Merial Animal Health). Upon 
confirmation of death, eyes were enucleated using curved forceps and curved tip scissors 
(World Precision Instruments, WPI) and pierced using a 35g needle, and placed in cold 
4% PFA for 1 hour. Eyes were then placed in a petri dish with approximately 100µl PBS, 
and connective tissue surrounding the eye was carefully dissected away. An incision was 
made anterior to the ora serrate (figure 2.1A) and microdissection vannas scissors (WPI) 
were used to cut around the circumference of the eye. The iris, lens and cornea were 
discarded. One blade of a fine pair of forceps (WPI) was placed between the retina and 
the sclera (figure 2.1B) and slid gently around the eye cup, to separate the retina from the 
sclera, followed by 4 incisions being made at 90˚ to each other, vertically approximately 
2/3 down the eye. The sample was then turned over and sclera was carefully peeled back 
to expose the retina in a cross shape (figure 2.1C). Retinae are then transferred to a 24 – 
well plate and blocked in blocking solution (5% NGS, 3% Triton-X100 and 1%BSA) for 
2 hours. Blocking solution was then discarded and replaced with IB4 containing blocking 
solution (1:200). This was left to incubate at 4˚C overnight, followed by 3 PBS washes at 
5-minute intervals and then incubation with Alexa-fluor 488 (1:500, diluted in blocking 
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solution) at room temperature for 2 hours. After this incubation period, the fluid was 
carefully aspirated off and discarded, followed by 3 PBS washes at 5-minute intervals. 
After the last wash, samples were carefully flatmounted onto a microscope slide (VWR) 
and mounted with Vectashield containing DAPI. 
 
 
 
Figure 2.1. Schematic diagrams depicting where incisions are made to flat-mount retinae.  
 
 2.5.3. Cryosectioning and immunofluorescence 
 
 Animals were sacrificed and eyes were enuculeated and fixed in 4% PFA for 1 
hour. Eyes were dissected to eye cups are shown in figure 2.1B, and embedded in O.C.T 
medium (R.A Lamb), carefully ensuring no air bubbles were trapped in the eye cup. 
Samples were gently frozen in isopentane (Sigma), which was solidified upon contact 
with liquid nitrogen. Once the O.C.T had solidified, samples were stored at -20˚C. 
Samples were then sectioned using a Bright cryostat; 18µm thick sections were then 
placed onto Superfrost slides (Fischer Scientific), and also stored at – 20˚C.  
 When staining, slides were air dried at room temperature for 10 minutes, and the 
perimeter around sections was drawn around using a hydrophobic pen. Samples were 
washed with 1xPBS for 5 minutes, 3 times. This is followed by blocking for 2 hours at 
room temperature in block solution containing: 1% BSA, 2% normal goat serum (NGS) 
and 3% Triton X100. Following this 2-hour period, block solution was carefully 
discarded from slides and primary antibody, diluted in block solution at the appropriate 
concentration, was added to the slides and allowed to incubate at 4˚C overnight. Primary 
antibodies were then discarded from the slides gently, and washed in 1xPBS for 5 
minutes, 3 times. This was followed by addition of secondary antibodies (Alexa Fluor 
Ora Serrata 
Pupil 
Optic nerve 
(A) (B) 
Sclera 
Retina 
Incisions 
(C) 
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488 and 555 secondary antibodies, Invitrogen) diluted in block solution 1:500 for 2 hours 
at room temperature. Samples were then mounted in Vectashield containing DAPI and 
imaged on a confocal microscope at x40 or x63 maginification (Leica SPE).  
 
Antibody Working 
concentration  
Supplier 
Isolectin B4 (biotin conjugated) 
from Bandeiraea simplicifolia 
5µg/ml Sigma Aldrich 
Mouse anti-Neun 2µg/ml Millipore 
Mouse anti-occludin 4µg/ml Invitrogen 
Rat anti-ZO1 4µg/ml Invitrogen 
Rabbit anti – CD45 2µg/ml Abcam 
Rabbit anti GFAP 1µg/ml Abcam 
 
Table 2.3. Primary antibody concentrations used for immunofluorescence staining  
2.6. Image analysis  
 
2.6.1. Analysis of cell immunofluorescence 
 
Images were analysed using a custom made macro on Image J that creates a 
binary image of the picture and a mask overlay that subtracts the nucleus from each 
image, therefore excluding any nuclear staining. Staining intensity was then calculated 
relative to control cells.  
 
2.6.2. Image analysis of IB4 stained retinae 
 
Samples were imaged within 24 hours of staining using either an epifluorescence 
microscope (Nikon Eclipse E400) or a confocal microscope (Leica SPE). Retinae were 
imaged at 40x magnification and 5 images were taken per retina and analysed using 
Image J and Imaris software. Further details are described below. 
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2.6.2.1. Manual vessel count 
Vessels were manually counted per field of view using Image J and then an 
average of each eye was calculated based on the 5 fields of view taken per sample.  
 
  2.6.2.2. Integrated density 
All images were converted to 8 bit images and integrated density was measured 
using Image J. Average integrated density was calculated upon the 5 fields of view taken 
per sample. 
 
 2.6.2.3. Analysis using Imaris software 
The “surfaces” tool on Imaris software was used to calculate area and volume 
occupied by vasculature. Minimum vessel diameter was set to 3µm and areas highlighted 
that were deselected. The “surfaces” tool also calculated vessel straightness (tortuosity) 
and branch points and endpoints were manually positioned and vessel straightness was 
measured according to the following formula: height / length of vessel, as shown by 
figure 2.3. 
 
Figure 2.3. Calculation of vessel tortuoisity using Imaris software (www.bitplane.com). 
 
 2.6.3. Analysis of immunfluorescent retinae sections 
  
 Immunofluorescent cells of interest were either manually counted or total 
fluorescence per field of view was calculated using integrated density, as previously 
described.  
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2.4. DNA work 
  
 2.4.1. Transformation of bacteria and amplification of plasmid DNA 
 
 Chemically “competent” DH5-α cells (α-Select, Bioline) were aliquoted at 50µl, 
and were incubated with 5 -10 µl of DNA for 30 minutes on ice. Samples then underwent 
“heat shock” at 42˚C for 1 minute, followed by a further 5-minute incubation on ice. 
After this incubation period, 1ml of SOC medium (Invitrogen) was added to each sample, 
followed by another incubation period at 37˚C for 60 minutes. This would ensure that 
plasmids containing antibiotic resistance genes would be sufficiently expression, and 
therefore can be successfully used as a selection marker of all appropriately transformed 
bacteria. Samples were then carefully smeared, using a sterile spatula, on lysogeny both 
(LB) / agar plates (10cm2, Greiner) with the appropriate antibiotics. Plates were 
incubated at 37˚C overnight, following bacterial colony selection using a sterile, 
autoclaved pipette tip. DNA from these colonies were amplified using mini – prep kits 
(GenElute, Sigma). Clones that expressed the appropriate DNA were mixed with glycerol 
and frozen at -80˚C, ensuring multiple stocks and long term storage. For a larger scale 
amplification, a sterile pipette tip was used to scrape a fragment of a desired plasmid 
glycerol stock, and was expelled into a flask containing autoclaved 25% (w/v) LB 
medium, Flasks were incubated overnight at 37˚C with vigorous agitation of flasks. DNA 
from flasks was amplfied using a mega-prep kit (EndoFree Plasmid Megaprep Kit, 
Qiagen).  
 
 2.4.2. Cloning  
 
 Vectors were usually cloned by using restriction enzymes (New England Biolabs) 
to remove the insert fragment at the backbone vector to ensure “sticky end” ligation. 
Alternatively, digestion products were blunted using the Klenow polymerase digestion 
method, to adjust for the 5’ overhangs. Quality assurance of vectors were verified by 
restriction enzyme digest and sequencing. DNA was quantified using a NanoDrop 
ND1000 Spectrophotometer (LabTech Int.) using photospectroscopy at 260nm. 
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2.4.3. Restriction enzyme digests 
 
 To verify plasmids or generate fragements for further study, vectors were cut in 
specific regions using restriction enzymes (New England Biolabs). The reaction mix 
consisted of: 1µg DNA, 0.5µl per restriction enzyme, 1.6µl 10x buffer 1, 2, 3 or 4 (New 
England Biolabs) and 1.6µl BSA (New England Biolabs). The mixture was topped up 
with sterile, deionised water create a total of 16µl in volume. The mixture was incubated 
at 2hours at 37˚C.  
 
 2.4.4. Ligation of DNA 
 
 Follwing enzyme digest, purified DNA was inserted into vector backbones at a 
1:10 molar ratio of backbone : insert. To ensure correct, site-specific ligation, any 
residual “sticky ends” were melted at 45˚C for 5 minutes, followed by immediate cooling 
on ice.  Ligation mixes contained : 4µl of DNA, 5µl of ligation buffer (2x LigaFast, 
Promega) and 1µl of T4 DNA Ligase (LigaFast, Promega). The mixture incuabted at 4˚C 
overnight, followed by heat inactivation of the ligase at 65˚C for 10 minutes.  
 
2.4.5. Electrophoresis and gel extraction 
 
 A 3% (w/v) agarose gel was prepapred using 1xTBE buffer containing ethidium 
bromide (Sigma, 1:50 dilution). The samples generated from restriction enzyme digest 
were mixed with 6x loading dye (Blue/Orange loading dye, Promega) and loaded into the 
wells, with the final well used for a DNA ladder (1kb, Promega). DNA fragments were 
separated at 190V for a minimum of 30 minutes or until all bands are separated. Gels 
were imaged using ultraviolet transillumination (Geldoc EZ, BioRad).  
 Bands of interest were extracted using an ultraviolet light box (and appropriate 
protection) and a scalpel blade. DNA was was extracted from these isolated bands using a 
QIAquick Gel Extraction Kit (Qiagen)., and further quantified using a NanoDrop. 
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2.5. Production of Adeno-associated viruses (AAVs) 
 
 2.5.1. Plasmid transfection 
  
 A 3-plasmid transfection system was adopted in the production of all viruses. The 
plasmids used were: 
• viral genomic plasmid, expressing the gene of interest. This plasmid is based on a 
pd10 backbone and will be inserted between the capsid and the ITR. All maps are 
located in appendices. 
• A pHGTI helper plasmid containing various parts of the adenovirus 4 genome, 
and supplies the AAV with the necessary genes required for A AAV package and 
assembly. 
• An AAV2/8 packaging plasmid, containing the Rep78 gene and the viral capsid 
gene.  
 
The plasmids in a ratio of 1:3:1 respectively were combined with a polyethylenimine 
(PEI) and OptiMEM (Invitrogen, UK) transfection reagent to a total volume of 50ml, and 
allowed to equilibrate for 10 minutes at room temperature. PEI was used in the ratio of 
2.25:1 PEI: µg DNA. Following the incubation period, the transfection mix was divided 
amongst 20x 15cm cell culture plates of confluent HEK293t cells grown in DMEM 
(Invitrogen, UK), leaving 2.5ml per plate. The mixture was carefully added; drop wise, to 
ensure minimal disruption to the cell monolayer. The cells were placed back in the 
incubator and were allowed to grow as normal (37˚C and 5% CO2) until 2-days post-
transfection, when cells would be harvested. 
 
2.5.2. Virus Purification 
 
 Cells were scraped off the plate using cell scrapers and re-suspended in total of 
15ml TD buffer (140mM NaCl, 5mM KCl, 0.7nM K2HPO4, 25 mM Tris HCl (pH 7.4)). 
The lysate was then subjected to 4 freeze (-80˚C, 20 minutes) /thaw (37˚C, 20 
minutes)/vortex cycles to liberate the vector. A further volume of TD buffer was added to 
the lysate, to increase the volume to approximate 45ml, at which point 50U/ml benzonase 
(Sigma, UK) was added to the lysate and allowed to incubate at 37˚C for 1 hour, with 
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intermittent inversion of the falcon tube to allow sufficient mixing of the reaction 
mixture. This was to ensure that any non–packaged DNA in the lysate would be 
destroyed.  
The lysate is then centrifuged for 30 minutes (2000g) and the supernatant is then 
filtered through a 0.4µM PVDF filter (Millipore, UK). Upon confirmation that the lysate 
is endotoxin-free, filtered lysate was purified using a 2-step AKTA prime fast protein 
liquid chromatography (FLPC) ion-exchange system (GE Healthcare, USA), whereby the 
virus was purified according to its binding affinity to a resin, chosen according to its 
binding affinity with the virus. After the lysate has been prepared, fractionating tubes 
containing purified virus were chosen according to the peak they produced during the 
elution stage, and pooled together, and topped up with an equal volume of PBS-MK. The 
mixture was then divided between two Vivaspin 4 (GE healthcare) columns (10kDa) and 
centrifuged (5000g) for 15-minute intervals until the total volume of virus is 
approximately 100µl. The virus is then pooled into a tube and topped with an equal 
volume of PBS-MK, and then distributed into 30µl aliquots and stored at -80˚C.  
 
 2.5.3. Quantifying Viral Genome Copy Numbers 
 
 Viral genome copy numbers were determined by dot blot hybridisation and 
also by qPCR.  
  
  2.5.3.1. Titering of AAV using qPCR 
 
 To establish virus titre by qPCR, a PD10 plasmid was linearised using HindIII 
(New England Biosciences, USA) and diluted in a series of 6-fold dilution steps (105 – 
1011 molecules), to establish a standard curve. Each virus sample was diluted in a series of 
4 10-fold serial dilution steps, in triplicate. The amplification reaction mix contained: 5µl 
AAV2/8 sample or standard, 12.5µl Master Mix (Sigma-Aldrich, USA), 1µl ITR forward 
primer diluted to 100nM, 3.4µl ITR reverse primer diluted to 340nM, 1µl probe diluted to  
(Sigma-Aldrich, USA), 2.1µl ddH2O, resulting in a final volume of 25µl per well. A 
7900HT Fast Real-Time PCR system (Applied Biosystems, USA) was used to run the 
reactions (50˚C for 2 minutes, 95˚C for 10 minutes, 95˚C for 15 seconds and 60˚C for 1 
minute, 40 cycles). The Sequence Detection Systems programme (SDS 2.2.2, Applied 
Biosystems, USA) plotted a graph of cycle number against fluorescence intensity, where 
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the thresholds were determined on the most linear part of the graph. The value obtained at 
this point of the graph, the cycle number at threshold (Ct) value was plotted against 
number of molecules, equation of the best-fit line (y=mx+c) was then used to calculate 
the titre of the virus. 
 
  2.5.3.2. Titering of AAV using dot blot hybridisation 
 
Viral genome copy number was also established by dot blot hybridization. 
Aliquots of 5µl and 1µl of each virus was used to establish viral titre. To each sample, 
95µl or 99µl of ddH2O respectively was added, followed by 100µl proteinase k buffer 
(2x, Sigma) and 1µl proteinase k and the reaction mixture was incubated at 56˚C for 30 
minutes. Following this incubation, 20µg glycogen (Sigma), 21µl sodium acetate (3M 
NaOAc) and 500µl ethanol absolute (Sigma) was added to the mixture, which was 
followed by another 30-minute incubation, at -20˚C. The samples were centrifuged for 10 
minutes at 14000 rpm, followed by pellet wash with 70% ethanol (sigma) and an 
additional 2 minute spin. The pellet was then dissolved in 200µl sodium hydroxide 
(Sigma) and 10mM Ethylenediaminetetraacetic acid (EDTA, Sigma). A dilution series of 
plasmid DNA was used to calculate the viral genome copy number. When calculating the 
titre of the AAV.VEGF165b, a probe was used against the CMV promoter, however 
AAV.Null does not have a CMV promoter, and so an alternative biotinylated probe was 
made. The desired fragment was excised from a 1% agarose gel using a gel-extraction kit 
(Invitrogen). The fragment was resuspended in 65µl ddH2O, and a 34µl aliquot was 
denatured at 95˚C for 2 minutes, followed by a 2-minute incubation on ice. To the 
reaction mix, the following was added in this order: 10µl 5x labeling mix (containing 
random octomers), 5µl dNTP mix, 1µl Klenow fragment (New England Biosciences) and 
left to incubate at 37˚C for a minimum of 1 hour. The biotinylation reaction was 
terminated by adding 5µl 0.2M EDTA, pH 8. The probe was then precipitated by adding 
5µl 3M NaOAc, 150µl 100% ethanol and incubating at -20˚C for 20 minutes. The 
mixture was then centrifuged at 14000 rpm for 10 minutes at 4˚C. The probe was 
resuspended in 20µl TE buffer (Invitrogen). 5µl of the probe was added to 0.4M NaOH 
and 10mM EDTA in a total of 180µl, and denatured for 95˚C for 2 minutes, and then 
transferred to ice.  
Following preparation of samples and probe, a nylon membrane (GE Healthcare, 
USA) was attached to a dot blot manifold (Bio-Rad, USA). The wells to be used were 
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filled with 200µl ddH2O, vacuumed, and then filled with 200µl of each sample and 
diluted plasmid DNA, vacuumed and then filled with 200µl 0.4M NaOH 10mM EDTA, 
and vacuumed a final time. The membrane was dried for 2 hours at 95˚C. Meanwhile, the 
Church’s hybridization buffer (500ml NaHPO4, 10g BSA, 2ml 0.5M EDTA, 70g SDS, in 
1L ddH2O) was heated to 65˚C, and the membrane was placed in the warmed solution, 
and allowed to rotate for a minimum of 30 minutes. 5µl of the denatured biotinlyated 
probe was added to the mix, and allowed to hybridize overnight. Following this 
incubation, the Church’s mix is discarded, and the membrane is washed in 40ml 33mM 
NaPi for 5 minutes. This process is repeated a further three times, upon which the 
membrane is placed in a tray and submerged in block solution (5% SDS, 125nM NaCl, 
25nM NaPO4), for 5 minutes at room temperature, and then repeated for another 5 
minutes but with streptavidin diluted 1:1000 (New England Biosciences, USA). This is 
followed by two 5-minute washes in wash solution I (diluted block solution 1:10). The 
solution is then drained off and then replaced with 1:1000 biotinylated alkaline 
phosphatase (New England Biosciences, USA), diluted in block solution, for 5 minutes, 
followed by a 5 minute incubation in block solution alone and two 5-minute washes in 
wash solution II (50mM Tris-HCl, 1mM MgCl2, 1mM NaCl, pH 9.5). The membrane was 
removed, and placed on acetated and CDP-Star reagent mix (New England Biosciences, 
USA) was added to the blot for 5 minutes. The solution was drained and imaged on a 
Fujifilm LAS-500 at 470nm.  
 
 2.5.4 Assessment of Virus purity 
 
To establish the purity of the virus, proteins in the AAV2/8 virus were separated 
electrophoretically on a 10% polyacrylamide gel. Then 5µl and 1µl of each virus were 
tested with 5µl 2x Laemmli buffer (4% SDS, 20% glycerol, 10% 2-mercaptoethanol, 
0.004% bromphenol blue and 0.125 M Tris HCl, pH6.8.), 0µl and 4µl of PBS-MK 
respectively, giving a total of a 10µl reaction mixture for each sample. The samples were 
incubated at 95˚C for a maximum time of 10 minutes, and then loaded onto the gel. The 
samples were allowed to run until the blue dye ran to the bottom of the gel. The gel was 
then placed in 100ml fix solution (50% methanol, 7% acetic acid in dH2O) and was 
placed on a shaker at 55rpm for 30 minutes at room temperature. The solution was then 
poured off, and 100ml SYPRO® Ruby gel stain was added to the gel, and allowed to 
incubate overnight at room temperature at 55rpm, surrounded in foil to prevent entry of 
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light. Following this incubation period, the solution is poured off, and replaced with wash 
solution (10% methanol, 7% acetic acid in dH2O), for 30 minutes followed by another 30-
minute wash. After the second wash, the gel is washed in ddH2O for a minimum of 2 
minutes, and then imaged (GelDoc, Syngene), bands were expected at 80kDa, 65kDa and 
59kDa representing the presence of the VP1, VP2 and VP3 proteins within the AAV2 
capsid.  
 
In vivo work 
 
Mice and rats were maintained in the animal facility at University College 
London, University of Bristol and the University of Nottingham. Experiments were 
conducted in accordance with the Policies on the Use of Animals and Humans in 
Neuroscience Research, revised and approved by the ARVO statement for the Use of 
Animals in Ophthalmic and Vision Research. 
2.6. Intraocular Injections 
  
 Two types of intraocular injections were performed during the course of this 
study: intravitreal and subretinal. Intravitreal injections were used to deliver drugs to the 
eye for short–term evaluation of PBS and rhVEGF165b. Sub–retinal injections were used 
to deliever AAVs to the retina, and ensure long – term expression of our vector of 
interest.  
 
 2.6.1. Intravitreal injections 
 
 Intravitreal injections were performed under a dissection microscope in 
anaesthetised rats. Rats were anaesthetised with a single 10mg/ml intra-peritoneal (i.p) 
injection of Dormitor (medetomine hydrochloride, Pfizer, UK) and Ketaset (ketamine 
hydrochloride, Zoetis, USA). Pressure was applied either side of the eye using fine, 
curved forceps (World Precision Instruments), allowing the eye to become more exposed. 
The eye was then grasped at the conjunctiva and a 1.5cm 34-gauge hypodermic needle 
(Hamilton, Switzerland) attached to a 5µl syringe (World Precision Instruments) was 
inserted into the posterior chamber of the eye at a 45˚ angle. 5µl of either sterile PBS or 
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50ng rhVEGF165b was injected into the vitreous. Animals were then recovered and 
monitored for approximately 2 hours and returned to their cages with wet mash. 
  
 2.6.2. Subretinal injections 
 
 Subretinal injections were carried out under general anaesthesia using an 
operating microscope (Zeiss). Rats were anaesthetised as described above, and pupils 
were dilated using 1% w/v tropicamide (Bausch and Lomb). A 5mm coverslip (Fischer) 
was attached to the eye using Viscotears ® (Novartis Pharmaceuticals), to minimise 
corneal refraction of light. Fine forceps (World Precision Instruments) were placed either 
side of the eye with slight pressure, to expose the eye further. Whilst holding the eye at 
the conjunctiva, a 1.5cm, 34 gauge needle in a 5µl syringe (both Hamilton, World 
Precision Instruments). The needle was placed under the coverslip and pierced the sclera 
under the ora serrata and into the subretinal space. Contents of the syringe were then 
expelled into the subretinal space to form a retinal detachment or “bleb”. Animals usually 
had two subretinal injections, one in the superior region of the retina and one inferior. The 
needle was carefully removed to prevent backflow of injected material from the vitreous, 
and 1% w/v chloramphenicol (FDC International) was applied to the eye to prevent 
infection and the anaesthesia was reversed. Mice had 2 x 2µl injections and rats were 
subject to 2 x 4µl, 5µl or 6µl injections. 
2.7. Streptozotocin–induced diabetes 
 
2.7.1 Induction of 8–weeks diabetes 
 
Female Sprague-Dawley rats (200-300g, Harlan and Charles River in University 
of Bristol and University of Nottingham respectively, n = 45) were weighed and fasted 
overnight, prior to diabetes induction. The following morning, rats were given a single 
intraperitoneal (i.p) injection of streptozotocin (STZ, 50mg/kg, Sigma) freshly made in 
ice cold saline and a foil  covered bijou, control rats were injected with 300µl saline i.p. 
Rats were then given 30% sucrose (Fischer Scientific drinking water and normal food ad 
libitum. On the same day, a third of an insulin capsule (LinShin) was implanted 
subcutaneously using a 15g trocar under isofluorane anaesthesia (3-5%), to maintain body 
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weight over the following 8 weeks. On day 4 post–induction of STZ, blood glucose was 
tested from a bolus of blood extracted from the tail vein and assayed using an AccuChek 
monitor. Rats with blood glucose of 15mmol/l and above were deemed diabetic. If any 
STZ–injected rats did not become hyperglycaemic on day 4, they were re-fasted 
overnight and then re-injected with STZ the following morning. Diabetic rats were treated 
with 20ng/g rhVEGF165b (i.p, R&D Systems) biweekly for the experimental period or 
saline (n = 15 for both). Control groups remained untreated for the duration of the 
experiment. Drinking water supplemented with 30% sucrose was replaced with normal 
drinking water 3–days post induction of diabetes. Oestrus stages were not controlled 
during the experiment. Rats were weighed biweekly for the duration of the experiment. 
 
2.7.2 Induction of 1-week diabetes 
 
Female Sprague dawley rats (200- 250g, Harlan) were weighed and fasted 
overnight prior to induction of diabetes. The following morning, rats were injected with 
freshly prepared STZ in PBS (50mg/kg) as mentioned previously. On day 6 post-
induction, blood glucose was assessed using an Accuchek monitor, and those with a 
blood glucose ≤15mmol/l were sacrificed. Those that had higher blood glucose were 
subject to an intravitreal injection of vehicle (5µl PBS) in one eye and VEGF165b (50ng) 
in the contralateral eye. Control animals had vehicle in one eye and no injection in the 
contralateral eye. On day 7, rats were terminally anaesthetised and subject the Evans’ 
blue dye perfusion technique. 
2.8. Evans’ blue dye perfusion  
  
 An Evans’ blue dye perfusion experiment was conducted to assess BRB 
breakdown. Evans Blue has been shown to quantitatively measure vascular leakage in the 
retina (Xu et al., 2001), therefore a similar protocol has been adopted with minor 
changes.  
Evans’ blue dye (Sigma) was prepared by dissolving it in normal saline (45mg/kg) 
and filtered were anaesthetised with 10mg/ml Vetalar (ketamine hydrochloride, 
Boehringer Ingelheim, Germany) and Dormitor (medetomine hydrochloride, Pfizer, UK) 
with additional anaesthesia provided as needed. The left jugular vein and femoral artery 
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were cannulated with with 33 gauge tubes filled with saline and heparinised saline 
(400UI/ml) respectively. Evans’ blue was injected via the left jugular vein over 10 
seconds, followed by 100µl saline. Two minutes post-infusion, 200µl blood was removed 
from the femoral artery, to establish the initial Evans’ blue concentration. Fifteen minutes 
post-infusion, 100µl blood was removed, and this volume was withdrawn every 15 
minutes for two hours, which would determine the time-averaged Evans blue-plasma 
concentration. Eyes were kept moist using Viscotears (Novartis Pharmaceuticals).  Two 
hours post-infusion, the chest cavity was opened and 200µl blood was withdrawn from 
the left ventricle, to determine the final plasma Evans blue concentration. Following this, 
the rats were perfused with 50ml saline through the left ventricle at a physiological 
pressure of 120 mm Hg, to flush out Evans’ blue from the circulation.  
Immediately after perfusion, both eyes were enucleated and bisected at the 
equator. The retinas were dissected and weighed (wet weight) and then dried at 70˚C 
overnight, and weighed again (dry weight). 120µl formamide was added to each sample 
and was kept at 70˚C overnight, to extract the Evans blue from the samples. Following 
the dye extraction, the samples were centrifuged at 12000 rpm at 4˚C for 45 minutes. The 
supernatant was used to determine the Evans blue concentration, and was diluted 1:1 in 
formamide.  
 The blood samples were kept on ice through the experiment and then centrifuged 
at 4˚C at 12000 rpm for 45 minutes and diluted 1/100 in formamide (Sigma). The 
absorbance of all samples was then measured at 620nm, and the concentration of Evans’ 
blue dye in formamide was calculated using a standard curve of Evans’ blue in 
formamide. Formulae for solute flux and permeability – surface area product (PA) are in 
the appendix.  
2.9. Imaging of the eye in vivo 
 
 To assess changes in vasculature, thickness and overall atrophy in vivo, animals 
were imaged using the Spectralis ® (Heidelberg Engineering, Germany). All in vivo 
imaging was carried out under general anaesthesia, followed by dilation of the pupil using 
tropicamide. Following imaging, animals were then recovered or sacrificed according to 
experimental end point. All imaging was quantified using Image J by calibrating the scale 
appropriately, circling a region of interest and measuring the area of that region.  
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 2.9.1. Scanning Laser Ophthalmoscopy  
 
Scanning Laser Ophthalmoscopy (SLO) was used to assess changes in geographic 
atrophy in the retina using the Spectralis HRA with a 55˚ lens (Heidelberg engineering). 
Anaesthetised animals were positioned in front of the lens such that the whole eye was in 
focus, with the pupil in the centre. This was facilitated using the infrared setting (790nm) 
on the machine (figure 2.XA). Once the optimal position was acquired, settings were 
changed to the 488nm laser at a power setting of 95% and images were taken, and an 
average was taken over 30 individual frames. One image was captured focused on the 
retina and a second image was taken focused as much on the choroid as the camera would 
allow (figure 2.4A).  
 This was then repeated for the contralateral eye.  
The same protocol was adopted when assessing fluorescein leakage in the 
choroid, with the addition of a single ip injection of 200µl of 2% fluorescein (Sigma) in 
sterile water. Fluorescein was injected immediately before dilation of pupils, and images 
were taken over a 90 second period, as decribed above.  
 
 2.9.2. Optical Coherence Tomography 	 		 Retinal thickness was measured using spectral domain optical coherence 
tomography (SD-OCT) with minor modifications to accommodate the rat eye. To ensure 
that differences in refraction power, eyeball length, focal length and maximal pupil 
dilation between humans and rats could be adjusted for (Guo et al. 2010), a customised, 
achromatic 30˚, ±25 – diopter doublet lens was attached to the machine. A single B–scan 
(figure 2.4) was taken at 8 different points in the retina, as shown by figure 2.4C. 
 OCT images were usually carried out immediately after capturing SLO images 
under the same anaesthesia, with additional maintenance of anaesthesia as required. Eyes 
were kept moist using 0.3% w/v hypromellose drops (Martindale Pharma) and were 
carefully removed using cotton swabs. Already – dilated eyes were focused on, with 
particular emphasis on the radial lines formed by the nerve fibre layer on the infrared 
setting. When a satisfactory position was acquired, OCT mode was selected and cursor 
was placed according where the desired B – scan would take place, and a 30 frame image 
was captured, as well as the location at which the B – scan was taken. This ensured that at 
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subsequent monthly time points, the software would recognise where the image was taken 
and re-capture a B-scan at that same place.  	
	 		
Figure.2.4. in vivo imaging using the Spectralis ® HRA + OCT. 
Anaesthetised animals were imaged using a 55˚ lens under infrared settings (A) to 
establish a central optic disc. The setting was then switched to a confocal SLO 488nm 
laser to assess autofluorescence (AF) of the retina and choroid. OCT images (B) were 
also taken under the same anaesthesia to determine thickness of the retina. Individual B–
scans (C) were captured at 8 different points within the retina, and repeated at these same 
points, monthly.  
2.10. Electroretinograms 
 
Changes in retinal neural architechture were assesed in vivo by measuring the 
electroretinogram (ERG) once a month (Espion 6, Diagnosys UK) in dark adapted 
Infrared AF - retina  AF - choroid (A) 
(B) 
(C) 
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(minimum 5 hours) diabetic and non-diabetic Lewis rats. Lewis rats were anaesthetised 
using Dormitor and Ketaset as described above. Pupils were dilated using tropicamide 
and phenylephrine (1% w/v, Bausch & Lomb, UK). Anaesthetised rats were then 
connected to four electrodes, 2 on each cornea, 1 under the tongue and 1 in the tail to 
ensure a complete circuit with minimal external electrical activity interfering with the 
readings. Corneal electrodes were placed on eyes with Viscotears ® (Novartis) on the 
eyes to ensure good connectivity and low impedence within the circuit. Following an 
additional 5 minute dark adaptation, an 11-step scotopic program with light intensities 
ranging from 0.0001 (S)cd.s/m2 to 75.28(S)cd.s/m2 was started. After the scotopic 
programme, a 6-step photopic programme was started following a 5-minute light 
adaptation, with intensities from 0.1(S)cd.s/m2 to 75.28 (S)cd.s/m2.  
2.11. Laser–induced choroidal neovascularization 
 
 To assess the anti-angiogenic properties of vectors, mice were subject to laser 
induced CNV 2 - weeks post – subretinal virus administration. Mice were anaesthetised 
and 3 laser burns were delivered to retina of each eye using a slit – lamp – mounted diode 
680 nm laser (Keeler, UK). The laser burns were at 210mM for 100ms with a 100µm spot 
diameter (Balaggan et al. 2006). A successful breach of Bruch’s membrane was noted 
down when a small gas bubble was evident, subretinally. Burns where there was no 
“successful” subretinal bubble were excluded from further analysis. This was repeated in 
the contralateral eye. Mice were then subject to fluorescein angiography at 3, 7 and 14 
days post – laser, using the Spectralis ® (Heidelberg Engineering), as described 
previously. On day 14, mice were sacrificed after imaging and choroids were flatmounted 
and stained for IB4. Flatmounts were imaged using a Leica SPE confocal microscope 
Analysis of in vivo and ex vivo images were carried out using Image J and any burns that 
had merged were also excluded from analysis.  
2.12. Statistical Analyses 
 
Unless otherwise stated, all data are shown as mean ± SEM. All data, graphs and 
statistical analyses were calculated with Microsoft Excel (Microsoft Office Software), 
GraphPad Prism (GraphPad Software Inc.), Image J and Imaris (Bitplane). Parametric 
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and non-parametric statistical tests were chosen upon the results of the D’Agostino-
Pearson normality test in Graphpad Prism (GraphPad Software Inc.). All results were 
considered statistically significant at p<0.05 (*), p<0.01 (**) and p<0.001 (***).  
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Chapter 3: Assessing RPE 
barrier properties in vitro
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3.1. Introduction 
 The retina is the most metabolically active tissue in mammals (Xu et al. 2011) and 
therefore requires a rich blood supply. The inner retina, including retinal ganglion cells 
(RGCs), Müller glia and amacrine cells, is supplied by the central retinal artery, which 
branches into a complex retinal microvascular network. The outer retina, including RPE 
and photoreceptors, is supplied by the choriocapillaris, a dense area of fenestrated 
capillaries in the choroid (Xu et al. 2011). The BRB is similarly subdivided. The inner 
BRB is formed by retinal microvascular endothelial cells and the outer BRB, formed by 
the RPE, both of which exert a protective role over the inner and outer retina respectively 
from cytokines and inflammatory factors of the systemic circulation (Omri et al. 2011). 
Traditionally, PDR and DME are thought to be diseases of inner BRB dysfunction, as 
most exudate formation occurs as a result of lipid leakage, protein leakage and cyst 
formations from microvascular endothelial cells with compromised TJs. As a result, less 
emphasis has been placed on dysfunction of the RPE and the outer BRB in the 
pathogenesis of DR. 
The RPE is a monolayer of epithelial cells and provides a selectively permeable 
barrier to ions, lipids and fluid between the outer retina and the choriocapillaris. 
Paracellular flux is highly regulated by tight-junctions (TJs) in the cell membrane that 
allow the RPE layer its barrier function, including the family of claudins, occludin and 
the zonula occludens (ZO) family (Xu et al. 2011). RPE are polarised cells and express 
VEGF receptors (Ivana Kim et al. 1999) and GLUT receptors (Takata 1996) and also 
supply VEGF and glucose to the choriocapillaris and neural retina to maintain synchrony 
with the high metabolic demand of the rest of the eye and maintain fenestrations of the 
choroidal endothelium respectively (Simó et al. 2010). When the extracellular 
environment stresses RPE, for example during hypoxic conditions where there are high 
levels of VEGF, TJs such as occludin and the claudins are compromised and undergo 
phosphorylation and ubiquitination, causing their internalisation (Murakami et al. 2009). 
Upon internalisation, TJs are either degraded or recycled back to the cell membrane 
(Harhaj & Antonetti 2004).  It is this internalisation of TJs that allows increased 
paracellular transport of fluid, which can then accumulate in the subretinal space. If left 
unimpeded, this can result in oedema and retinal detachment. 
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 Pigment epithelium derived growth factor (PEDF) and VEGF are two of the 
principal growth factors secreted by the RPE, and exert opposing actions. PEDF is 
proposed to have anti-angiogenic properties (Dawson 1999) and VEGF is well known for 
its potent angiogenic activity (Leung et al. 1989). Whilst it is well-documented that up-
regulated VEGF results in TJ breakdown (Antonetti 1999), reductions in anti-angiogenic 
PEDF also elicit a similar effect (Dawson 1999), and by increasing PEDF, VEGF-
induced increases in RPE permeability are inhibited (Simó et al. 2010).  
Relative to RECs, the importance of RPE and their involvement in the 
pathogenesis of DME has only recently been established. Changes in the RPE proteome 
occur early on in patients with DR in a “pre-retinopathic” phase, whereby markers of 
increased metabolism and oxidative stress are up-reglated (Decanini et al. 2008). Patients 
also showed increased fluorescein leakage from the RPE in the peri-macular region, 
independent of cystic changes, a characteristic of inner BRB breakdown (Weinberger et 
al. 1995; Xu et al. 2011). In experimental models of diabetes, studies have shown an 
impaired C-wave amplitude (Pautler & Ennis 1980), leakage of fluorescein in the outer 
retina  (Xu & Le 2011) and morphological changes in RPE (Aizu et al. 2002), all 
indicative of RPE dysfunction.  
 
There is mounting evidence to suggest that dysfunction of the RPE layer has a 
significant role in the progression of DME. I wanted to investigate this notion with the 
hypothesis VEGF-induced dysfunction of the ORB may be prevented using anti-
angiogenic therapy. To address this hypothesis further, this study looked at cultured 
primary human RPE (primary hRPE) and established if VEGF and hyperglycaemia 
induced changes in barrier properties such as reduced TJ expression and increased 
paracellular flux, as published in the literature, could be prevented using VEGF165b. 
Furthermore, I wanted to establish an in vitro model of DME using cultured RPE and 
culturing them in high-glucose environments to observe changes in TJ integrity, and if so, 
to reverse them with VEGF165b treatment.   
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3.2. Methodology  
Human primary RPE (1˚RPE) were extracted from donor eyes (Bristol Eye 
Hospital and Institute of Ophthalmology) and were cultured for use in vitro. RPE were 
assayed for tight junction (TJ) immunofluorescence and protein expression with and 
without VEGF intervention. Furthermore, RPE were assayed for changes in paracellular 
flux by assessing trans-epithelial electrode resistance (TEER) upon VEGF treatment. 
Hyperglycaemia assays were also carried out on RPE cells, and assayed for TJ integrity 
through occludin immunofluorescence and protein expression and TEER, with and 
without VEGF co-treatment. 5mM and 35mM glucose were added to media already 
supplemented with glucose (17mM). These concentrations were chosen because RPE 
cultured in media without supplemented glucose were difficult to maintain. Conditioned 
media from these treatments were assayed for VEGF expression (ELISA). Unless 
otherwise stated, all replicates are technical replicates. All methods are described in detail 
in Chapter 2. 
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3.3 Results 
3.3.1. Effect of VEGF165 on 1˚RPE cells and tight junction integrity 
 
To assess the effect of VEGF165 on the outer BRB in vitro, RPE cells were subject to a 
rhVEGF165 dose-escalation experiment. Staining was quantified using ImageJ (see 
chapter 2 “Materials and Methods”). As the dose of VEGF165 increased, occludin 
fluorescence intensity decreased (figure 3.1A). There was a significant reduction upon 
1.0nM VEGF165 treatment (0.75±0.03, figure 3.1B) when compared with untreated cells. 
This is further noticeable when the dose increases to 2.5nM (0.592±0.0346) and 5.0nM 
(0.461±0.0628), when compared with untreated controls. 
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Figure.3.1. VEGF165 dose dependently reduces TJ expression in RPE cells. 
RPE cells were treated with increasing doses of rhVEGF165 for 24 hours (n=3). Cells were 
fixed and (A) stained for TJ marker, occludin (green) and nuclei co-stained with Hoechst 
(blue). Normalised data (B) showed that as the dose of VEGF165 increases, occludin 
expression decreases at the cell membrane achieving significance at 1.0nM (p<0.05), 
2.5nM (p<0.001) and 5.0nM (p<0.001) (One-way ANOVA, Dunnett's post-hoc, *p<0.05, 
***p<0.001). 
 
Although a loss in TJs is indicative of increased barrier permeability in vivo, to 
confirm that TJ loss results in increased barrier permeability in vitro, RPE cells were 
plated on 8-well ECIS plates, and TEER was measured upon VEGF165 treatment (0, 0.1, 
0.5, 1.0, 2.5 and 5.0nM). As time progressed, permeability increased in all groups treated 
with VEGF165, however, it became significant upon 2.5nM and 5nM treatment (figure 
3.2A). Interestingly, 1nM treatment showed no significant change in paracellular flux, 
however, when calculating the area under the curve (figure 3.2B), there was a clear trend 
showing that as VEGF165 concentration increased, so too did the area under the curve, 
indicating a trend in increased paracellular flux. These data were normalised and (figure 
3.2C) and then log transformed (figure 3.2D) showing an EC50 of 0.97nM, further details 
are in chapter 2 “Materials and Methods”.  
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Figure 3.2 VEGF165 dose-dependently increase paracellular flux in RPE cells. 
RPE cells were plated on ECIS plates (n=3, mean+SEM) and subject to a range of 
VEGF165 concentrations (0 – 5.0nM). Impedance was measured every hour for 24 hours 
and permeability was calculated as 1-resistance. As concentration increased, so did 
permeability (A) achieving significance at 15 hours post treatment at 5.0nM and 20 hours 
post treatment at 2.5nM (2-way ANOVA with Bonferroni post-hoc, significance shown at 
5-hour intervals). This was reflective in the area under the curve (B). When normalised 
(C) and then transformed (D) and constrained between 0 and 100%, the EC50 could be 
calculated (red line) as 0.97nM (*p<0.05, **p<0.01, ***p<0.001). 
 
The RPE layer has been proposed to be the primary source of VEGF in the outer 
retina in vivo, and that VEGFR1 and VEGFR2 are preferentially expressed on the 
basolateral aspect of the cell (nearest to the choriocapillaris) (Saint-Geniez et al. 2009a). 
Decreased VEGFR2 expression in endothelial cells is associated with a reduction in 
permeability (Whittles et al. 2002), and so I hypothesised that an increase in VEGFR2 
expression in RPE cells would correlate with a decrease in TJ expression. To test this 
hypothesis, RPE cells were treated with VEGF165 of varying doses for 24 hours, and 
protein lysate was assayed by western blot for occludin expression and VEGFR2 
expression.  
 As the concentration of VEGF165 increased, occludin expression decreased (figure 
3.2A) as it did in figure 3.1A. Again, much like figure 3.1A, the change in expression was 
significant upon 1.0nM VEGF165 treatment (0.724±0.0302, figure 3.2B) and a greater 
decrease was seen at 2.5nM VEGF165 (0.558±0.153) and 5.0nM (0.424±0.0506), with an 
IC50 of 1.11nM (figure 3.2C, red line). VEGFR2 expression increased, upon an increase 
in VEGF165 concentration (figure 3.2B), again being significant at 1.0nM (0.929±0.0417) 
and further increasing with 2.5nM (0.996±0.0100) and 5nM (0.998±0.0142) with an 
EC50 of 0.62nM (figure 3.2C, blue line).  
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Figure 3.3. VEGF165-induced occludin degradation is mediated through VEGFR2 in RPE 
cells. 
RPE cells (n=2, mean+SD) were subject to VEGF165 treatment of varying doses for 24 
hours (0nM – 5.0nM). Protein lysate was then extracted and immunoblotted for occludin 
and VEGFR2 expression. Membranes were stripped and reprobed for α-tubulin 
expression to confirm equal loading of protein (A). VEGF165 significantly reduced 
occludin expression at 1.0nM, 2.5nM and 5nM (B). VEGFR2 expression conversely 
increased upon VEGF165 treatment, also significantly at 1.0nM, 2.5nM and 5nM (B). 
These data were normalised, log transformed and constrained to 0% and 100% to 
calculate IC50 (red line) and EC50 (blue line) of occludin (1.11nM) and VEGFR2 
(0.62nM) respectively (C). (One way ANOVA with Dunnett’s post hoc test, *p<0.05, 
**p<0.01, ***p<0.001) 
3.3.2 Effect of VEGF165b on primary human RPE tight junction integrity 
 
It has been hypothesised that diabetes induces a switch in splicing in the human 
eye that favours pro-angiogenic isoforms relative to anti-angiogenic isoforms (Perrin et 
al. 2005), and that this imbalance of both isoforms attributes to DR. VEGF165b is anti-
angiogenic in the eye as shown by a reduction in neovascular area in rodents with laser-
induced CNV, a model for AMD (Konopatskaya et al. 2006). It is possible that if the 
imbalance of both isoforms is redressed, VEGF165b may also elicit an anti-angiogenic 
response in the diabetic eye and therefore may be a potential target in treating PDR. To 
test the feasibility of using VEGF165b, RPE cells were subject to a dose-escalation 
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experiment using VEGF165b at 0, 0.1, 1.0, 2.5 and 5.0nM, to keep consistent with figure 
3.2. Cells were then assayed for changes in TEER over 24 hours.  
There was a slight increase in paracellular flux upon VEGF165b treatment, which 
was not dose dependent and not significantly different when compared to 0nM when 
assessing changes in permeability (figure 3.4A). Interestingly, when measuring area 
under the curve, it indicated that as the VEGF165b concentration decreased, paracellular 
flux increased with an IC50 of 0.7nM. 
 
Figure 3.4 Increasing doses of VEGF165b has minimal effect on paracellular flux 
RPE cells were plated on ECIS plates (n=3, mean+SEM) and treated with varying 
concentrations of VEGF165b (0nM – 5.0nM) and impedance was measured over 24 hours 
(A). There was no significant difference between any concentration at any time point over 
24 hours (2-way ANOVA with Bonferonni’s post hoc). When measuring area under the 
curve, data were normalised and log transformed to show an IC50 of 0.7nM.  
 
I wanted to assess the ability of VEGF165b to abrogate VEGF165 induced changes 
in TJ expression and permeability, however we needed to establish at what proportions of 
each drug to co-treat with and how this may affect solute flux. To assess this, I treated 
RPE cells with a single concentration of VEGF165 and increasing VEGF165b, thereby 
changing the proportion of VEGF165: VEGF165b. I chose 1nM VEGF165 as my constant as 
the IC50 (figures 3.1 and 3.3) or EC50 (figure 3.2) of VEGF165 was approximately 1nM 
when assessing TJ dysfunction and it was also the minimum concentration required to 
induce any change in TEER. Once treated, TEER was assayed for 24 hours. When 
compared with untreated wells (figure 3.5A), the minimum concentration required to 
prevent VEGF165–induced changes in solute flux was 0.2nM VEGF165b at 24 hours 
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(0.972±0.105). When assessing area under the curve (figure 3.5B), the IC50 was 
calculated as 1.07nM VEGF165b. 
   
Figure 3.5. VEGF165 co-treatment with a dose escalation of VEGF165b reduced 
paracellular flux.  
RPE cells were treated with different proportions of VEGF165b: VEGF165 and TEER was 
measured over 24 hours (n=3, mean+SEM). (A) At 24 hours, there was a significant 
difference between 1.0nM VEGF165 + 0.0nM VEGF165b and untreated wells and 1.0nM 
VEGF165 + 0.1nM VEGF165b (***p<0.001, two-way ANOVA with Bonferroni’s post 
hoc). When the area under the curve was assessed, normalised and log transformed (B), 
the IC50, 1.07nM VEGF165b, could be determined.  
 
It has been published that 2.5nM VEGF165b co-treatment with 2.5nM VEGF165 
prevented HUVEC migration (Bates et al. 2002b). Given that VEGF165 and VEGF165b 
bind to VEGFR2 with equal affinity (Woolard et al. 2004), I hypothesised that 2.5nM 
VEGF165b would be sufficient to prevent VEGF165-induced changes in permeability by at 
least 50%.  RPE were treated with 2.5nM VEGF165, 2.5nM VEGF165b and 2.5nM 
VEGF165 co-treated with 2.5nM VEGF165b for 24 hours. Cells were then fixed and stained 
for ZO1, an alternative TJ marker, and fluorescence intensity was measured using 
ImageJ.  
Figure 3.6 shows that VEGF165b by itself had no significant effect on ZO1 
expression or location (86.3%±25.0). VEGF165 significantly reduced ZO1 expression 
(43.7%±5.6), similar to when 2.5nM VEGF165 reduced occludin expression in figure 3.1. 
Co-treatment of VEGF165 and VEGF165b (“both”) showed no significant change in ZO1 
expression (84.3%±5.6), compared to untreated, but showed a significant difference 
relative to VEGF165 treated wells.  
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Figure 3.6 VEGF165b can restore VEGF165-induced changes in ZO1 expression. 
RPE cells (n=3, mean+SEM) were treated with 2.5nM VEGF165b, 2.5nM VEGF165 and 
2.5nM of both VEGF165 and VEGF165b for 24 hours. (A) Cells were stained for ZO1 
(green) and fluorescence intensity was calculated. VEGF165b had no effect on ZO1 
staining intensity (B). VEGF165 treatment reduced ZO1 intensity significantly, which was 
restored upon 2.5nM VEGF165 co-treatment. (One-way ANOVA, Tukey post-hoc test, 
*p<0.05). 
 
To confirm the results of figure 3.6, RPE cells were again treated with 2.5nM 
VEGF165, 2.5nM VEGF165b and 2.5nM VEGF165 co-treated with 2.5nM VEGF165b for 24 
hours. Protein lysate was extracted and assayed for ZO1 and occludin expression (figure 
3.7). Similarly to figure 3.6, VEGF165b has no detrimental effect on ZO1 and occludin 
expression. VEGF165 reduces ZO1 and occludin expression (0.126±0.09 and 0.227±0.15 
respectively). VEGF165 and VEGF165b co-treatment shows no significant TJ loss, as there 
was no significant difference when compared with untreated control wells.  
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Figure 3.7 VEGF165b ameliorates VEGF165-induced TJ degradation. 
RPE cells treated with 2.5nM VEGF165, 2.5nM VEGF165b and 2.5nM VEGF165 co-treated 
with 2.5nM VEGF165b for 24 hours (n=3, mean+SEM). Protein lysate was immunoblotted 
for ZO1 and occludin expression. Membranes were stripped and reprobed for α-tubulin 
expression. There was no significant difference between VEGF165b treated cells in both 
TJ markers. 2.5nM VEGF165 significantly reduced occludin and ZO1 expression, which 
was restored upon co-treatment with 2.5nM VEGF165b. (one-way ANOVA, Tukey post-
hoc test, *p<0.05). 
 
I have shown that VEGF165b can ameliorate VEGF165–induced TJ reorganisation, 
but I wanted to see if this would translate, functionally. I hypothesised that VEGF165b co-
treatment would prevent VEGF165–induced changes in permeability, as it did with TJ 
immunofluorescence and protein expression (figures 3.6 and 3.) To assess this, I 
performed the same experiment as above (figures 3.6 and 3.7) and measured TEER.  
 As predicted, 2.5nM VEGF165 treatment caused a significant increase in 
permeability over time compared to untreated wells (10%±1.30 at 15 hours). RPE treated 
with 2.5nM VEGF165b alone showed no significant difference at any time point when 
compared to untreated wells (figure 3.8A). There was however a significant difference 
between VEGF165b-treated wells and VEGF165-treated wells across all time points 
(p<0.001 at every time point). There was no significant difference between wells treated 
with both VEGF165 and VEGF165b and untreated wells, however there was a consistently 
significant difference between VEGF165 treated wells and wells treated with both 
isoforms (p<0.001 at every time point).  
 
Figure 3.8 Co-treatment of both isoforms restores VEGF165 – induced changes in 
permeability. 
RPE cells treated with 2.5nM VEGF165, 2.5nM VEGF165b and co-treatment of 2.5nM of 
both isoforms (A) showed that VEGF165 significantly increased permeability relative to 
untreated wells and that this was abrogated by co-treatment of VEGF165b (2-way 
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ANOVA with Dunnett’s post hoc, **p<0.01, ***p<0.001). Area under the curve analysis 
showed that this was only reflected when comparing VEGF165 and untreated wells (n=4, 
mean+SEM, 1-way ANOVA, Tukey’s post-hoc test, *p<0.05). 
3.3.3 Effect of VEGF and hyperglycaemia on 1˚RPE cells 
  
It is well established that hyperglycaemia-induced increased activity of PKCβ and 
PKCδ, NFΚΒ and p38 MAPK result in pericyte death and retinal microvascular 
dysfunction and subsequent hypoxia/ischaemia (Aiello 2002; Geraldes et al. 2009). As a 
result, VEGF165 is up-regulated in the diabetic retina causing excessive VEGFR1 and 
VEGFR2 stimulation and TJ reorganisation (Antonetti 1999a). As there is an increase in 
pro-angiogenic isoforms relative to anti-angiogenic VEGFxxxb isoforms in the diabetic 
eye (Perrin et al. 2005), we wanted to see if we could induce an in vitro model of 
hyperglycaemia-induced outer BRB dysfunction in 1˚RPE, and if any pathology could be 
reversed with VEGF165b.  
To test the hypothesis that hyperglycaemia could induce TJ reorganisation in RPE 
cells, RPE were cultured in difference concentrations of glucose: none (0mM), low 
glucose (5mM) to represent normal glycaemic levels, high glucose (35mM) to represent 
diabetic blood glucose levels and mannitol (5mM glucose + 30mM mannitol) as an 
osmotic control. Many groups have identified changes in RPE barrier properties between 
20mM glucose and 40mM glucose treatment (Gillies et al. 1997; Qin et al. 2013). 
However, as there has been conflicting evidence using 20mM treatment, whereby some 
groups see changes in barrier properties and others do not (Villarroel et al. 2009), 
therefore I chose 35mM to represent diabetic conditions as a compromise.  
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Figure 3.9. VEGF165b prevents hyperglycaemia – induced TJ degradation in RPE cells. 
RPE cells were cultured in 5mM glucose ± 2.5nM VEGF165b, 35mM glucose ± 2.5nM 
VEGF165b and mannitol ± 2.5nM VEGF165b for 24 hours and immunoblotted against 
occludin. Blots were then stripped and reprobed for β-actin (A). There was a significant 
decrease in occludin expression (B) upon 35mM glucose treatment, which was reversed 
upon 2.5nM VEGF165b co-treatment (n=2, mean+SD, 1-way ANOVA, Tukey’s post-hoc 
test, **p<0.01). 
 
After 24 hours, protein lysate was extracted and immunoblotted against occludin 
and actin (figure 3.9). I hypothesised that high glucose treatment will reduce TJ 
expression and that this may be reversed with VEGF165b co-treatment.  
Cells cultured in 35mM glucose expressed significantly less occludin 
(0.332±0.066) than untreated cells (0.776±0.0660). There was no significant difference in 
occludin expression upon 5mM glucose (0.567±0.101) or mannitol (0.655±0.109) 
treatment. Co-treatment of 35mM glucose and 2.5nM VEGF165b restored occludin 
expression (0.542±0.0684) relative to 35mM glucose alone. Although there was no 
significant difference between 35mM and 35mM + 2.5nM VEGF165b, there was a trend 
that indicates VEGF165b is able to reduce TJ degradation. There was no significant 
difference between any VEGF165b-treated group and untreated groups. 
 
 As it is well established that VEGF is secreted from RPE, particularly when 
stressed (Shima et al. 1995), I assessed the conditioned media from the above assay 
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(figure 3.9) for total VEGF isoforms by ELISA. I observed that upon treatment with 
35mM glucose, there was a significant increase in VEGF secretion by RPE (9.05±1.03) 
relative to untreated wells (4.78±0.160). There was no significant difference between 
mannitol treated wells and untreated wells. There was a significant difference between the 
amount of VEGF secreted by 5mM treated RPE (2.41±1.61). There was no significant 
difference in VEGF secretion in wells treated with VEGF165b, compared to conditions 
without VEGF165b co-treatment.  
 
Figure 3.10. RPE cells cultured in high glucose conditions secrete increased VEGF 
compared to control treated cells.  
RPE cells were treated with 5mM glucose ± 2.5nM VEGF165b, 35mM glucose ± 2.5nM 
VEGF165b and mannitol ± 2.5nM VEGF165b for 24 hours. Conditioned media was then 
assayed for VEGF expression. There was a significant increase in VEGF secretion upon 
35mM glucose treatment relative to control wells. There was no significant difference 
between VEGF165b co-treated wells when compared to untreated wells and when 
compared to all other treatments (1-way ANOVA with Sidak’s post hoc test, *p<0.05, 
**p<0.01). 
 
To corroborate these findings, I wanted to see if this was reflected in occludin 
immunofluorescence. As the osmotic control showed no significant difference in occludin 
expression or VEGF secretion, I omitted them from further experiments. I hypothesised 
that occludin immunofluorescence would reflect protein expression (figure 3.9). To 
assess this I treated RPE cells with 5mM glucose, 5mM glucose + 2.5nM VEGF165 to see 
if pro-angiogenic VEGF would exacerbate occludin degradation, 5mM glucose + 1µM 
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56/8 to neutralise VEGF165b also to see if occludin degradation increased. The high 
glucose (35mM) remained the same as figures 3.9 and 3.10, 35mM ± 2.5nM VEGF165b. 
Cells cultured in low glucose conditions alone (0.952±0.052) showed no 
difference in occludin expression relative to untreated wells (0.893±0.0390). Co-
treatment of 5mM glucose and 2.5nM VEGF165 induced no significant difference in 
occludin staining (0.772±0.127). Co-treatment of low glucose cultured RPE with 1µM 
56/8, a VEGF165b monoclonal antibody, also showed no signicant difference in occludin 
expression (0.803±0.052). When cultured in 35mM glucose, RPE cells express 
significantly less occludin (0.295±0.026) when compared with untreated cells and 
compared with 5mM glucose. When co-treated with 2.5nM VEGF165b, there was a no 
significant change in occludin expression (0.362±0.096).  
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Figure 3.11. Occludin expression is reduced in RPE cells cultured in high glucose media. 
RPE (n=3) were cultured in 5mM glucose, 5mM glucose + 2.5nM VEGF165, 5mM 
glucose + 1µM 56/8, 35mM glucose and 35mM glucose + 2.5nM VEGF165b for 24 hours 
(A) and stained for occludin (green) and nuclei were stained for Hoechst (blue). There 
was a significant reduction in occuldin expression (B) upon 35mM treatment compared to 
untreated wells and 5mM treated wells. There was also a significant difference between 
35mM glucose + 2.5nM VEGF165b treated cells and untreated cells. (2-way ANOVA with 
Tukey’s post-hoc, **p<0.01, ***p<0.001). 
 
It appears that upon 35mM glucose treatment, occludin was no longer localised to 
the cell membrane, but rather transported to the cytoplasm. This fits with previous studies 
that suggest that TJs internalise when compromised. However, unlike protein expression 
(figure 3.9), 2.5nM VEGF165b co-treatment was unable to restore occludin 
immunofluorescence. To assess whether we have functionally induced a change in 
paracellular flux, I assessed the same conditions as above (3.11) using TEER.  
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 Interestingly, the TEER more closely reflects the immunofluorescence data as 
opposed to the protein expression (figures 3.11 and 3.9 respectively). There was increased 
permeability at 24 hours (22.5%±4.70) relative to control treated cells (0.144%±0.143). 
VEGF165b co-treatment reduced permeability at 24 hours (17.0%±4.73), but it was not a 
significant difference when compared to 35mM glucose alone. There was no significant 
difference between all other groups when compared to untreated cells. This is reflected 
when measuring area under the curve, there was a significant difference between 
untreated wells (4.33±1.12) and 35mM treated wells (250±57.6) and untreated and 35mM 
+ VEGF165b (183±29.3). Whilst there was no change in permeability upon 35mM + 
VEGF165b relative to 35mM glucose alone. However, power calculations showed that 
whilst not showing a significant difference, the actual power of these data is 0.95 and 
would show significance if I increased my sample size from n=3 to n=5. The area under 
the curve indicates that whilst not significant, 5mM glucose causes a slight increase in 
permeability at 24 hours, which may be increased with VEGF165 co-treatment.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.12. Hyperglycaemic conditions induce increased permeability in RPE cells. 
TEER was assayed in RPE (A) cultured in 5mM glucose, 5mM glucose + 2.5nM 
VEGF165, 5mM glucose + 1µM 56/8, 35mM glucose and 35mM glucose + 2.5nM 
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VEGF165b for 24 hours. There was an increased in permeability upon 35mM glucose 
treatment after 24 hours, which was not significantly reduced upon 2.5nM VEGF165b co-
treatment (n=3, 1-way ANOVA with Tukey’s post-hoc test, **p<0.01). 
 
It is apparent that 2.5nM VEGF165b may not be sufficient to restore hyperglycaemia 
(35mM glucose)–induced changes in RPE cells, despite appearing to restore occludin 
protein expression (figure 3.9). 
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3.4. Discussion 
3.4.1 VEGF165 induces tight junction disassembly in RPE. 
 
It is widely accepted that VEGF is up-regulated in diabetic retinopathy (Aiello 
1994). It is also well established that VEGF165 is a potent permeability factor and is 
implicated in increasing vascular permeability in many conditions including tumour 
progression, blood-brain barrier disruption and diabetic retinopathy, the mechanisms are 
still yet to be fully understood.  
 Studies looking at the inner BRB, specifically RECs, have shown that increasing 
levels of VEGF both in vitro and in vivo induce “rapid phosphorylation” of occludin and 
ZO1 resulting in increased barrier permeability (Antonetti 1999b). In this chapter I 
showed that VEGF165 could dose-dependently reduce occludin expression (figures 3.1 
and 3.3) in RPE cells, by almost 50%. I also saw that this decrease in occludin expression 
coincided with an increase in paracellular conductance (figure 3.2), confirming that 
occludin expression is tightly linked with paracellular flux. As VEGF165 concentration 
increased from 0nM to 5nM, occludin protein expression decreased by almost half (figure 
3.3) and this was indirectly proportional to VEGFR2 expression. As one would expect, an 
increase in VEGF165 concentration would likely induce an increase in VEGFR2 
expression in RPE. An increase in VEGFR2 stimulation results in increased VEGFR2 
phosphorylation and increased activity of PKC (Harhaj et al. 2006). Increased PKC 
activity is hypothesised to induce changes in the actin cytoskeleton, which would in turn 
induce changes in the ZO1 – occludin complex. This conformational change is 
hypothesised to result in a separation of the ZO1-occludin complex, resulting in occludin 
internalisation into a soluble cytoplasmic pool that will be recycled at a later time, or 
degraded (Antonetti 1999b; Wang et al. 2001). It also hypothesised that VEGF induces 
phosphorylation of occludin at the serine/threonine region and tyrosine phosphorylation 
of ZO1 (Wang et al. 2001; Harhaj & Antonetti 2004), resulting in endocytosis of occludin 
and ZO1 and again either recycled or degraded. This pathway, although well understood 
in RECs, is assumed to have similar characteristics in RPE. I have shown that VEGF165 
elicits a very similar effect on RPE as published in RECs, and this therefore may play a 
role in DME. 
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3.4.2. VEGF165b prevents VEGF165–mediated changes in barrier properties.  
 
VEGF165b, whilst it binds to VEGFR2 with equal affinity as VEGF165, does not 
activate the receptor completely. When it binds, it only partially phosphorylates 
VEGFR2, and therefore elicits a different downstream effect of reducing permeability, 
promoting cell survival and reducing angiogenesis (Harper & Bates 2008).  
It has previously been acknowledged that there is a switch in isoform splicing in the 
diabetic eye in favour of pro-angiogenic isoforms such that VEGF165 levels overwhelm 
VEGF165b levels (Perrin et al. 2005). This means that competitive binding of both 
isoforms to VEGFR2 will also be in favour of VEGF165, resulting in increased 
angiogenesis and increased permeability. I showed that unlike VEGF165 (figure 3.2), 
VEGF165b alone does not elicit an increased paracellular flux in RPE (figure 3.4) when 
treated at the same concentrations, lending confidence to the notion that VEGF165b does 
not impair TJ integrity. Figures 3.6 and 3.7 show that 2.5nM VEGF165b treatment alone 
has no significant effect on location of ZO1 or on ZO1 and occludin expression. 
Nevertheless, translocation of TJs are synonymous with increased paracellular flux 
(Wang et al. 2001), and we did not see any changes in permeability upon dose escalation 
of VEGF165b, we can infer that it was unlikely that there was any change in location or 
distribution of TJs in RPE membranes. 
 Although I showed that concentrations as little as 0.2nM VEGF165b can prevent 
1nM VEGF165 induced increase in permeability (figure 3.5), I chose to use published 
values of 2.5nM VEGF165 and VEGF165b in future in vitro studies (Woolard et al. 2004). I 
saw that VEGF165 alone, as predicted, reduced occludin and ZO1 expression (figures 3.6 
and 3.7), and this was reflected functionally when we saw increased permeability in RPE 
(figure 3.8). Other models have shown similar results using brain microvascular 
endothelial cells (BMECs) and bovine retinal endothelial cells (BRECs), as models for 
the BBB and BRB respectively (Antonetti 1999a; Wang et al. 2001). By co-treating 
VEGF165 with VEGF165b, we saw a restoration in TJ expression and a reduction in 
permeability to baseline (figures 3.6, 3.7 and 3.8). Similar but less robust effects have 
also been shown using typical and atypical PKC inhibitors, whereby VEGF-induced 
increased TER and occludin phosphorylation was reduced (Harhaj et al. 2006; Titchenell 
et al. 2012). As mentioned earlier, VEGF165b binding to VEGFR2 results in incomplete 
autophosphorylation of the receptor in endothelial cells. As a result, downstream 
signalling events such as activation of PKC is reduced (Harper & Bates 2008). This 
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points to a potential mechanism by which VEGF165b protects barrier integrity by reducing 
PKC activation, in an environment where both isoforms are balanced, although the 
mechanisms of VEGFR2 activation or inhibition in RPE cells remain to be elucidated. 
This is encouraging as it supports my hypothesis that anti-angiogenic therapy 
using VEGF165b may be a potential treatment in DME.  
3.5. Hyperglycaemia induces changes in barrier properties in vitro. 
 
The characteristic hyperglycaemia observed in diabetes is directly linked to 
disruptions in the TJ complex, in the BBB and the BRB, as when patients observe “good 
glycaemic control” the progression of DR slows down. I wanted to see if I could induce a 
model of hyperglycaemia-induced TJ dysfunction in vitro.  
  I observed that upon additional 5mM glucose treatment, after 24 hours there was 
no significant difference in TJ expression (figures 3.9 and 3.11), nor any difference in 
paracellular flux (3.12). Mannitol treatment also showed no effect on protein expression 
(figure 3.9). Both 5mM (low glucose) and mannitol treatment were tested to illustrate that 
the effects seen upon high glucose treatment (35mM glucose), were in fact due to a 
hyperglycaemic environment and not as a result of osmotic shock to the cell. These data 
are consistent with published data (Gillies et al. 1997) 
 I then wanted to see if I could mimic the effects of hyperglycaemic insult by co-
treating 5mM glucose with 2.5nM VEGF165. This concentration proved to be sufficient to 
induce a change in TJ expression and permeability, and so I deemed it appropriate to co-
treat with. However there was no difference in TJ expression or paracellular flux. This 
unexpected result could be explained by the levels of VEGF secreted by RPE upon 
glucose treatment (figure 3.10), 5mM glucose treatment reduces VEGF secretion into 
media, compared to both untreated and mannitol treated media.  Low glucose treatment 
may be beneficial to RPE, which is why they secrete less VEGF and why co-treatment of 
VEGF165 elicits no significant effect on TJ expression or function. However, to confirm 
this 5mM glucose would need to be co-treated with a VEGF165 dose-escalation and 
assayed for TJ integrity.  
 By co-treating 5mM glucose with 56/8, I attempted to neutralise any VEGF165b 
that may be in the cell or media, and assess how this would influence RPE barrier 
integrity. There was no significant difference in occludin expression or TEER (figures 
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3.11 ad 3.12 respectively), however this could again be resolved under the hypothesis that 
5mM glucose is a closer representation to normal physiological conditions, and therefore 
metabolic processes that normally occur in untreated media, are occurring at a slightly 
enhanced rate upon 5mM treatment, and therefore 2.5nM VEGF165 will not elicit the 
same effect in this environment. In a model of oxidative stress in ex vivo rat lenses, co-
treatment with 2mM glucose prevented superoxide-induced damage (Kletzky et al. 1986), 
upon which they concluded that low levels of glucose may exert a protective mechanism 
when subject to stress. 
 
 Upon high glucose treatment (additional 35mM), there was a significant reduction 
in occludin protein expression (figure 3.9), which was restored upon VEGF165b co-
treatment. However this result was not reflected when looking at occludin 
immunofluorescence data (figure 3.11). VEGF165b co-treatment did not significantly 
reverse hyperglycaemia-induced occludin breakdown. However, it appears that upon 
35mM glucose treatment alone, occludin staining appeared to be cytoplasmic rather than 
at the membrane. It is possible that this particular anti-occludin antibody (Invitrogen), 
may detect only membrane-bound occludin in protein lysate. This also seems like a 
reasonable explanation when considering TEER data. Upon high glucose treatment, 
paracellular flux increases by 20% relative to untreated RPE (figure 3.12A), which is not 
reversed upon 2.5nM VEGF165b co-treatment. There is a trend that would suggest the a 
slight reduction in permeability and slight increase in occludin fluorescence upon 
VEGF165b co-treatment, however they are both not significant and indicate that, although 
promising, the dose of VEGF165b is not sufficient to reverse the functional effects of high-
glucose exposure. Few studies show a reversal in hyperglycaemia-induced insult using 
TEER. One group using taurine extracted from goji berries showed that taurine reversed 
high-glucose mediated increase in paracellular permeability in ARPE19 cells, an 
immortalised RPE cell line, through VEGF inhibition (Pavan et al. 2014).  
 These data indicate a potential in vitro model of outer BRB dysfunction in DME 
whereby high glucose concentrations result in an increase in AGE production and 
superoxide production, both of which increase levels of VEGF secreted by the cell. This 
increased extracellular VEGF results in increased VEGFR2 activation, and as a result 
increased activation of typical PKC isoforms, resulting in TJ phosphorylation and 
internalisation, resulting in reduced TEER. Increased glucose also results in increased 
atypical PKC isoform activation, which can also directly affect TJ integrity. This 
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hypothesis would be confirmed upon culturing RPE in 35mM glucose ± PKC inhibitors 
and characterising changes in barrier integrity. 
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3.5. Concluding Remarks 
 RPE cells, when subject to hyperglycaemia, secrete increased levels of VEGF165, 
which contributes to TJ dysfunction and an increased in cellular permeability, which is 
not reversed by VEGF165b in vitro. VEGF165 treatment alone also reduces TJ expression 
and increases parcellular permeability, however this is reversed by VEGF165b co-
treatment.  
 As VEGF165b treatment alone has no significant effect on TJ expression or 
function (TEER) on RPE, we hypothesise that it is safe to use on the outer-retinal barrier 
in vivo. I also hypothesise that VEGF165b may have therapeutic potential in preventing 
VEGF–induced BRB breakdown in a model of diabetes in vivo.
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Chapter 4: rhVEGF165b in 
Diabetic Retinopathy 
4.1. Introduction 
DR affects both type 1 and type 2 diabetics, and as the population of patients 
diagnosed with diabetes rises, so will the number of patients diagnosed with DR 
(http://www.who.int/blindness/causes/priority). Hyperglycaemia triggers a multitude of 
events that result in an increase in hypoxia (Pe’er et al. 1995), pro-inflammatory 
cytokines (Joussen et al. 2004) and an increase in ROS (Al-Shabrawey et al. 2008), 
amongst others. Much like wet AMD, there is a hypoxia and inflammation-mediated 
upregulation of VEGF production (Hoeben et al. 2004; Tang & Kern 2011) in the diabetic 
eye, and therefore much research is focused on anti-VEGF therapy in treating DR.   
In the UK, the current treatment for the earlier, proliferative stage of DR is pan 
retinal laser photocoagulation (PRP), as recommended by the Royal College of 
Ophthalmologists (https://www.rcophth.ac.uk/standards-publications-research/clinical-
guidelines). PRP alleviates retinal hypoxia bye RPE-focused laser treatment. However, 
despite the restoration of oxygen levels, the success of this procedure is limited by the 
fact that patients subject to laser therapy show variable improvements in vision. Regions 
of the retina will be lost to laser therapy and as well as loss of photoreceptors due to their 
outer retinal location, resulting in poor vision. Moreover, PDR is the major cause of 
vision loss, but rather DME is; and therefore laser treatment is often used as a precursor 
to or an adjunct with anti-VEGF treatment.  
The consensus in treating wet AMD appears to be in favour of anti-VEGF 
therapy, with the main candidate drugs being: bevacizumab (Avastin, Genentech Inc., San 
Francisco), a monoclonal VEGF-A antibody (Ferrara et al. 2004), ranibizumab (Lucentis, 
Genentech Inc., San Francisco) a pan VEGF fragment antibody (Ferrara et al. 2006) and 
aflibercept (Eyelea Regeneron Pharmaceuticals Inc., New York) a soluble decoy receptor 
for extracellular VEGF and a VEGFR1 and VEGFR2 inhibitor (Holash et al. 2002). 
However, there are concerns over anti-VEGF therapy, considering that the outer BRB is 
also compromised in DME, IVT anti-VEGF therapy can enter the systemic circulation. 
This may be a disadvantage to diabetic patients as this may prevent wound healing, 
induce hypertension and result in increased cardiac events (Simó & Hernández 2008). 
 
 Part of the discovery of new anti-angiogenic agents in the treatment of DR is 
using reproducible and representative models. There are several models of both type 1 
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and type 2 diabetes, with the most commonly used being the streptozotocin (STZ)-
induced model of both insulin and non-insulin dependent diabetes. STZ, synthesised from 
Streptomycetes achromogenes (Szkudelski 2001). STZ is transported into pancreatic β-
cells via GLUT2 transporters and induces β-cell necrosis through DNA fragmentation and 
alkylation-mediated toxicity (Szkudelski 2001; Lenzen 2008). STZ is also a NO donor 
and generates ROS within β-cells, also contributing to DNA damage (Szkudelski 2001). 
STZ inhibits the Krebs cycle and subsequently, drastically reduces ATP production 
within β-cells resulting in poly ADP-ribosylation (PARP) activation as a way to rectify 
the damage (Szkudelski 2001; Lenzen 2008). However this only further depletes ATP 
reserves and further induces β-cell necrosis and subsequent ablation of insulin secretion 
(Lenzen 2008). Eventually, more β-cells die resulting in hyperglycaemia and subsequent 
retinal ischaemia.  
Unfortunately, there is no single model of DR that encompasses all 3 arms of the 
condition, but rather animal strains and models of diabetes are chosen to assess particular 
aspects of the condition. To investigate outer BRB dysfunction in the diabetic retina, 
STZ-induced diabetes in Sprague-Dawley rats (Kern et al. 2010) is the preferred method. 
PDR can be assayed by counting immunostained vessels in the presence and absence of 
diabetes. DME involves changes in solute flux across the BRB, and so the Evans’ blue 
dye perfusion technique has been used to assess changes in retinal “permeability” in vivo 
(Xu et al. 2001; Qaum et al. 2001; Abcouwer et al. 2010). Evans’ blue (EB) is low 
molecular weight dye (961Da) that binds to albumin and wherever there is albumin 
leakage, for example from vasculature with compromised TJs, there will also be EB 
leakage. This will eventually accumulate into the surrounding tissue, which when 
analysed for EB absorbance at 620nm will give an indication of how “leaky” that 
particular tissue is.  
The purpose of this study was to assess whether 8 weeks of STZ-induced diabetes 
would be a satisfactory method of modelling PDR and DME, and whether VEGF165b 
would be able to reverse hyperglycaemia-induced retinal pathology.   
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4.2. Methodology 
Sprague-Dawley (SD) female rats (Harlan and Charles River in Bristol and 
Nottingham respectively), aged 6-8 weeks and weighing between 200-250g were used in 
models of DR. SD rats have been successfully used to document changes in retinal 
vasculature upon induction of diabetes (Kern et al. 2010; Robinson et al. 2012). Diabetes 
was induced using streptozotocin (STZ) as it is a well-established model of diabetes and 
is regularly used to study complications associated with diabetes including diabetic 
nephropathy and diabetic neuropathy, as well as DR (Brownlee 2001; Kern et al. 2010).  
Animals were fasted overnight prior to induction of diabetes, and injected with 
STZ (50mg/kg) the next day. Rats used for 8 weeks diabetes also had an implantation of 
1/3 of a slow release insulin pellet implanted into the neck scruff under isofluorane 
anaesthesia on the same day as STZ injection. Rats were either studied for 1 or 8 weeks. 
Diabetic cohorts studied for 8 weeks were injected i.p biweekly for 8 weeks with saline or 
VEGF165b. Cohorts studied for 1 week were subject to IVT injections under recovery 
anaesthesia, 6 days after injection of STZ.  
 Cohorts studied for 1 week were subject to the Evans’ blue dye (EB) perfusion 
technique to assess diabetes-induced changes in BRB properties, as described by Xu and 
colleagues (Xu et al. 2001). 3 cohorts were studied for 8 weeks, 1 cohort was subject to 
EB perfusion and 2 cohorts were sacrificed at 8 weeks and retinae were excised and either 
unfixed for protein lysate extraction and western blotting, and contralateral retinae were 
fixed, stained and flat-mounted for Isolectin B4, a vessel marker, and neuronal nuclear 
antigen (NeuN), a marker of retinal ganglion cells. Immunofluorescence was quantified 
using ImageJ and Imaris software. All methods are described in detail in Chapter 2. 
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4.3. Results 
4.3.1. Systemic VEGF165b treatment reduces diabetes-induced changes in vascular 
remodelling. 
 
There are multiple models of diabetes in rodents, however most physiological 
changes in rat retinae typically occur 6-8 weeks after onset of diabetes (Robinson et al. 
2012b). To assess whether systemic administration of VEGF165b can prevent diabetes-
induced changes across the BRB, 7 SD rats (200-250g, figure 4.1A) were induced with 
diabetes using STZ and supplemented with insulin, with two groups: STZ + vehicle 
(saline i.p, biweekly) and STZ + VEGF165b (20ng/g i.p, biweekly), and a third untreated, 
non-diabetic group injected with saline at week 0 (n=3). Rats with blood glucose 
≥15mmol/l were deemed diabetic (figure 4.1B). All animals were culled at 7-8 weeks 
post-confirmation of hyperglycaemia, and retinae excised, fixed and stained for isolectin 
B4, a vessel marker. Vessels were manually counted per field of view on Image J and 
then confirmed using integrated density on Image J.  
All of the control group (no STZ) retinae were badly damaged by an accident 
during processing, and I could not image them. There were significantly fewer vessels per 
field of view (figure 3.1A) in the VEGF165b treated animals (274.8 ± 8.878, n=4) than in 
the vehicle treated animals (302.3 ± 8.738, n=3). This was corroborated when measuring 
fluorescence using integrated density (figure 4.1B), with the notion that the greater the 
number of vessels, the greater the total fluorescence which would translate to a greater 
integrated density. Retinae of VEGF165b treated diabetic rats showed lower integrated 
density (50.23 ± 2.181, n=4) compared to vehicle treated rats (77.34 ± 9.039, n=3).  
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Figure 4.1. VEGF165b can significantly alter retinal vessel density in diabetic rats.  
Sprague-Dawley rats induced with diabetes were treated with vehicle (PBS) or VEGF165b 
(20ng/g) biweekly (i.p) for 7 weeks after onset of hyperglycaemia. Animals were 
weighed weekly (A) and blood glucose measured 1 day before (week 0), 1 week after and 
7 weeks after STZ induction (B). At week 7 retinae were excised and stained for IB4 
(green). Diabetic rats treated with VEGF165b (C) showed a lower vascular density (E) and 
integrated density (F) than vehicle treated diabetic rats (C) (unpaired, 2-tailed Student’s t-
test, *p<0.05). 
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To assess whether the diabetic retinae had a reduced TJ expression and increased 
VEGF expression typically associated with diabetes (Antonetti 1999b), contralateral eyes 
from the above cohort were subject to protein extraction, and lysate was immunoblotted 
against VEGF-A, occludin and ZO1. I hypothesised that diabetic rats would express 
greater VEGF-A and reduced TJs relative to control rats, based on data in chapter 3 and 
published data. Protein extraction from the diabetic rats treated with VEGF165b was 
unsuccessful due to an accident in processing. 
 There was a small, yet significant increase in VEGF-A in diabetic retinae 
(0.81±0.03) relative to control animals (0.709±0.0212) (figure 4.2A). The same retinae 
showed a significant reduction in TJ expression in diabetic rats (0.681±0.0246) relative to 
control retinae (0.843±0.0428). There was a similar trend observed with occludin 
expression, whereby diabetes reduced occludin expression (0.460±0.0176) relative to 
control animals (0.521±0.0203), however this did not achieve significance (figure 4.2B).  
 
 
Figure 4.2. Diabetes causes an increase in VEGF in diabetic Sprague-Dawley retinae and 
a decrease in TJ expression.  
Control and STZ + vehicle (Cx and Dx respectively) Sprague-Dawley rats were culled 
after 7 weeks of onset of hyperglycaemia and protein lysate extracted from retinae was 
immunoblotted against ZO1, occludin and VEGF-A. Blots were then stripped and 
reprobed for α-tubulin (A). Densitometry analysis (B) showed there was a significant 
increase in VEGF expression, and a significant decrease in ZO1 expression, however 
there was no change in occludin expression (unpaired, 2-tailed T test, *p<0.5, **p<0.01).  
 
Although these data were encouraging and show VEGF165b could reduce vessel density in 
the diabetic eye (figure 4.1), as I did not have untreated, non-diabetic animals, I could not 
infer whether the vessels seen in STZ + vehicle groups were a result of neovascularisation 
or if the reduction induced by VEGF165b was a subnormal value and potentially 
pathological. To readdress this, I repeated the above pilot experiment (figures 4.1 and 4.2) 
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with the addition of an untreated, control group of rats (figure A). This would also give 
me a complete data set from which I could also extract protein lysate from contralateral 
eyes not used for immunofluorescence. Following fixation, retinae were hemisected and 
stained for different markers to maximise the data obtained from one study in order to 
reduce the numbers of animals used, whilst still achieving statistical power.  
All images were taken under standardised settings on a confocal microscope (488 
laser power = 30%, offset = 15%, gain = 800), all on the same imaging session in order to 
reduce variability between images. To increase the reliability and accuracy of analysis, 
rather than manually counting vessels in IB4 stained retinae (figure 4.3B), which can be 
vulnerable to error, I calculated volume occupied by vasculature using Imaris software 
(figure 4.3C). Vessel density was inferred from area and volume occupied by vasculature. 
I hypothesised that diabetic rats treated with vehicle would express a greater volume of 
vasculature in their retinae, relative to untreated retinae, and that this could be reversed 
upon treatment with VEGF165b. There was a significantly increased vascular area in the 
diabetic retinae (figure 4.3D) when compared with control retinae (1.15± 0.08 mm2 and 
0.85±0.007 mm2respectively). VEGF165b treated diabetic retinae showed a reduction in 
vascular area compared to both control retinae and diabetic + vehicle treated retinae. As 
would be expected, these data were mirrored in the volume occupied by vasculature. 
Diabetic + vehicle treated retinae expressed a greater vascular volume (figure 4.3E) 
relative to control retinae (5.6x106µm3±4.8x105 and 3.8x106 µm3±3.8x105 respectively). 
VEGF165b treatment prevented diabetes-induced vascular remodelling 
(2.3x106µm3±2.9x105), but also showed a significant difference relative to control retinae. 
I also analysed the integrated density of these data (figure 4.3F) to assess whether they 
showed a similar trend to figure 4.1. There was an increase in integrated density in the 
diabetic + vehicle retinae (48.2±2.63) relative to control retinae (34.4±0.615). This 
increase was significantly prevented upon VEGF165b intervention (40.1±0.490). The 
diabetic data from figure 4.3 mirrors 4.1, indicating that this model is also reproducible.  
		 98	
 
0 1 2 3 4 5 6 7 8
240
280
320
360
400
Week after STZ induction 
A
ve
ra
ge
 W
ei
gh
t (
g)
Control
STZ + Vehicle
STZ + VEGF165b
0 1 2 3 4 5 6 7 8
0
10
20
30
40
Week after STZ induction 
B
lo
od
 g
lu
oc
se
 (m
m
ol
/l)
Control STZ + Vehicle STZ + VEGF165b
0
2×106
4×106
6×106
8×106
1×107
Vo
lu
m
e 
(µ
m
3)
Total volume occupied by vasculature
* ***
*
Control STZ + Vehicle STZ + VEGF165b
0.0
5.0×105
1.0×106
1.5×106
2.0×106
A
re
a 
(µ
m
2 )
Total area occupied by vasculature
** ***
*
100µm 100µm 100µm 
Control STZ + Vehicle STZ + VEGF165b 
IB4 / DAPI Scale: 100µm 
(B) 
(C) 
(D) (E) 
(A) 
Control STZ + VehicleSTZ + VEGF165b
0
20
40
60
M
ea
n 
G
re
y 
Va
lu
e
(G
re
y 
sc
al
e)
** *
Integrated Density
(F) 
		 99	
Figure 4.3. Systemic administration of VEGF165b prevents diabetes-induced 
neovascularisation in vivo.	
STZ (50mg/kg, i.p) was used to induce diabetes in Sprague-Dawley rats (n=10). Saline 
was injected in vehicle controls (i.p, n=4). Diabetic rats were either treated with 
VEGF165b (20ng/g, biweekly i.p, n=5) or saline (biweekly i.p, n=5). All groups were 
weighed weekly and rats with a blood glucose ≥15mmol/l were deemed diabetic (A). Rats 
were sacrificed at 8 weeks and retinae were stained for blood vessels (B) using isolectin 
B4 (IB4) and DAPI. Vascular density was calculated using Imaris software (C). There 
was an increase in the area occupied by vessels per field of view (D) in diabetic + vehicle 
treated rats, relative to untreated controls, which was reversed by VEGF165b treatment. 
There was also an increase in the volume occupied by the vasculature per 3D stack (E) in 
the diabetic + vehicle treated animals, relative to control rats. This was also reversed upon 
VEGF165b treatment. Integrated density was calculated using Image J (F) and showed that 
there was increased fluorescence of our fluorescent marker in STZ + vehicle retinae 
relative to controls, and that this was prevented upon VEGF165b treatment (1-way 
ANOVA, Tukey’s post hoc test, *p<0.05, **p<0.01, ***p<0.001). 
 
 
The data from figure 4.3 shows that diabetes causes an increase in vascular area, 
volume and fluorescence, per field of view, indicative of increased vascularisation 
relative to untreated controls, corroborating what is observed in clinical settings. VEGF165 
shows a reduced vascular area and IB4-fluorescence per field of view, when compared to 
vehicle-treated diabetic rats. Vessel tortuosity is a another pathological feature of PDR 
(Gardner et al. 2002; Miller et al. 2013) where vessels dilate in response to ischaemia and 
become more curved. This aspect usually precedes neovascularisation (Hart et al. 1999) 
and is often used as an indicator of severity of disease in other ocular diseases as well as 
DR. I predicted that since I observed changes in vessel density at 8 weeks, I might also 
see a change in vessel tortuosity in diabetic retinae relative to control retinae. To assess 
this, I used Imaris software to measure “vessel straightness” on IB4 stained retinae from 
figure 4.3. I used this value to calculate the change in vessel straightness (figure 4.4) and 
observed that there was a trend in diabetic + vehicle animals where individual rats 
showed an increase in tortuosity (figure 4.4A) relative to control rats and diabetic + 
VEGF165b treated rats. Although there was a non-statistically significant difference 
between diabetic + vehicle retinae (0.087±0.003) when compared with control retinae 
(0.074±0.003), power calculations show had we increased the sample size from n=4 to 
n=6, we would achieve statistical significance with a power of 0.95. Systemic VEGF165b 
intervention showed a statistically significant reduction in average vessel tortuosity 
(0.074±0.004). There was no difference between untreated and VEGF165b treated groups.  
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Figure 4.4. Systemic administration of VEGF165b prevents diabetes-induced vessel 
tortuosity. 
IB4 stained retinae from control, STZ + vehicle and STZ + VEGF165b injected rats were 
assessed for vessel straightness using Imaris software. STZ + vehicle treated retinae 
showed a trend whereby there was increased change in straightness, therefore increased 
tortuosity (A) relative to control retinae. However this was not statistically significant 
development (B). There was a statistically significant reduction in tortuosity upon 
VEGF165b treatment, compared to STZ + vehicle retinae (1-way ANOVA, Tukey’s post-
hoc test, *p<0.05). 
 
With the remaining, contralateral, retinae I extracted protein lysate to immunoblot 
against various markers of angiogenesis. I hypothesised that the pathology observed from 
this model was hypoxia-mediated, thus causing an upregulation of VEGF, resulting in 
subsequent angiogenesis. To assess this, I immunoblotted against HIF-1α and pan VEGF 
(figure 4.5A), and observed that there was no change in HIF-1α expression (figure 4.5B) 
in diabetic retinae (1.56±0.643) relative to control retinae (0.996±0.712) despite it 
appearing that there is increased HIF expression in the diabetic retinae. VEGF165b-treated 
rats only saw a slight reduction in HIF-1α expression, however this was not significant. 
VEGF expression increased significantly in diabetic retinae (1.72±0.451) relative to 
control retinae (0.988±0.265). This elevated VEGF level remained unchanged upon 
VEGF165b treatment (1.63±0.351), however this may be due to the VEGF antibody 
detecting elevated VEGF165b isoforms present in treated retinae. Unfortunately I was 
unable to obtain a successful VEGF165b western blot to confirm this. Power calculations 
show that to achieve statistical significance with 0.95 power, between control and STZ + 
vehicle groups, the sample size would have to be n=4, considering the sample size in this 
(A)$ (B)$
7 bl 7 / 8 bl 8 / 9 bl 9 /10 bl 10 / 10 //11 bl 11 /12 bl 12 / 12 //
0.00
0.05
0.10
0.15
1 
- s
tr
ai
gh
tn
es
s 
of
 v
es
se
l
Individual Straightness
Control STZ + Vehicle STZ + VEGF165b
Control STZ + Vehicle STZ + VEGF165b
0.00
0.02
0.04
0.06
0.08
0.10
1 
- A
ve
ra
ge
 s
tr
ai
gh
tn
es
s 
of
 v
es
se
l Change in Straightness
*
		 101	
study was n=3, this only 1 extra animal would be needed to achieve statistical 
significance therefore we can infer that this is a reliable trend. 
 
 
Figure 4.5. STZ-induced diabetic neovascularisation in SD rats is VEGF mediated. 
Protein lysate from control retinae (n=3), STZ-induced (50mg/kg) diabetic retinae (n=3) 
and diabetic retinae + VEGF165b (20ng/g, biweekly i.p) was collected 8 weeks after onset 
of diabetes. Lysate was immunoblotted (A) against HIF-1α and VEGF-A; western blots 
were then stripped and reprobed for α-tubulin (C, D, T = Control, STZ + vehicle, STZ + 
VEGF165b respectively). Densitometry analysis (B) showed that there was an increase in 
HIF-1α and VEGF expression (C) in diabetic retinae, relative to controls, however there 
was no significant difference in VEGF165b treated groups (1-way ANOVA with Tukey’s 
post hoc test, *p<0.05). 
 
 To further investigate whether the pathology is indeed VEGF-mediated, I 
immunoblotted protein lysate from the same cohort against VEGFR2 (figure 4.6B) and 
phosphorylated VEGFR2 (pVEGFR2, figure 4.6C), with the hypothesis that both 
expression and activation of VEGFR2 would increase in diabetic retinae, resulting in 
proliferation, and that this could be reduced with VEGF165b intervention (figure 4.6A). 
When pVEGFR2 expression was analysed relative to VEGFR2 expression (figure 4.6D), 
there appeared to be no difference between the treatment groups. However, this is likely 
due both proteins changing expression in the same direction. Looking at VEGFR2 
expression alone (figure 4.6B), although there appears to be an increase in VEGFR2 
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expression in diabetic retinae (1.30±0.224) relative to control retinae (0.904±0.230), it 
was not significant. Similarly, there was no change in expression in VEGF165b-treated 
groups (1.048±0.126) relative to diabetic groups, despite appearing to decrease. This 
trend was mirrored in pVEGFR2 expression (figure 4.6C), where there was no change in 
expression although appearing as though as there was an increase in expression in 
diabetic retinae (1.18±0.200) relative to control retinae (0.842±0.060), and this slightly 
reduced with VEGF165b intervention (1.05±0.234).  
 
Figure 4.6. STZ-induced diabetes causes increased expression and phosphorylation of 
VEGFR2 in the retina.  
Protein lysate from control retinae (n=3), STZ-induced (50mg/kg) diabetic retinae (n=3) 
and diabetic retinae + VEGF165b (20ng/g, biweekly i.p) was collected 8 weeks after onset 
of diabetes. Lysate was immunoblotted (A) against VEGFR2 and pVEGFR2; western 
blots were then stripped and reprobed for α-tubulin (C, D, T = Control, STZ + vehicle, 
STZ + VEGF165b respectively). There was no change in VEGFR2 expression (B) in 
diabetic retinae, relative to controls, and a non-significant difference in VEGF165b treated 
groups relative to diabetic groups. PVEGFR2 expression (C) also showed no change in 
diabetic retinae, compared to both control and VEGF165b-treated groups Densitometry 
analysis (D) showed that there was no change in pVEGFR2 expression relative to 
VEGFR2 expression in all conditions. (1-way ANOVA with Tukey’s post hoc test). 
 
 Although the densitometry appeared to show a change in VEGFR2 activation, this 
did not achieve statistical significance with the n numbers and sensitivity of the assay, I 
wanted to see if a more robust difference could be elucidated in the differences of 
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intracellular pathways involved in angiogenesis and diabetes. To test this hypothesis, I 
tested the protein lysate for ERK, phosphorylated ERK (pERK) and cleaved-caspase 3 
with the hypothesis that increased angiogenesis will result in increased ERK 
phosphorylation and apoptosis in diabetic retinae, and that this may be reduced upon 
VEGF165b treatment, (figure 4.7A). ERK expression relative to α-tubulin (figure 4.7B) 
appears to be unchanged across all groups, however pERK expression relative to α-
tubulin (figure 4.7C) appears to increase in diabetic retinae (1.11±0.198) relative to 
control retinae (0.885±0.235), although not statistically significant. VEGF165b treatment 
shows a minute reduction relative to diabetes alone (1.05±0.226), however the difference 
is so minimal; it is unlikely that it is indicative of a reduction in ERK phosphorylation. 
There was an increase in pERK expression relative to ERK in diabetic retinae 
(1.39±0.215) compared to control retinae (1.06±0.15) (figure 4.7D), which showed a 
reduction upon VEGF165b treatment (1.21±0.122), although both trends did not achieve 
significance. Unexpectedly, there was a decrease in cleaved caspase-3 expression (figure 
4.7E) in diabetic retinae (0.877±0.170) compared to control (1.01±0.293) and VEGF165-
treated retinae (1.05±0.215). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
		 104	
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.7. STZ-induced diabetes results in increased ERK phosphorylation, which is not 
reversed in VEGF165b treated groups  
Protein lysate from control retinae (n=3), STZ-induced (50mg/kg) diabetic retinae (n=3) 
and diabetic retinae + VEGF165b (20ng/g, biweekly i.p) was collected 8 weeks after onset 
of diabetes. Lysate was immunoblotted (A) against ERK, pERK and cleaved caspase-3 
expression; western blots were then stripped and reprobed for α-tubulin (C, D, T = 
Control, STZ + vehicle, STZ + VEGF165b respectively). Densitometry analysis (B) 
showed that there was a slight increase in pERK expression relative to ERK expression in 
in diabetic retinae relative to control and VEGF165b-treated diabetic retinae. There was no 
change in ERK expression (C) across all groups. pERK expression (D) also showed a no 
change in diabetic retinae, compared to both control and VEGF165b-treated groups. There 
was no change in cleaved caspase-3 expression (E) in diabetic retinae relative to control 
and VEGF165b (1-way ANOVA with Tukey’s post hoc test). 
 
Having seen changes in vascular density, I wanted to see if this model would also 
induce changes in barrier properties, as observed in figure 4.2. To assess this, I used 
protein lysate from the same cohort as above and I immunoblotted against VE-cadherin, 
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an endothelial cell-specific TJ marker and occludin, which is expressed in RPE as well as 
RECs.  
 Both TJ markers showed a reduction in expression in diabetic conditions (figure 
4.8A). This was significant for VE-cadherin expression (figure 4.8B) in diabetic retinae 
(0.685±0.125) relative to control retinae (1.06±0.123). There was a slight increase in VE-
cadherin expression in VEGF165b treated rats (0.904±0.115), however this was not 
statistically significant. This was also reflected in occludin expression (figure 4.8C), 
diabetes resulted in a non-significant decrease in occludin expression in diabetic retinae 
(1.02±0.426) relative to control, non-diabetic retinae (1.50±0.124). VEGF165b treatment 
appeared to have an increase in occludin expression, however this was not significant 
(1.57±0.329).  
 
Figure 4.8. VEGF165b potentially prevents diabetes-induced TJ dysfunction. 
Protein lysate from control retinae (n=3), STZ-induced (50mg/kg) diabetic retinae (n=3) 
and diabetic retinae + VEGF165b (20ng/g, biweekly i.p) was collected 8 weeks after onset 
of diabetes. Lysate was immunoblotted (A) against VE- cadherin and occludin; western 
blots were then stripped and reprobed for β-actin (C, D, T = Control, STZ + vehicle, STZ 
+ VEGF165b respectively). Densitometry analysis (B) showed VE-cadherin expression 
decreased in diabetic retinae relative to control and VEGF165b-treated retinae. This trend 
was reflected in occludin expression (C) however this was not statistically significant (1-
way ANOVA with Tukey’s post hoc test, *p<0.05). 
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4.3.2. VEGF165b prevents diabetes-induced increase in solute flux. 
 
Given that figure 4.8 indicated that TJ expression decreased in diabetic retinae, 
and there may be a potential rescue with VEGF165b, we wanted to see if we could see 
functional changes in barrier properties, as observed in DME. To investigate this further, 
a third cohort of SD rats were induced with diabetes using STZ (figure 4.9A), and 
repeated as cohort 2. Diabetes was confirmed 4 days post-induction and rats with blood 
glucose ≥15mmol/l were deemed diabetic (figure 4.9B). Diabetic rats were either injected 
with vehicle (saline, biweekly i.p, n=5) or VEGF165b (20ng/g, biweekly i.p, n=5). Non-
diabetic rats were injected with saline (i.p) as opposed to STZ on day 0 (n=5). After 8 
weeks, rats were injected subject to the EB technique.   
Plasma was collected every 15 minutes for two hours (figure 4.9D), followed by 
cardiac perfusion of saline at 120mmHg, to remove EB-albumin from the vascular 
volume, followed by tissue extraction (figure 4.9C). EB solute flux and permeability-
surface area product (PA) were calculated to give an indication of EB tissue accumulation 
and EB extravasation relative to plasma EB absorbance respectively (Further details 
described in chapter 2, “Materials and Methods”). 
I hypothesised that based on figure 4.8, there will be an increase in EB solute flux 
and PA in diabetic retinae relative to control retinae, and that this could be prevented in 
the VEGF165b-treated groups. Upon excision of retinae I observed that STZ + vehicle 
treated retinae, were noticeably more blue (figure 4.9C) than both control and STZ + 
VEGF165b-treated retinae. EB solute flux (figure 4.9E) significantly increased in diabetic 
retinae (0.148±0.047µg/min/g) relative to control retinae (0.012±0.028 µg/min/g). 
VEGF165b-treated retinae had a significantly reduced EB solute flux (0.0002±0.021 
µg/min/g) relative to diabetic + vehicle retinae. There was no statistically significant 
difference between control and diabetic + VEGF165b treated retinae. This trend was also 
observed in EB PA (figure 4.9F), there was a significantly increased EB PA in diabetic 
retinae (0.007±0.002µl/g/hr) relative to control retinae (1.12x10-5 ±4.08x10-4 µl/g/hr). 
There was a significant decrease in EB PA in VEGF165b treated groups (6.63x10-5 
±8.96x10-4 µl/g/hr), relative to diabetic + vehicle treated groups. There was no significant 
difference between control and VEGF165b treated groups.  
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Figure 4.9. Systemic VEGF165b administration prevents diabetes-induced Evans’ blue 
extravasation.  
Sprague-Dawley female rats were induced with diabetes using STZ (50mg/kg i.p, n=10) 
and control rats (n=5) were injected with saline (i.p) on day 0 and weighed weekly (A). 
After 4 days, blood glucose was tested and blood glucose ≥ 15mmol/l were deemed 
diabetic (B). Diabetic rats were treated with either vehicle (saline, biweekly i.p, n=5) or 
VEGF165b (20ng/g, biweekly i.p, n=5). At 8 weeks post-STZ induction, Evans’ blue (EB, 
45mg/kg) was injected i.v into terminally anaesthetised rats. Plasma was collected every 
15 minutes for 2 hours, after which, animals were sacrificed and retinae excised (C). 
Retinae were weighed and EB was extracted using formamide. EB solute flux (E) was 
calculated from the amount of EB per wet weight of tissue per hour. EB solute flux 
significantly increased in the diabetic retinae relative to control retinae and VEGF165b-
treated retinae. Permeability-surface area product (F) calculated from solute flux relative 
to the mean plasma Evans blue level during the 2-hour circulation. This also increased in 
diabetic retinae relative to control and VEGF165b treated animals (Kruskall-Wallis test 
with Dunn’s post-hoc test, **p<0.01, ***p<0.001).  
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These data indicate that we can model diabetes-induced BRB dysfunction, and 
that VEGF165b when administered systemically can prevent TJ reorganisation in vivo. 
However, most treatments for DR and AMD are administered locally, either intravitreally 
(IVT) or subretinally, as most drugs are hypothesised to not cross the BRB effectively. I 
wanted to see whether local administration of VEGF165b in STZ-induced diabetic rats 
would also prevent diabetes-mediated TJ dysfunction. However, given the short half life 
of VEGF165b (Rennel et al. 2008), the 8 week STZ model would be unsuitable as the rat 
would require several intraocular injections a week, which would require the animal to be 
anaesthetised and subject to a procedure that has a 1% risk of endophthalmitis, multiple 
times per week. To address this problem, I shortened the length of diabetes to 1-week, as 
many studies have shown that microvascular complications associated with diabetes can 
occur after 1 week-post STZ injection (Qaum et al. 2001; Xu et al. 2001). As the duration 
of diabetes was significantly shorter, I did not supplement with insulin.  
 To establish whether IVT VEGF165b could prevent EB extravasation in diabetic 
retinae, I based a 7-day protocol on Xu et al., 2001. SD rats were induced with diabetes 
using STZ, and on day-6 post-induction, diabetic rats were anaesthetised and subject to 
IVT injection VEGF165b (50ng) in one eye and vehicle (saline) in the contralateral eye, 
followed by recovery. Control rats were injected with saline on day 0, and vehicle 
injection in one eye and the contralateral eye serving as an untreated control. On day 7 
rats were terminally anaesthetised and subject to the Evans’ blue (EB) dye perfusion 
technique as described earlier in this chapter and in chapter 2. I hypothesised that based 
on EB data acquired earlier (figure 4.9), that local administration of VEGF165b would 
prevent diabetes-mediated EB leakage into the retina. I observed that upon excision of 
retinae, diabetic + vehicle treated retinae were considerably more blue than contralateral, 
VEGF165b injected eyes (figure 4.10A). Plasma EB absorbance (4.10B) decreased in both 
treatment groups over time, as expected as the volume of circulating plasma also 
decreases every 15 minutes. EB solute flux was calculated as described earlier in this 
chapter, and showed a significant increase in EB tissue accumulation (figure 4.10C) in 
diabetic retinae (0.244 ±0.05µg/min/g) relative to control + vehicle injected retinae (0.089 
± 0.024 µg/min/g) VEGF165b treatment induced no change in EB solute flux (0.131 ± 
0.038µg/min/g). Interestingly, there was no significant difference between vehicle 
injected control retinae and untreated retinae (0.067 ± 0.016µg/min/g) indicating that the 
IVT injection did not exert a significant, inflammatory effect. When measuring EB PA 
(figure 4.10D), diabetes alone caused a significant increase in EB extravasation (0.012 ± 
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0.004 µl/g/hr) relative to vehicle treated and untreated controls (0.002 ± 0.008 µl/g/hr and 
0.002 ± 4.0x10-4 µl/g/hr respectively). VEGF165b treatment significantly reduced EB 
extravasation (0.005± 0.001 µl/g/hr) relative to contralateral diabetic retinae. There was 
no significant difference between STZ + VEGF165b-treated, control + vehicle and 
untreated groups. When we normalised these data to data obtained earlier at 8 weeks 
(figure 4.9), we saw that relative solute flux (figure 4.10E) increased robustly between 1 
and 8 weeks in diabetic animals (3.63±0.744 µg/min/g and 46.1±14.6 µg/min/g 
respectively), whereas relative solute flux in VEGF165b injected animals remained 
relatively unchanged between 1 and 8 weeks of treatment (1.95±0.568 µg/min/g and 
1.03±6.81 µg/min/g respectively). The difference between STZ + vehicle-treated solute 
flux and STZ + VEGF165b-treated solute flux at 1 and 8 weeks is significantly different at 
both time points. This trend is similar in relative PA (4.10F). Relative PA is greater at 8 
weeks than 1 week in diabetic + vehicle retinae (11.0±3.54 µl/g/hr and 6.47±2.35 
µl/g/hr), however the opposite trend is observed in VEGF165b-treated retinae, where there 
is a reduction in PA at 8 weeks relative to 1 week (0.107±1.44 µl/g/hr and 2.61±0.544 
µl/g/hr respectively).  
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Figure 4.10. Intravitreal VEGF165b administration can prevent diabetes-induced Evans’ 
blue extravasation in 1-week diabetic rats. 
Sprague-Dawley rats were induced with diabetes using streptozotocin (STZ, 50mg/kg). 
After 6 days, 5µl saline was injected into one eye of each diabetic rat, and 5µl 10ng/µl 
rhVEGF165b injected into the contralateral eye (n=5). Control rats had no injection in one 
eye, and 5µl saline in the contralateral eye (n=5). On day 7, Evans blue (EB, 45mg/kg) 
was injected into anaesthetised rats (iv) Plasma was collected every 15 minutes for 2 
hours (B), after which, animals were sacrificed and retinae excised (A). Evans blue solute 
flux (C) was calculated from total EB absorbance after 2 hours and permeability-surface 
area product (PA) was calculated (F) using solute flux as a measure of plasma EB 
absorbance. Solute flux and relative solute flux increased after 1 week in STZ + vehicle 
treated retinae (C) and at 8 weeks (E) relative to VEGF165b treatment. PA increased in 
diabetic retinae at 1 week (D) and 8 weeks post STZ induction (F) relative to vehicle 
treated and VEGF165b-treated retinae (B and C = 1-way ANOVA with Bonferonni's post-
hoc test, E and F = 2-way ANOVA with Tukey's post-hoc test, *p<0.05, **p<0.01) 
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These data suggest that TJ dysfunction associated with diabetes occur as early as 1 
week post STZ, and that 24 hours treatment of rhVEGF165b is sufficient to prevent onset. 
These data also suggest that the model is more robust at 8 weeks and that 8 weeks of 
systemic STZ administration is sufficient to reverse it to the extent that there is no 
significant difference between controls or between 1-week STZ + VEGF165b.  
 
EB extravasation in the CNS was also assessed, as the BRB and BBB share 
similar properties, to investigate whether STZ-induced diabetes could reflect a similar 
result as in figure 4.9. To assess this, spinal cords and brains were dissected from the 
same animals as figure 4.9 and EB solute flux and PA was calculated as described 
previously.  
I observed that there was slight increase in brain EB solute flux (figure 4.11A) in 
diabetic brains (0.009±0.005 µg/min/g) relative to control brains (0.005±0.003 µg/min/g), 
however this was not significant. VEGF165b-treated retinae had a noticeable reduction in 
EB solute flux (0.001±0.001 µg/min/g) relative to control brains, however this did not 
achieve statistical significance. Brain PA (figure 4.11B) showed a large variance, and 
therefore there was no significant difference between control and diabetic retinae 
(2.15x10-4 ±8.28x10-5 µl/g/hr and 3.02x10-4 ±1.59x10-5 µl/g/hr respectively). There was a 
more noticeable difference in VEGF165b-treated groups (4.77x10-5 ± 2.48x10-5 µl/g/hr) 
relative to diabetic brains, although this did not achieve significance. I saw a trend in the 
opposite direction in the spinal cord. EB solute flux in diabetic spinal cords (figure 
4.11C) decreased relative to control spinal cords (0.162±0.025 µg/min/g and 0.350±0.079 
µg/min/g). VEGF165b-treated rats showed an increased EB solute flux relative to diabetic 
spinal cords (0.633±0.246 µg/min/g), however this was not significant. Spinal cord PA 
followed a similar trend (figure 4.11D); diabetic spinal cords showed a decreased EB PA 
(0.007±0.0009 µl/g/hr) compared to control spinal cords (0.011 ± 0.00092 µl/g/hr). 
VEGF165b treated animals showed an increased EB PA in the spinal cord (0.0157±0.005 
µl/g/hr) relative to diabetic spinal cords, however both changes were not significant. 
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Figure 4.11. STZ-induced diabetes has no significant effect on Evans’ blue extravasation. 
(In collaboration with Dr. Richard Hulse) 
Sprague-Dawley female rats were induced with diabetes using STZ (50mg/kg i.p, n=10) 
and control rats (n=5) were injected with saline (i.p) on day 0 and weighed weekly 
Diabetic rats were treated with either vehicle (saline, biweekly i.p, n=5) or VEGF165b 
(20ng/g, biweekly i.p, n=5). At 8 weeks post-STZ induction, Evans’ blue (EB, 45mg/kg) 
was injected i.v into terminally anaesthetised rats. Plasma was collected every 15 minutes 
for 2 hours, after which, animals were sacrificed and brains and spinal cords were 
collected. Brain solute flux (A) was calculated relative to hours of EB circulation and 
showed there was no change in diabetic brains relative to control and VEGF165b treated 
animals. Brain PA (C) was calculated relative to EB plasma absorbance and showed a 
similar trend, where STZ alone increased EB PA relative to control and VEGF165b treated 
animals. The opposite trend was observed in spinal cord solute flux (C) and PA (D) 
(Kruskall-Wallis test with Dunn’s post-hoc test).  
 
DR and diabetic neuropathy are both neurovascular disorders that occur in both 
type 1 and type 2 diabetics, and have similar pathogeneses (Bloomgarden 2005). 
Sufferers of diabetic neuropathy experience vascular dysfunction in the peripheral 
nervous system, particularly in tissue involved in nociception. Previous data from our 
group has shown that 8 weeks of STZ-induced diabetes results in increased mechanical 
allodynia and thermal hyperalgesia, indicative of increased pain sensitivity. This was 
reversed upon 20ng/g biweekly VEGF165b treatment (Hulse et al, unpublished). I 
hypothesised that there would there would be a change in EB extravasation in the diabetic 
nervous tissue (figure 4.12) relative to control tissue, which would be translated to the 
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hind paw plantar skin, where the nociceptors would be hyper-sensitised. I also 
hypothesised that any changes seen in diabetic animals could be reduced in VEGF165b 
treated diabetic animals.  
I observed that there was a significant increase in both EB solute flux and PA in 
diabetic dorsal root ganglia (DRG, R3, R4, R5), relative to control DRGs (figures 4.12A 
and 4.12B respectively). This was reduced in VEGF165b treated diabetic rats, however 
this was not significant. Similarly there was an increase in saphenous nerve solute flux 
(figure 4.12C) and PA (figure 4.12D) in diabetic rats relative to control rats, and this was 
significantly reversed upon VEGF165b treatment. However, in the sciatic nerves, this 
trend wasn’t fully observed. Diabetic sciatic nerves showed more EB solute flux (figure 
4.12E) and a greater PA (figure 4.12F) relative to control tissue, however this was not 
statistically significant. There was no significant or discernable difference between 
diabetic + vehicle treated groups, and diabetic + VEGF165b treated groups for both solute 
flux and PA. However, there was a statistically significant difference between control and 
VEGF165b treated sciatic nerves. Perhaps indicating that dysfunction of the sciatic nerve 
cannot be reversed with our current treatment strategy. EB solute flux (figure 4.12G) and 
PA (figure 4.12H) increased in diabetic plantar skin relative to control skin, however this 
was not statistically significant in both assays. This result was prevented in VEGF165b 
treated groups, achieving significance in both assays.  
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Figure 4.12. Diabetes induced changes in peripheral neurovascular function can be 
prevented by VEGF165b treatment.  
Sprague-Dawley female rats were induced with diabetes using STZ (50mg/kg i.p, n=10) 
and control rats (n=5) were injected with saline (i.p) on day 0 and weighed weekly 
Diabetic rats were treated with either vehicle (saline, biweekly i.p, n=5) or VEGF165b 
(20ng/g, biweekly i.p, n=5). At 8 weeks post-STZ induction, Evans’ blue (EB, 45mg/kg) 
was injected i.v into terminally anaesthetised rats. Plasma was collected every 15 minutes 
for 2 hours, after which, animals were sacrificed and dorsal root ganglia (DRGs R3, 4, 5), 
saphenous nerves, sciatic nerves and plantar skin were collected. EB solute flux increased 
in diabetic DRGs (A), saphenous nerves (C), sciatic nerves (E) and skin samples (G) 
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relative to respective controls. VEGF165b reduced this in all groups except in sciatic 
nerves. The same trend was observed when assessing permeability-surface area product 
(PA), which increased in diabetic DRGs (B), saphenous nerves (D), sciatic nerves (F) and 
skin samples. Similarly, this increase was prevented in all VEGF165b-treated groups 
except for sciatic nerves (Kruskall-Wallis test with Dunn’s post-hoc test, *p<0.05, 
**p<0.01).  
 
These data indicate that diabetes causes vascular dysfunction in the retina, 
indicated by increased EB extravasation into the tissue. This suggests that there is indeed 
BRB dysfunction in this model and as blood vessels leak albumin-bound EB into the 
retina. This dysfunction is ameliorated in VEGF165b treated groups, suggesting that 
VEGF165b may be a useful therapeutic target in treating DME. As well as DME, these 
data suggest that other complications associated with diabetes, such as diabetic 
neuropathy, show promising results upon VEGF165b intervention.   
4.3.3. Assessing the effect of VEGF165b on diabetes-induced retinal 
neurodegeneration 
 
Data presented in this chapter indicate that VEGF165b can prevent characteristic 
vascular features of DR. Retinal neurodegeneration, another canonical feature of DR, 
precedes vascular dysfunction in DR. Loss of the retinal ganglion cell layer (RGC) is a 
prominent feature of DR and attributes to the poor visual acuity that sufferers of DR 
experience (Barber et al. 1998; Alistair J. Barber 2003). It has previously been shown that 
loss of RGC occurs in SD rats with STZ-induced diabetes (Barber et al. 1998). I wanted 
to assess if retinal neurodegeneration would occur in this model, to mimic the neuronal 
dysfunction observed in diabetic patients, and whether any changes could be reversed 
with VEGF165b. To investigate this hypothesis, I used the remaining hemisected retinae 
from figure 4.3 and stained RGCs (figure 4.13A) using neuronal nuclear antigen (NeuN). 
Both cell count and cell body area were assessed using Image J. I observed that there was 
no change in number of RGCs (figure 4.13B) expressed in diabetic + vehicle retinae 
(67±15.8) relative to control retinae (94±9.07). There was a slight increase in RGC 
number in VEGF165b treated diabetic retinae (76.9±2.97), however this was not 
significant. When assessing RGC body area (figure 4.13C), a similar trend was observed. 
Diabetes alone showed  no change in average cell body area (87.5µm2±19.5) compared 
with control retinae (113µm2±8.53). There was no change in cell body area upon 
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VEGF165b treatment (127.9µm2±9.35) relative to diabetes alone. When this information 
was further analysed and separated according to size profile (4.13D), it was evident that 
there was indeed a difference in RGC body area amongst treatment groups. Diabetic RGC 
bodies were smaller than control cell bodies, with most RGCs being 0 -39µm2 and 80-
19µm2 respectively. Diabetic rats treated with VEGF165b also had peak expression within 
80-119µm2. Interestingly, at 0-30µm2, there was significantly more RGC bodies within 
that range in diabetic retinae (4.19±0.908) relative to both control (0.583±0.583) and 
diabetic + VEGF165b (0.021±0.917).  
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Figure 4.13. VEGF165 prevents diabetes-induced RGC body shrinkage. 
Sprague-Dawley rats induced with diabetes were treated with vehicle (saline i.p, n=4) or 
VEGF165b (20ng/g i.p, n=4) biweekly for 8 weeks. Animals were then sacrificed and 
retinae excised and stained (A) for retinal ganglion cell marker (RGC) NeuN. There was 
non-significant decrease in RGC population (B) in diabetic groups relative to control 
(n=3) and VEGF165b-treated groups. There was a non-significant increase RGC shrinkage 
in the diabetic retinae (C), relative to control retinae with most RGCs being ≤ 39µm2 and 
≤119µm2 respectively (D). This was also significant compared to diabetic + VEGF165b 
treated retinae. This leftward shift in average RGC area was restored upon VEGF165b 
treatment (2-way ANOVA with Tukey’s post hoc test, **p<0.01). 
 
These data indicate a general trend that diabetes induces a cell shrinkage, which 
may precede a potential cell death, and that this could be prevented in VEGF165b treated 
groups. However as figures 4.13A and 4.13B did not achieve significance, possibly due to 
a low n number or due to deficiencies in the model, conclusions need to be drawn with 
care.  
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4.4. Discussion 
4.4.1. STZ-induced diabetes as model for PDR and testing rhVEGF165b prevention 
of vascular remodelling 
 
The use of STZ-induced hyperglycaemia is a widely used and accepted model of 
type 1 diabetes due to its rapid, reliable and robust phenotypic onset. STZ, combined with 
the addition of long-term insulin enables a more accurate model of type-1 diabetes. It has 
been hypothesised that PDR is the predominant “sight-threatening lesion” in type 1 
diabetic patients (Simó et al. 2010), however, comorbidities associated with diabetes 
typically take many years of poor glycaemic control to develop. To compensate for this, 
the experimental protocol duration was set at 7-8 weeks. This time frame has been shown 
to produce reproducible features of diabetic neuropathy (Hulse et al. 2015), and as 
diabetic neuropathy and retinopathy occur over a similar time frame, we hypothesised 
that this would also be a suitable model of PDR.  
We wanted to assess the how addition of VEGF165b systemically would influence 
diabetes-mediated pathology in the eye, by measuring IB4-positive retinal vessel density 
in untreated, diabetic + vehicle and diabetic + VEGF165b treated groups. However we 
were unable to stain control retinae with IB4 (figure 4.1), therefore hindering any 
conclusions as whether the model we are using works and also whether our systemic 
VEGF165b treatment is having any effect. However, there was a small but significant 
decrease in retinal vessel density and fluorescence per field of view in the VEGF165b-
injected diabetic animals relative to vehicle treated diabetic animals (figure 4.1B). This 
was promising as it indicated that systemically administered VEGF165b was affecting the 
retina, that the duration of the experiment was suitable enough to see differences in 
treatment and that the n numbers we chose were sufficient enough that the experiment 
had a suitable statistical power.  
There was a difference in VEGF expression in the first cohort of rats (figure 4.2). 
All VEGF isoforms were up-regulated, however it is widely accepted within the literature 
that in the retina, hypoxia-mediated VEGF upregulation is principally the predominant 
pro-angiogenic VEGF165 isoform (Shima et al. 1995; Shima et al. 1996). It is also well 
established that the characteristic hyperglycaemia observed in diabetes results in hypoxia-
mediated elevated VEGF expression in the eye (Brownlee 2001), resulting in many of the 
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pathologies seen in DR. Therefore, it is probable that the elevated VEGF expression 
observed in the STZ + vehicle treated eyes is driving the concurrent reduction in occludin 
and ZO1 expression (figure 4.2). Reduction in TJ expression is a hallmark feature of DR, 
particularly DME, which often follows from PDR. Again, these data combined with the 
results of figure 4.1 indicate that the model may be working and that systemic VEGF165b 
administration is sufficient enough to induce a change in retinal vascular density.  
The experiment was then repeated, building on the pilot data and changing the 
method of analysis from manual vessel counts to using Imaris software to semi-automate 
it. By calculating both area and volume, potential counting error was reduced, and takes 
into account changes in vascular depth. Manual vessel counts are a 2D representation of 
what occurs in these retinae, however calculating the volume gives a 3D view of how 
diabetes may affect retinal vasculature. It was evident that there was indeed an increase in 
retinal vascular density in diabetic retinae compared to untreated, after 8 weeks of 
diabetes. Increased area and volume occupied by vasculature both increased in vehicle 
treated, diabetic retinae (figures 4.3D and E). This change was prevented in the diabetic 
rats treated with VEGF165b and a similar trend was also observed when assessing 
integrated density (figure 4.3F). Similarly, there was an increase in change in vessel 
straightness (figure 4.4), or increased vessel tortuosity in diabetic retinae, relative to 
untreated and VEGF165b-treated diabetic retinae. The increase in vessel density in the 
diabetic eye is consistent with what is traditionally observed in patients with PDR, 
however it cannot be described as neovascularisation without confirmation of 
proliferation using Ki67 staining.  
Changes in protein expression for markers of angiogenesis (figures 4.5-4.7) have 
not been robust despite the changes observed in vascular remodelling. Whilst I expected 
to see a marked upregulation of VEGFR2 and pVEGFR2, as well as increased perk, I saw 
increases that were not statistically significant, and therefore firm conclusions cannot be 
made. However, this is not surprising as hypoxia-mediated changes in angiogenic 
markers occur in hypoxic microenvironments and are likely to be transient once new 
vessels have formed in response to the hypoxic stimuli. The whole diabetic retina is 
unlikely to be globally hypoxic at any given time, and therefore changes in markers such 
as VEGFR2 may be subtle and difficult to detect. A potential experiment to test this 
hypothesis would be staining retinal flat-mounts for the above markers and observing 
whether these changes are indeed global or local. However, due to limited retinae I was 
unable to pursue this experiment. 
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4.4.2. VEGF165b prevents diabetes-induced vascular remodelling: a potential 
mechanism 
 
The microvascular phenotypes observed in the diabetic retinae was likely due to 
hyperglycaemia-induced hypoxia (figure 4.5). Hypoxia results in increased VEGF 
expression and VEGFR2 activation (figure 4.6). This causes increased endothelial nitric 
oxide synthase expression (eNOS), resulting in a change in NO production thus affecting 
vasomotor tone (Ho et al. 2012) in the retina. Vessel tortuosity typically precedes 
angiogenesis and is indicative of a hypoxic environment. Instances where there are 
changes in NO expression in the retina, will also result in changes in vasodilatation both 
longitudinally and radially, both occurring at different rates and therefore resulting in a 
meandering structure (Hart et al. 1999), as observed in the diabetic + vehicle-treated rat 
retinae (figure 4.4). Interestingly, in VEGF165b-treated groups there was less vessel 
tortuosity, reflected in a trend to a reduction in HIF and VEGF protein expression (figure 
4.5). This may indicate that VEGF165b, when applied systemically, can cross the BRB and 
potentially interferes with eNOS signalling by preventing HIF transcription or by 
interfering with NO production. This would prevent the need for the vessels to constantly 
dilate and reperfuse, as the vasculature may not be occluded at all. This demonstrates the 
importance in maintaining the correct balance between both VEGF isoforms. To 
investigate this hypothesis further, one could potentially assess the effect of VEGF165b on 
eNOS production in models of OIR. Assaying levels of eNOS, NO and HIF-1α mRNA in 
VEGF165b treated hypoxic retinae would test my hypothesis sufficiently, however as this 
goes beyond the scope of my project, it was not pursued.  
Despite the reperfusion efforts, HIF levels stay elevated, resulting in increased 
pro-angiogenic VEGF expression in diabetic retinae (figure 4.5). This lead to increased 
expression and phosphorylation of VEGFR2 in diabetic retinae (figure 4.6). Increased 
VEGFR2 phosphorylation results in increased ERK-mediated endothelial cell 
proliferation and migration, key factors of angiogenesis (Brownlee 2001; Geraldes et al. 
2009). We observed a no change in both VEGFR2 and ERK phosphorylation (figure 4.7), 
despite appearing to increase in expression. It is likely that the proliferation seen in these 
retinae are likely due to this pathway. This increased proliferation is potentially why there 
is reduced cleaved caspase expression in the diabetic retinae, relative to control and 
VEGF165b-treated retinae (figure 4.7E). The elevated angiogenesis observed in figure 4.3 
is likely to be mediated by delta-like ligand 4 (DLL4). In hypoxic microenvironments 
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where there is increased VEGF expression and VEGFR2 activation, endothelial cells in 
these regions may express more DLL4. This results in tip cell formation of those DLL4-
expressing cells, DLL4 then binds to its cognate Notch receptor in neighbouring cells, 
thus inhibiting further DLL4 expression, turning neighbouring cells into stalk cells. This 
results in tubule formation and, eventually, widespread angiogenesis (Hellström et al. 
2007; Suchting et al. 2007). In models of CNV and choroidal hypoxia, angiogenesis has 
been linked with increased VEGF-induced DLL4 expression (Dong et al. 2011). This has 
been consistently shown to be the key aspect of retinal angiogenesis (Suchting et al. 
2007), however without protein expression showing elevated DLL4 in these diabetic 
retinae, we are unable to conclude this.  
VEGF165b-treated retinae show a reduced vascular density (Figure 4.3) relative to 
diabetic retinae. In a model of in vitro haemangioma, VEGF165b treatment does not 
induce DLL4 expression and furthermore, VEGF165b prevents VEGF165-induced DLL4 
expression in haemangioma endothelial cells (Dr. Ye, manuscript submitted). This, 
combined with the data obtained in this chapter, indicates that in the diabetic + VEGF165b 
treated retinae there was competitive binding of both isoforms to VEGFR2 preventing 
excessive VEGF165-induced VEGFR2 activation. As a result, more VEGF165b binding to 
VEGFR2 and a resultant weakened activation of the receptor, as observed in figure 4.6C. 
This results in a diminished downstream pathway activation, including weakened ERK 
signalling (figure 4.7), which has been shown to directly mediate DLL4 expression 
(Estrach et al. 2011). A reduction in ERK phosphorylation would likely result in a 
reduced DLL4 expression, and therefore reduced angiogenesis, as observed in figure 4.3. 
Future studies may involve electron microscopy analysis of these retinae, to assess 
whether VEGF165b can prevent-diabetes mediated basement membrane thickening and 
pericyte dropout. 
We do not have DLL4 expression data. Nevertheless, this pathway is a highly 
established pathway involved in sprouting angiogenesis, and therefore the assumption 
that it is DLL4-mediated is not unreasonable. However, there are other key factors 
involved in angiogenesis, for example increased NO production in the diabetic retinae 
could trigger angiogenesis as well was increased VEGF-induced NFκB expression. 
Multiple pathways have been implicated in retinal angiogenesis and it is likely that they 
are all involved.  
		 122	
Figure 4.3 shows that VEGF165b treatment reduces vessel density in the diabetic 
retina significantly, relative to control, healthy rat retinae. However it is not apparent 
whether this difference is detrimental to the eye. If VEGF165b reduces the vasculature in 
the eye, the retina may become hypoxic and trigger the very cascade of events it aims to 
block. In this case, if the retina does become hypoxic and increases pro-angiogenic VEGF 
expression, as long as VEGF165b is continuously administered, as in this model, then 
VEGF165b will prevent VEGF-induced pathological neovascularisation. A future 
experiment to investigate this further could involve performing electroretinograms (ERG) 
on all groups, particularly at week 8. If no change was observed in A- and B-wave 
amplitudes of the VEGF165 b-treated diabetic retinae, this would indicate that long-term 
VEGF165b treatment, if it crosses the BRB, would not cause a detrimental effect on visual 
function. As changes in the neural architecture often precede changes in vasculature in 
the diabetic retina, it would be possible to determine whether VEGF165b negatively 
impacts upon the visual pathway. However, this was not part of the experimental aim, SD 
rats were chosen for this study for their ability to develop a vascular pathology within 6 
weeks. Diabetic SD rats supplemented with insulin have been reported to not develop any 
neuro-retinal phenotype during this time (Kern et al. 2010), and therefore ERGs were not 
included in this experiment.  
4.4.3. STZ-induced diabetes as a model of DME and the effect of rhVEGF165b on 
diabetic hyperpermeability 
  
DME has been linked with sufferers of type 2 diabetes (Simó et al. 2010), 
however many type 1 diabetic patients initially present with PDR, that eventually 
escalates to DME. For this reason, and with support from published data (Xu et al. 2001; 
Qaum et al. 2001), we used the STZ model of diabetes to assess changes in retina solute 
flux. A study showed that in a rat model of insulin-supplemented diabetes, there was an 
insulin-induced increase in VEGF expression in the RPE (Poulaki et al. 2002), indicating 
that this model may be suitable for assessing changes in the outer BRB. 
 To assess how retina solute flux and PA is affected by SD rats, I modelled an 
experiment pioneered by Xu and colleagues in 2001, whereby Evans’ blue was injected 
intravenously in diabetic and non diabetic animals ± intravitreal VEGF administration 
(Xu et al. 2001). With minor modifications, I implemented this semi-quantitative 
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technique to investigate my hypothesis that VEGF165b could prevent diabetes-induced 
increase in PA in the retina. Despite being a model of type 1 diabetes, it is evident that 
there is indeed a change in EB solute flux and PA in the diabetic retina after 8 weeks of 
diabetes, and even after as little as 1 week post induction (figures 4.9 and 4.10 
respectively).  
There was an increase in EB solute flux and PA after 8 weeks of diabetes (figure 
4.9), in the vehicle treated diabetic retinae relative to healthy rat retinae. This, combined 
with the reduction in ZO1, occludin and VE-cadherin expression (figures 4.2 and 4.8) 
indicate that there is a disruption of the BRB upon diabetes, however despite appearing to 
be a marked change, decreases in occludin expression never reach statistical significance. 
VE-cadherin is an endothelial specific TJ, and therefore we can support already 
established hypotheses that DME involves the inner BRB. However, there is growing 
evidence in the literature that support the importance of the outer BRB. Previous in vivo 
permeability assays have shown low and high MW FITC-dextran accumulation at the 
outer BRB in models of diabetes, OIR and endotoxin-induced uveitis (Xu et al. 2011), 
thus reiterating the importance of the outer BRB in DME. However, as there is no RPE-
specific TJ, we are unable to confirm this hypothesis in this particular model.  
VEGF165b-treated diabetic rats show a statistically significant reduction in EB 
extravasation into the retina, relative to vehicle-treated diabetic rats, indicating an 
inhibition of hyperglycaemia-induced insult on TJs. This is further supported by 
significant increases in VE-cadherin expression (figure 4.8). A similar result was 
observed after 1-week of non-insulin supplemented diabetes (figure 4.10). There was an 
increase in EB extravasation in the diabetic vehicle-injected retinae relative to control, 
vehicle-injected retinae and untreated retinae. This supports previously published findings 
that 7 days of diabetes is sufficient to induce changes in retinal “permeability”. 
Intravitreal administration of VEGF165b for 24 hours was sufficient to reduce changes in 
EB extravasation, indicating that once it is definitely across the outer BRB, VEGF165b has 
a very robust effect. These data also suggest that the 8 weeks diabetes cohorts from 
figures 4.1, 4.3 and 4.9, were not treated with VEGF165b prophylactically, but rather upon 
onset of retinal pathology. Diabetic rats were first treated with vehicle or VEGF165b 1-
week post confirmation of hyperglycaemia, and as I, and others have shown, 1-week is all 
that is required to see changes in “permeability”(Xu et al. 2001; Qaum et al. 2001). As an 
increase in solute flux and accumulation of fluid is the major sight-threatening aspect of 
DME, it is fair to hypothesise that this both the 1-week and 8-weeks model of diabetes 
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can be regarded as models of DME, and the VEGF165b, whether administered IP or IVT, 
is able to prevent fluid accumulation in the retina, induced by diabetes.  
Figures 4.10E and 4.10F show the differences between both models, and it 
appears that 8 weeks of diabetes provides a more robust phenotype, relative to 1-week 
diabetes as there is an increase in both EB solute flux and PA in the 8 week model 
relative to the 1 week model. This could be due to excessive insulin-induced VEGF 
expression in the RPE resulting in a more compromised outer BRB than perhaps would 
be seen without insulin treatment. It also shows that there is no significant difference 
between 24 hours of IVT VEGF165b treatment versus 8 weeks systemic VEGF165b 
treatment, indicating the robust nature of IVT treatment.  
With regards to the BBB (figure 4.11), this model may not be robust enough to 
induce changes in permeability in other regions of CNS, despite seeing significant 
decrease in spinal cord permeability after 1 week of diabetes and seeing changes in the 
retina at both time points. However there were marked increases in both EB solute flux 
and PA in the DRGs, sciatic nerves, saphenous nerves and plantar skin in the diabetic + 
vehicle treated rats, relative to control animal tissue (figure 4.12). These regions are all 
associated with neuropathic pain and the same rats were more sensitive to mechanical and 
thermal stimuli, indicating peripheral neuropathy (Hulse et al. 2015). VEGF165b treatment 
reduced EB extravasation in these tissues, which correlated with a reduction in pain 
sensitivity. This indicates that the 8-weeks model of insulin-supplemented type 1 diabetes 
is a good model to assess complications associated with diabetes and that the EB 
technique is a robust method at detecting neurovascular dysfunction.  
 
 The Evans’ blue dye perfusion technique has limitations whereby as it is only 
semi-quantitative, we cannot categorically claim changes in permeability. When vessels 
are perfused with EB, it is difficult to tell how much EB is unbound. Previous studies 
have shown that approximately 50% of EB does not bind to albumin and circulates as free 
dye (Levick & Michel 1973). Considering EB is only 961 Da, if left unbound it could 
pass through pores in the vasculature, smaller than those created by loss of TJs or induced 
by pathology, and may give a false positive result. Another caveat to this experiment does 
not account for changes in blood pressure. Whilst diabetic patients have a high incidence 
of hypertension (The National High Blood Pressure Education Program Working Group 
1994), there are conflicting data whether STZ diabetic rats are hypertensive (Kusaka et al. 
1987).  The EB technique requires constant removal of blood from the femoral artery that 
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will reduce blood pressure throughout the experiment. Changes in blood pressure will 
affect flow of EB across capillary walls (Levick & Michel 1973), and therefore EB 
accumulation in the tissue could, in part, be also due to fluctuating blood pressure. Whilst 
we cannot definitively say that the diabetic eyes were more “permeable” than the non-
diabetic eyes, changes in solute flux and PA are often regarded as markers of 
permeability,  
4.4.4. VEGF165b prevents diabetes-induced permeability: a potential mechanism 
 
There are many pathways by which fluid extravasation occurs in this model, many 
experts within the field suggest that is likely to be PKC mediated-TJ phosphorylation. 
This relies on the assumption that the increased solute flux is due to diabetes, and not due 
to other changes in vasoactivity. Similar models using the EB technique are in agreement 
that diabetes increases EB leakage and is likely mediated by PKC (Aiello 2002; Harhaj et 
al. 2006; Titchenell et al. 2012). There are two families of PKC isoforms, typical and 
atypical, and both families of isoforms have been implicated in the pathogenesis of DME. 
In the diabetic retina, there is an increase in extracellular glucose, which upon binding to 
cells, triggers de novo synthesis of DAG, which in turn upregulates typical PKC isoforms, 
including -α, -β, -δ and -γ (Brownlee 2001). These PKC isoforms have been linked 
directly to occludin phosphorylation in vitro and in vivo predominantly at the serine and 
threonine residues, and potentially these residues on ZO1 (Harhaj et al. 2006; Titchenell 
et al. 2012), resulting in their internalisation to an intracellular pool. However the Food 
and Drug Administration (FDA) did not approve a PKCβ inhibitor, ruboxistaurin, for the 
treatment of DME until another phase III clinical trial is completed (Javey et al. 2012). 
Furthermore, typical PKC inhibition only partially prevented hyperglycaemia-induced 
increase in permeability in RECs (Harhaj et al. 2006). Indicating that perhaps the RPE / 
outer BRB are involved more than previously thought and that also perhaps other PKC 
isoforms may be involved. Inhibition of atypical PKC isoforms, such as PKCζ, have 
shown promising results with regard to VEGF-induced but not diabetes-induced 
permeability in vivo (Titchenell et al. 2012). Activation of PKCζ is not calcium or DAG 
dependent like the typical PKCs, furthermore, inhibition of PKCζ also results in a 
reduction in tumour necrosis-α (TNF-α), a potent inflammatory factor. In a model of 
type-2 diabetes, Goto Kakizaki rats showed an increase in PKCζ activation in the RPE 
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layer resulting in inflammatory cell trafficking between the choroid and the RPE. There 
was a resultant increase in microglia and macrophage accumulation in the subretinal 
space (Omri et al. 2011), further confirming that the importance of the outer BRB in DR.   
Activation of DAG and PKC results in an upregulation of VEGF165 (or the mouse 
equivalent, VEGF164) and NFΚΒ, both of which are pro-inflammatory and upregulate 
expression of intracellular adhesion molecule (ICAM-1) and TNF-α. It has been 
suggested that an increase in these pro-inflammatory cytokines result in increased retinal 
permeability (Ishida 2003; Joussen et al. 2004; Tang & Kern 2011). VEGF165b has been 
shown to reduce TNF-α mediated ICAM activation in RPE cells, and therefore is 
potentially anti-inflammatory (Thichanpiang et al. 2014). Furthermore, VEGF165 has 
shown to activate PKC (Hulse et al. 2014b), whereas VEGF165b blocks PKC activation in 
vitro (S. Bestall, unpublished data).  
However, both types PKC of treatment show partial prevention in permeability, 
whereas data in this chapter shows almost a complete reversal of pathology. A potential 
mechanism by which VEGF165b prevents permeability could be by targeting both families 
of isoforms. VEGF165b competitively binds to VEGFR2, and therefore only partially 
activates DAG and therefore partially activates typical PKC isoforms; therefore there is 
little or no phosphorylation of TJs. VEGF165b also reduces TNF-α expression in the outer 
BRB, perhaps by blocking atypical PKC activation in the RPE, also preventing TJ 
phosphorylation and subsequent hyperpermeability. This again further underlines the 
importance of maintaining both pro- and anti-angiogenic VEGF isoforms. However, to 
test this hypothesis, the above experiments would need to be repeated with and without 
inhibitors of each PKC family ± VEGF165b co-treatment.  
4.4.5. STZ-induced 8 –weeks diabetes is not a robust enough model to induce retinal 
ganglion cell death  
 
RGC loss is a prominent feature of the neurodegenerative arm of DR and is 
significantly part of vision loss. To assess if this change would be observed in STZ-
induced diabetes, retinae 8-week diabetic rats ± VEGF165b and control retinae were 
stained for NeuN, a marker of RGCs (figure 4.13A). When counting the NeuN-positive 
cells, there was a non-significant decrease in these cells in diabetic + vehicle treated eyes 
relative to control eyes, and there was a slight increase in VEGF165b treated groups 
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(figure 4.13B). These findings have been supported in previous work that shows SD rats 
develop a non-significant reduction in RGCs even after 4 months of insulin-supplemented 
diabetes (Kern et al. 2010). This conflicts with what is seen in diabetic patients as RGC 
layer thinning occurs before the onset of any vasculopathy (Kern & Barber 2008), 
indicating that STZ-induced diabetes in SD rats does not produce all aspects of DR.  
There was no significant difference in total RGC area (figure 4.13C), however 
when these findings were dissected further and categorised by size (figure 4.13D), it was 
evident that diabetic + vehicle treated rats showed RGC shrinkage, relative to control and 
VEGF165b treated rats. This suggests that whilst the model may not be successful in 
reducing RGC number, it is causing dysfunction in the RGC layer. It is possible that the 
thinning of the RGC layer in patients is also due to RGC shrinkage, and that shrinkage 
precedes RGC death. A future direction for this experiment may be to repeat this 
experiment, with the addition of assaying ERGs of each eye at the end of the 8-week 
period.  
VEGF is upregulated in the diabetic retina, particularly in insulin-treated diabetes 
in SD rats (Poulaki et al. 2002) and is possibly exerting a neuroprotective role on the 
RGC layer as it does in other models of eye disease (Jin et al. 2000; Shima et al. 2004; 
Foxton et al. 2013). Furthermore, insulin has been hypothesised to prevent RGC 
apoptosis in rat models of DR (Kern & Barber 2008), again conflicting with what is 
observed in patients whereby insulin therapy in fact causes a transient worsening of 
retinopathy (Dahl-Jorgensen et al. 1985; Anon 1993; Chantelau & Kohner 1997). VEGF 
and insulin may be protecting the RGC layer from the vascular dysfunction in the earlier 
stages of DR. It is possible that over time, once the vascular dysfunction develops and 
there is an increase pro-inflammatory markers, RGCs are no longer sufficiently protected 
by VEGF and insulin and start to shrink. If we extend this model to a significantly longer 
time point there may be RGC dysfunction. An additional caveat to this experiment is that 
some NeuN antibodies have been known to also stain cholinergic amacrine cells that have 
been displaced to the GCL. However this is usually only 15-20% of cells stained by 
NeuN, and it is therefore likely that the majority of these results are from RGCs (Schlamp 
et al. 2013). Nevertheless, VEGF165b does appear to protect against RGC shrinkage and 
perhaps amacrine cell shrinkage, both cell types associated with visual dysfunction in 
DR. At the time of writing this study, is the only treatment that appears to treat 
neovascularisation, oedema and neuronal dysfunction in the diabetic eye.  
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4.5. Concluding Remarks 
The current gold-standard treatments for DR involve a combination of PRP laser 
therapy and anti-VEGF therapy in treating both PDR and DME. Systemic VEGF165b 
administration appears to be less invasive than laser therapy, as no anaesthesia or 
analgesia is required in systemic application of this drug. Furthermore, laser therapy is 
only a temporary measure and often results in neural retina damage and further sight loss. 
Laser-treated patients will usually require further laser treatment or a combination of laser 
treatment and anti-VEGF therapy (Hammes 2013). 
A major concern associated with using anti-VEGF therapy is the risk of anti-
VEGF agents entering the choroidal and then systemic circulation, resulting in adverse 
events in diabetic patients. As VEGF165b is already an endogenous cytokine, if it enters 
the systemic circulation, it is perhaps less likely to cause an adverse event than other 
treatments. When investigating peripheral tissue and kidney and heart tissue (data not 
shown) it appears that systemic VEGF165b had no adverse effect on vessel integrity in 
these regions. Also, having observed no difference between IVT and IP administration of 
VEGF165b on EB extravasation, VEGF165b could be administered whichever way would 
associate with less risk of possible adverse events. It is therefore plausible that VEGF165b 
could be a potential therapeutic agent in treating DME. 
 With regards to the vascular complications of DR, a future step may be to test the 
effect of VEGF165b in experimental DR in higher mammals and assessing if a similar 
result is observed as well as treatment associated toxicity. A more suitable method of 
BRB leakage may be to do fluorescein angiography, if using non-albino animals. An 
immediate future direction would be to reassess this model, and select a strain of rats 
more suitable for assessing neuronal dysfunction in the retina and investigating the 
whether VEGF165b improves visual function in the diabetic eye. 
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Chapter 5: AAV.VEGF165b 
and diabetic retinopathy 
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5.1. Introduction 
Anti-VEGF therapy for diabetic retinopathy has recently become widely used 
both experimentally and clinically, due to its ability to curb both PDR and DME (Ferrara 
et al. 2006; Stewart 2014). Although this has shown positive results in reducing NV, 
macular thickness and in some cases gaining of letters (Wells et al. 2015), anti-VEGF 
agents are not suitable for the early stages of DR. Retinal neurodegeneration precedes 
ischaemia-induced changes in retinal vasculature  (Lieth et al. 2000; Alistair J. Barber 
2003), furthermore, VEGF is neuroprotective in the retina (Foxton et al. 2013). Therefore 
by administering anti-VEGF therapy as an early treatment would likely prove to be 
detrimental. Nevertheless, early or even preventative treatment for DR directed towards 
neuroprotection may be a beneficial therapeutic strategy as there is an hypothesis that 
suggests that it is retinal neurodegeneration can contributes to the vascular pathology seen 
later on (Lieth et al. 2000). Also, most current therapies target the vascular component of 
DR, leaving the neurodegeneration as a secondary aspect.  
Gene therapy as a potential treatment for preventing retinal neurodegeneration is a 
widely investigated field showing promising results. Leber congenital amaurosis (LCA), 
a condition resulting in infant blindness can result from a defect in the RPE65 gene. Dogs 
that are deficient in this gene suffer from severe vision loss, and when treated with the 
rAAV-RPE65 vector showed a significant improvement in vision (Acland et al. 2001) 
and recent clinical trial data shows that there is also an improvement in retinal function in 
patients with LCA (Bainbridge et al. 2015). In a model of recessive retinitis pigmentosa, 
the retinal degeneration slow mouse (RDS) is unable to produce peripherin 2, due to a 
mutation in the gene that encodes it (Prph2; Chang et al. 1993). This membrane 
glycoprotein is essential for photoreceptor disc formation therefore RDS mice are unable 
to form proper outer segments and photoreceptor discs, and as a result show poor 
phototransduction. Eventually, photoreceptors undergo apoptosis starting approximately 
two weeks post-birth, resulting in gradual blindness (Chang et al. 1993). Introduction of 
the Prph2 minigene into these deficient eyes using AAV2 under a rhodopsin promoter 
resulted in stable outer disc formation and increased ERG A- and B-wave amplitude (Ali 
et al. 2000).  
Gene therapy to treat neovascular complications has also been widely 
investigated. Vectors expression anti-angiogenic compounds such as sFlt1 (Bainbridge et 
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al. 2002), PEDF (Auricchio et al. 2002) and endostatin (Balaggan et al. 2006) have all 
shown to reduce ocular angiogenesis in vivo. However few vectors aim to address 
neuroprotection as well as inhibiting angiogenesis. VEGF165b has shown to be 
neuroprotective against RGC death upon ischaemic insult (Beazley-Long et al. 2013) and 
against diabetic insult in the peripheral nervous system (Hulse et al. 2014b). It has also 
shown to be cytoprotective in culture and in the retina (Magnussen et al. 2010). 
Considering the progress being made in retinal gene therapy, using this approach may 
facilitate long-term expression if VEGF165b and also minimise the number of injections 
needed and therefore also reducing likelihood of possible injection-related side effects. I 
therefore attempted to test the hypothesis that Lewis rats induced with diabetes would 
show an increase in retinal neural dysfunction and this would be translated into a 
reduction in retinal thickness. I also attempted to test the hypothesis that AAV.VEGF165b 
would prevent diabetes-induced changes in neural dysfunction and retinal thickness.  
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5.2 Methodology 
This study used AAV2/8 due to its previously described low immunogenicity 
(Anand et al. 2002) and its ability to transduce RPE and photoreceptors efficiently (Buch 
et al. 2008). Three viruses were prepared: AAV.GFP, AAV.VEGF165b and AAV.Null 
(negative control, see appendices for details). As the primary aim of the experiment was 
to observe and potentially prevent neurodegeneration of the diabetic retinal architecture, 
Lewis rats were chosen for this experiment for their previous history of showing RGC 
loss within 4 months of induction of diabetes (Kern et al. 2010).  
Lewis rats (n=33) were divided into two main groups, diabetic and non– diabetic 
controls. Two weeks prior to induction of diabetes, rats were subretinally injected with 
two 5µl subretinal injections, superior and inferior, of approximately 1x1012 vp/ml of: 
AAV.VEGF165b, AAV.Null or no injection. Viruses were only injected in one eye, with 
the contralateral eye serving as an untreated control reference eye. The groups were 
further divided as shown by table 5.1. 
 
Diabetic (n=18) Non–diabetic (n=15) 
Untreated (n=5) Untreated (n=5) 
AAV.Null (n=6) AAV.Null (n=5) 
AAV.VEGF165b (n=7) AAV.VEGF165b (n=5) 
 
Table 5.1. Treatment groups for long–term diabetes study. 
 
 Two weeks following virus injection, the rats listed in table 5.1 were subject to 
STZ injection (i.p, 50mg/kg). Control rats were given a saline injection i.p. Diabetic rats 
were then implanted with 1/3 of an insulin capsule (LinShin) in the same afternoon. Three 
days post–injection, blood glucose was assessed for hyperglycaemia and rats with blood 
glucose >15mmol/l were deemed diabetic. One-week post confirmation of diabetes, rats 
were subject to ERG, SLO and OCT analysis under general anaesthesia to assess retinal 
function, atrophy and thickness respectively. This time point was regarded as month 0 
and in vivo assessment was repeated monthly for 4 months. At the end of the study, rats 
were sacrificed and eyes were fixed and frozen in OCT ready for sectioning and staining. 
For further details, see chapter 2 “Materials and Methods”.  
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 To validate the AAV.VEGF165b, I also used in the laser CNV model in C57BL6j 
mice. Adult female mice (6-8 weeks old) were given two 2µl injections of either 
AAV.VEGF165b or AAV.Null (titre- matched at 1x1012 vp/ml). Two weeks post injection, 
mice were subject to a 3 laser burns on each eye under general anaesthesia. At 3, 7 and 14 
days post-laser burn, FFA was carried out on all mice. On day 14, mice were sacrificed 
and choroids were fixed, flat-mounted and stained for IB4. Burn area was calculated in 
vivo and ex vivo using Image J. For further details, please see chapter 2, “Materials and 
Methods”. 
 To test the neuroprotectivity of AAV.VEGF165b in an alternative model, RDS 
(retina degeneration slow) mice were also injected with either AAV.VEGF165b or 
AAV.Null. However, as mice were injected at P10, only 1 subretinal injection was 
administered under general anaesthesia (2µl of virus at 1x1012 vp/ml). Two weeks post 
virus administration; mice were subject to monthly ERGs for 2 months. For further 
details, please see chapter 2, “Materials and Methods”.  
 
All viruses, unless otherwise stated, we administered via a subretinal injection under 
general anaesthesia.  
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5.3. Results 
5.3.1. Optimisation of vector dosage 
 
To determine whether we could transduce the Lewis rat eye appropriately, Lewis 
rats were injected with 2x5µl of vector at 1x1012 vp/ml, in one eye, with the contralateral 
eye serving as an untreated control. Volumes of virus injected were chosen based on 
relative GFP expression in SLO images (see Appendix 4). Two weeks following 
injection, rats underwent scanning laser ophthalmoscopy (SLO), and the fluorescence was 
observed (figure 5.1A). Immediately after imaging, rats were culled and eyes were fixed 
and imaged using the 488 laser to observe where GFP was transduced (figure 5.1B). The 
data showed that we were able to transduce the outer retina and most importantly to our 
hypothesis, the ORB (RPE).  
 
 
Figure 5.1. Infrared and SLO images of AAV.hrGFP injected Lewis rat eyes 
Lewis rats (n = 3) were injected with 2x5µl AAV.hr.GFP (1x1012 vp/ml) in the right eye, 
subretinally. The left eyes, served as an untreated control. Two weeks following injection, 
rats were subject to infrared and SLO (A) imaging and eyes were enucleated, sectioned 
and imaged and relative areas of fluorescence were observed (B). AAV.hrGFP is able to 
successfully transduce the rat eye when given two injections of 5µl AAV.hrGFP at 1x1012 
vp/ml.  
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To determine the amount of VEGF165b produced by AAV.VEGF165b, Lewis rats (n=4) 
were injected with the same dose and same volume (1x1012 and 2x5µl respectively) of 
AAV.VEGF165b in one eye (n=4), and AAV.Null (n=2) or untreated (n=2) in the 
contralateral eye. Two weeks post – injection, rats were culled and eyes were enucleated 
and retinae and choroids were assayed for VEGF165b expression. Retinae were subject to 
immunoblotting using the 56/8 anti-VEGF165b antibody (figure 5.2A). ELISA assayed 
both retinae and choroids for VEGFxxxb (figure 5.2C - E). There was a threefold increase 
in VEGF165b expression in the AAV.VEGF165b injected eyes compared to both negative 
control groups (figure 5.2B). There was a significant increase in VEGFxxxb expression in 
the AAV.VEGF165b injected groups, compared to AAV.Null and untreated groups, when 
calculating expression relative to total VEGF expression, and this trend was observed in 
both retinae (figure 5.2C) and choroids (figure 5.2E). However, when measuring 
VEGFxxxb expression relative to total protein expression, VEGFxxxb was only 
significantly overexpressed when compared with untreated groups in both retinae (figures 
5.2D and 5.2F respectively). However, we do observe a 1.5 fold increase in VEGFxxxb 
expression in AAV.VEGF165b injected groups compared to the other groups, relative to 
total protein in both retinae and choroid (figures 5.2D and 5.2F)   
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Figure 5.2. AAV.VEGF165b was able to successfully induce VEGF165b expression in 
retinae and choroids in Lewis rats. 
Lewis rats were injected with AAV.VEGF165b, AAV.Null or left untreated and were 
culled two weeks post – injection, at which point retinae and choroids were assayed for 
VEGFxxxb expression. Retinae were immunoblotted against 56/1, a VEGF165b specific 
antibody (A) and protein expression was quantified relative to β – actin expression (B). 
There was a significant increase in VEGF165b expression in the AAV.VEGF165b treated 
groups, relative to AAV.Null and untreated groups. Retinae and choroids were assayed 
for VEGFxxxb expression by ELISA. Values were either represented relative to total 
VEGF expression (C and E) where VEGFxxxb was significantly overexpressed relative to 
AAV.Null and untreated groups in retinae and choroids. When calculated as a measure of 
total protein expression (D and F), retinae and choroids injected with AAV.VEGF165b 
only expressed increased levels of VEGFxxxb relative to untreated groups (1-way 
ANOVA with Tukey’s post hoc test, *p<0.05, **p<0.01). 
 
 
Figure 5.2 shows that not only did we successfully cause overexpression of VEGF165b 
using AAV.VEGF165b but there was also no upregulation of VEGF165b upon injection of 
AAV.Null, confirming we have an adequate negative control. For further assays 
regarding AAV.Null expression, please see appendices.  
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5.3.2. STZ – induced diabetes does affect ERG amplitude or retinal thickness in 
Lewis rats 
 
 Having confirmed that AAV.VEGF165b did increase VEGF165b expression (figure 
5.2) and that AAV.Null does not induce VEGF165b or expression of the original 
RK.RPGR construct (appendix 3), the viruses could be used further. To investigate 
whether VEGF165b gene therapy could prevent degeneration of the retinal neural 
architecture, Lewis rats were injected with saline or STZ (50mg/kg, as described in 
Chapter 2: “Materials and Methods”). Each animal either received: AAV.VEGF165b, 
AAV.Null or no injection in the right eye, with the left eye serving as a reference eye  
(see table 5.1). Differences in neural retina were measured in vivo by ERG for 4 months 
as the Kern group have reported differences in ERG B–wave amplitude in insulin-
supplemented diabetic Lewis rats after 3–4 months (Engerman & Kern 1995; Kern et al. 
2010; Robinson et al. 2012b). As mentioned previously, the hypothesis of this experiment 
was to see whether we could prevent diabetes – induced degeneration of the neural retina 
using AAV.VEGF165b. To assess whether diabetes induced retinal neural degeneration in 
this model, I compared control rat ERGs with diabetic rat ERGs, both of which were 
untreated eyes, at 4 months of diabetes. I hypothesised that after 4 months of diabetes the 
ERG amplitude for almost all measurements, particularly the B–wave amplitudes, would 
be reduced relative to control rats. However despite maintaining a steady weight (figure 
5.3A) and being consistently hyperglycaemic (figure 5.3B), there was no significant 
difference between controls and diabetics in the rod mediated (scotopic) A or B wave 
(figure 5.3 B and C respectively). There was also no difference in A or B–wave amplitude 
in the cone–mediated (photopic) response between controls and diabetics. However, there 
did appear to be a small, but non–significant difference in the scotopic B–wave (figure 
5.3D) at the higher light intensities.  
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Figure 5.3 STZ–induced diabetes has no effect on relative ERG amplitude in Lewis rats at 
4 months 
Lewis rats were induced with diabetes (n=5) using STZ (50mg/kg, i.p) and supplemented 
with insulin (subcutaneous pellet) to prevent weight loss (A). Rats with a blood glucose 
≥15mmol/l were deemed diabetic (B) and were subject to monthly ERG assessment for 4 
months. Diabetics and saline–injected rats (control, n=5) were dark-adapted overnight 
prior to assessment to ensure no photo bleaching would skew scotopic measurements. A 
custom programme was designed to best assess amplitude for both scotopic and photopic 
responses. Scotopic measurements were assessed over an 11–step intensity protocol 
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ranging from 0.001(S).cd/s2 to 75.35(S).cd/s2. Photopic intensities were measured of a 
custom-designed 6–step protocol ranging from 0.1 (S).cd/s2 to 75.38(S).cd/s2. There was 
no significant difference between controls and diabetic in their rod–mediated A- or B-
wave amplitude (C an D respectively), Similarly there was no difference in cone–
mediated A- and B–wave amplitude (E and F respectively).  
 
Although there is no significant difference in ERG amplitude in any of the parameters, it 
is possible that there they may have been a difference during earlier time points. To 
assess this hypothesis, I plotted the scotopic A– and B–wave amplitudes obtained at 
minimal and maximal intensities (0.001 and 75.38 cd.s/m2 respectively) of control and 
diabetic ERGs over the 4–month period. As evident from figure 5.3, photopic A– waves 
were unreliable even in control animals, and have therefore been excluded from further 
analyses in this chapter, and so only amplitudes obtained at minimal and maximal 
photopic B wave intensities have been plotted (0.1 and 75.38 cd.s/m2 respectively). 
Figure 5.4 shows that there was no significant difference at any time point across any 
parameter. Interestingly, even the healthy animals show retinal dysfunction over the 4-
month period in all B–wave responses (figure 5.4C – 5.4F). Furthermore, in all B–wave 
responses diabetic seem to have greater amplitude than control B–waves, however these 
data are not statistically significant.   
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Figure 5.4. STZ–induced diabetes does not affect ERG amplitude in Lewis rats over a 4-
month period 
Lewis rats were induced with diabetes (n=5) using STZ (50mg/kg, i.p) and supplemented 
with insulin (subcutaneous pellet) Rats were subject to monthly ERG assessment for 4 
months. Diabetic rats and age-matched controls, injected with saline i.p (n=5) were 
subject to ERG assessment monthly, and minimal and maximal light intensities were 
plotted. There was no difference in rod mediated A– or B–response both at minimal 
intensity (A and C) or maximal intensity (B and D). There was also no difference in the 
cone-mediated response at both ends of the 6–step process (E and F).  
 
To investigate this further, I sectioned and stained these retinae for DAPI and measured 
GCL thickness by counting DAPI–positive cells within the GCL (figure 5.5A). I observed 
that there was no significant difference in the number of cells in the GCL between control 
retinae and diabetic retinae (figure 5.5B).  
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Figure 5.5. 4–months STZ–induced diabetes does not alter number of DAPI–positive 
cells in the GCL in Lewis rats. 
Lewis rats were induced with diabetes (n=5) using STZ (50mg/kg, i.p) and supplemented 
with insulin (subcutaneous pellet). Four months post–induction, diabetic and age–
matched controls (n=5) were culled and retinae were sectioned and stained for DAPI (A). 
Cells in the GCL were counted using Image J which showed there was no significant 
difference in DAPI–positive cells in the GCL between control and diabetic retinae 
(Student’s T-test).  
 
Diabetes usually causes thinning of the GCL and thickening of the macula, and 
although rodents are devoid of maculae, I initially wanted to characterise this model and 
see how retinal thickness may differ between control and diabetic groups. To investigate 
this further, on the same day as ERG measurements were undertaken and under the same 
anaesthetic regimen, I measured retinal thickness in 4 regions of the retina using OCT. I 
then quantified the retinal thickness by determining an ROI (GCL to RPE) using Image J 
(for further details please read chapter 2 “Materials and Methods”). I observed that in all 
regions of the retina, there was no difference in retinal thickness between control and 
diabetic groups.  
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Figure 5.6. 4–months STZ–induced diabetes does not alter total retinal thickness in Lewis 
rats. 
Lewis rats were induced with diabetes (n=5) using STZ (50mg/kg, i.p) and supplemented 
with insulin (subcutaneous pellet). Retinal thickness in diabetic rats and saline controls 
(i.p, n=5) were measured using OCT on the same day as ERG. Four main regions were 
imaged over the 4 month period: a horizontal cross section (A), a vertical cross section 
(B), a cross section the furthermost superior region of the eye (C) and a cross section 
through the furthermost inferior region of the eye (D). These same regions repeatedly 
imaged every month and showed no significant change at any time point over the 4–
month period.  
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5.3.3. Subretinal gene therapy induces retinal neurodegeneration not exacerbated by 
diabetes. 
 
 To investigate the effect that gene therapy had on the development of diabetic 
retinopathy, Lewis rats were induced with diabetes (as described in 5.3.2.) and 
subretinally injected with AAV.VEGF165b and AAV.Null, in tandem with experiment 
5.3.2. Rats were subjected to monthly ERGs to assess the progression of retinal 
neurodegeneration. I observed that subretinal administration of AAVs induced 
diminished ERG amplitudes in all measurements. When comparing treatments amongst 
healthy rats (untreated, AAV.Null and VEGF165b) there was a diminished response over 
the 4-month period in both vector-injected groups (figure 5.7). These data also indicate 
that AAV.Null injected eyes express a diminished response, particularly 2-months post-
injection. This became especially noticeable at the higher light intensities, reaching 
significance at 2 months post-induction of diabetes in the scotopic A-wave at 
75.38cd.s/m2 (figure 5.7B). Null vector injected eyes showed reduced peak amplitude 
(8.02±3.74 mV) relative to untreated eyes (10±0.22 mV) at 2 months. There was no 
significant difference between diabetic AAV.Null injected eyes (5±7.07mV) and 
untreated eyes or diabetic AAV.Null eyes control AAV.Null eyes. There was a similar 
trend when observing B-wave amplitudes at 75.38cd.s/m2 (figure 5.7D) whereby there 
was decreased amplitude at 2 months in the control + AAV.Null groups (296±100mV), 
that eventually improved after 3 months, relative to untreated groups (697±168mV) and 
diabetic AAV.Null groups (645±50mV).  There was a significant difference at 2 months 
and 3 months between untreated groups and control + AAV.Null groups. Paradoxically, 
in all parameters, the diabetic groups did not show any significant difference relative to 
untreated groups. Whilst there was also no difference between control AAV.Null and 
diabetic AAV.Null, it does appear that diabetes prevented the vector-induced 
degeneration. Furthermore, the curves of both untreated eyes and diabetes + AAV.Null 
are very similar amongst almost all parameters, further indicating that diabetes prevented 
vector-induced degeneration.  
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Figure 5.7. Null vector administration worsens ERG amplitude in control rats. 
Lewis rats (n=11) were injected subretinally with AAV.Null  (2x5µl of vector at 1x1012 
vp/ml). AAV.Null-injected rats were induced with diabetes 2-weeks post-subretinal 
injection (n=6) using STZ (50mg/kg, i.p) and supplemented with insulin (subcutaneous 
pellet). The remaining AAV.Null rats (n=5) were injected with saline (i.p). Age-matched 
control, untreated rats (n=5), diabetic AAV.Null rats and control AAV.Null rats subject to 
monthly ERG assessment for 4 months and minimal and maximal light intensities were 
plotted. There was no difference in rod mediated A– or B–response both at minimal 
intensity (A and C). There was a significant decrease in amplitude at 2 months when 
assessing maximal scotopic A-wave (B) between control + untreated rats and control + 
AAV.Null. There was also a significant decrease in maximal scotopic B-wave amplitude 
at 2 and 3 months post–induction of diabetes (D). There was also no difference in the 
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cone-mediated response at both ends of the 6–step process (E and F) (Student’s 2-tailed t-
test, *p<0.05). 
 
It is possible that VEGF165b over expression may prevent the neurodegeneration induced 
by vector administration. To test this hypothesis, I plotted AAV.Null injected control rats’ 
ERG data with AAV.VEGF165b control ERGs. I observed the opposite to my hypothesis 
when assessing rod-mediated low light intensity A-wave responses (figure 5.8A). There 
was a significantly lower amplitude observed at 1 month in AAV.VEGF165b (0±0mV) 
injected eyes relative to AAV.Null eyes (10±3.5mV). At all other time points and 
parameters (figure 5.8B-E), there was no significant difference in amplitude between both 
treatment groups. However, the AAV.VEGF165h groups did appear to have constantly 
lower amplitude 1 month onwards, despite only being significant in the 0.001cd.s/m2 
scotopic A-wave amplitude.  
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Figure 5.8. AAV.VEGF165b does not significantly worsen ERG amplitude relative to 
AAV.Null in healthy rats. 
Lewis rats (n=10) were injected subretinally (2x5µl of vector at 1x1012 vp/ml) with 
AAV.Null (n=5) or AAV.VEGF165b (n=5). All rats were injected with saline (i.p) two 
weeks post subretinal injection and subject to ERG assessment for 4 months 1 week post 
saline injection, and minimal and maximal light intensities were plotted. There was a 
significant reduction in A-wave amplitude at 0.001 cd.s/m2 at 1 month in the 
AAV.VEGF165b group relative to the AAV.Null eyes (A). There was no significant 
difference in high light intensity scotopic A-wave response (B), nor was there any 
difference between groups in the scotopic B-wave at low (C) and high (D) light 
intensities. There was also no significant difference between groups when looking at low 
light (E) and high light (F) intensities when assessing scotopic B wave amplitude (2-
tailed, Student’s t-test, *p<0.05).  
 
As diabetes appeared to have no significant effect on ERG amplitude (figures 5.4 and 
5.7), I wanted to see how diabetic AAV.Null amplitudes, which show no significant 
change when compared to untreated rats, compared to diabetic AAV.VEGF165b 
amplitudes. I hypothesised that there would be no significant difference between both 
treatment groups and I tested this hypothesis by plotting the amplitudes obtained from 
diabetic AAV.Null groups alongside diabetic AAV.VEGF165b groups. When measuring 
scotopic A-wave at 0.001 cd.s/m2 at 1 month, there was a significant reduction in ERG 
amplitude in diabetic AAV.VEGF165b injected groups relative to diabetic AAV.Null 
groups (Figure 5.9A). However, it is possible that this point is an outlier as it so 
significantly greater than all other points it is tested against, including control, untreated 
retinae. There was no significant difference between diabetic AAV.VEGF165b and 
diabetic AAV.Null in any parameter (figure 5.9). Despite the great variability in the 
AAV.VEGF165b groups, when just comparing mean values AAV.VEGF165b does appear 
to diminish the ERG amplitudes in all measurements and at all time points.  
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Figure 5.9. Diabetic Lewis rats injected with AAV.VEGF165b show no significant 
difference in ERG amplitude relative to diabetic AAV.Null rats and control rats. 
Lewis rats (n=13) were injected subretinally with AAV.Null (n=6) or AAV.VEGF165b 
(n=7) (2x5µl of vector at 1x1012 vp/ml) and then induced with diabetes 2-weeks post-
subretinal injection using STZ (50mg/kg, i.p) and supplemented with insulin 
(subcutaneous pellet). Control rats (n=5) were injected with saline (i.p). Control rats, 
diabetic AAV.Null rats and diabetic AAV.VEGF165b rats subject to monthly ERG 
assessment for 4 months and minimal and maximal light intensities were plotted. There 
was no difference in rod mediated A– or B–response both at minimal intensity (A and C) 
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and maximal intensity (B and D). There was also no difference in the cone - mediated 
response at both ends of the 6–step process (E and F).  
 
 Diabetic AAV.VEGF165b injected rats showed a reduction in ERG amplitudes in 
both scotopic and photopic measurements relative to control amplitudes. However, to 
assess whether this result is diabetes induced or as a result of the vector, I plotted the both 
saline and diabetic AAV.VEGF165b groups on the same graph. I hypothesised that there 
would be no difference in ERG amplitude between both treatment groups. I observed that 
there was no significant difference between both control and diabetic AAV.VEGF165b 
injected groups (figure 5.10). Moreover, when comparing both AAV.VEGF165b injected 
groups to control + untreated groups, there was no significant difference between diabetic 
AAV.VEGF165b groups and control groups in all parameters. There were differences in 
amplitude when comparing control amplitudes against control AAV.VEGF165b 
amplitudes. There was a significant difference in ERG amplitudes at 4 months when 
comparing control amplitudes (15±7.07mV) with control AAV.VEGF165b amplitudes (-
2.5±2.5mV) at the minimal scotopic A-wave intensity (figure 5.10A). When assessing 
peak A-wave amplitude at 75.38cd.s/m2 (Figure 5.10B), there was a significant difference 
in amplitude between control and control + AAV.VEGF165b amplitudes at 3 months (-
215±7.1 and -85.5±46.1mV respectively) and at 4 months (-215.0±21.2mV and -
62.5±36.1mV respectively). There was no difference in scotopic B-wave amplitude at the 
lowest light intensity (figure 5.10C) between control and control + AAV.VEGF165b 
amplitudes. This was not reflected in the scotopic B-wave amplitudes at the highest light 
intensity (figure 5.10D) where there was a significant difference between control 
amplitudes and control + AAV.VEGF165b amplitudes at 4 months (595±35.4mV and 
187.5±109.8mV respectively). The photopic B-wave response showed a difference in 
amplitude between control and control + AAV.VEGF165b at 2 months (13.1±2.4mV and 
1.11±3.1mV respectively) and 4 months (10±1.4mV and 2.96±1.74mV respectively) 
upon 0.1cd.s/m2 light stimulation (figure 5.10E). This was reflected when stimulating at 
the highest photopic intensity (figure 5.10F) as there was a significant decrease in ERG 
amplitude in the control + AAV.VEGF165b groups (58.0±30.3mV) and control + 
untreated groups (214.2±32mV). 
		 149	
Figure 5.10 Control Lewis rats injected with AAV.VEGF165b show no difference in ERG 
amplitude relative to diabetic Lewis rats injected with AAV.VEGF165b but do show a 
difference relative to control amplitudes.  
Lewis rats (n=17) were injected subretinally with AAV.VEGF165b (n=12, 2x5µl of vector 
at 1x1012 vp/ml) and then induced with diabetes 2-weeks post-subretinal injection using 
STZ (n=7, 50mg/kg, i.p) and supplemented with insulin (subcutaneous pellet) or saline 
(n=5). Control + untreated rats (n=5) were injected with saline (i.p) and no subretinal 
injection. Rats subject to monthly ERG assessment for 4 months and minimal and 
maximal light intensities were plotted. There was no difference in rod mediated A– or B–
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response both at minimal intensity (A and C) and maximal intensity (B and D) between 
control + AAV.VEGF165b and diabetic + AAV.VEGF165b. There was a decrease in ERG 
amplitude in the control + AAV.VEGF165b groups relative to control groups at minimal 
scotopic A-wave intensities (A) at 4 months and at maximal intensities for scotopic A-
wave at both 3 and 4 months (B). There was no difference in ERG amplitude at minimal 
light intensities when assessing scotopic B-wave responses (C) between control and 
control + AAV.VEGF165b groups. There was a difference between these groups at 4 
months, where control + AAV.VEGF165b groups had a significantly lower ERG 
amplitude than control groups. There was no difference in the cone - mediated response at 
both ends of the 6–step process (E and F) between control + AAV.VEGF165b and diabetic 
+ AAV.VEGF165b groups, however there was a decrease in control + AAV.VEGF165b 
amplitude relative to control amplitudes at both 2 and 4 months at both 0.1 and 
75.38cd.s/m2 (Students 2-tailed t-test, *p<0.05, ***p<0.01).  
 
Whilst in all the treatments I have compared, there was no significant difference 
between most groups (figure 5.4 and figures 5.7-5.10), when comparing all groups 
together overall there does appear to be a trend that suggests there is a slight difference 
between groups (figure 5.11). The groups that showed the lowest ERG amplitudes were 
the AAV.VEGF165b injected groups, followed by the AAV.Null groups. The diabetic 
groups tend to have a greater ERG amplitude relative to their control counterparts, for 
example diabetic + untreated groups to have a greater ERG amplitude than control + 
untreated groups when looking at scotopic and photopic B-wave responses at maximal 
light intensities (figure 5.11D and F respectively). Similarly, diabetic AAV.Null groups 
show a greater ERG amplitude than control AAV.Null groups when looking at maximal 
scotopic A- and B-wave responses (figure 5.11B D respectively), although many of these 
comparisons do not achieve significance. It is easier to observe these differences at the 
higher light intensities than at the lower intensities, indicating that the degeneration 
observed is either difficult to detect at lower intensities or that it does not affect the 
response at lower intensities.  
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Figure 5.11. ERG responses from control and diabetic rats injected subretinally show 
reduced ERG amplitude relative to untreated amplitudes. 
Lewis rats were injected subretinally with AAV.Null (n=11,2x5µl of vector at 1x1012 
vp/ml) or titre-matched AAV.VEGF165b (n=12) or left untreated (n=10). Two weeks post-
subretinal injections, rats were either injected with saline (n=15, i.p) or STZ (n=18, 
50mg/kg, i.p). One-week post injections, blood glucose were tested and rats with a blood 
glucose ≥15mmol/l were deemed diabetic. Rats were then subject to ERG assessment on 
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a monthly basis measuring scotopic A- wave (A and B) and B-wave (C and D) 
amplitudes in response to 0.001 cd.s/m2 and 75.38 cd.s/m2 light intensities. Photopic 
responses for B wave amplitudes were also measured at 0.1 and 75.38 cd.s/m2 (E and F 
respectively).   
5.3.4. Subretinal AAV.VEGF165b is detrimental to ocular health 
 
SLO was carried out in parallel with ERG and OCT assessment, and showed that 
over the 4-month period (figure 5.12A), there was an increase in retinal auto-fluorescence 
(AF) in the vector-injected groups (figure 5.12). These regions of AF are consistent with 
previously published findings of fundus geographic atrophy (GA) (Holz et al. 2001). GA 
usually occurs as a result of lipofuscin accumulation in the RPE and as lipofuscin is a 
fluorophore, as more accumulates it appears as small white speckles in an SLO image. 
Lipofuscin deposits in the retina are commonly associated with diseases such as AMD 
(Holz et al. 2001) and Stargardt disease (Birnbach et al. 1994), and so are indicative of 
increased retinal pathology. I observe that as time progressed, I was able to image fewer 
AAV.VEGF165b–injected eyes as the eyes became so damaged, there was no reflectivity 
from the retina, and by month 4 I was only able to image the outside of the eye and not 
the retina (figure 5.12A). At month 0 (figure 5.12) there was no significant difference in 
AF between treatment groups. At month 1, there was already an increase in AF in both 
AAV.VEGF165b injected groups although only reaching significance in the diabetic 
animals (37.0±3.60) relative to both control and diabetic + untreated groups (26.6±1.67 
and 26.4±1.18 respectively). At month 2 (figure 5.12D) control + AAV.VEGF165b 
injected animals showed a significantly greater fluorescence (37.9±1.16) than diabetic 
AAV.Null (28.4±2.11), control AAV.Null (28.8±1.75), diabetic + untreated (28.4±0.98) 
and control + untreated (27.8±0.92). As only 1 diabetic AAV.VEGF165b could be imaged, 
it could not be compared against the other groups, however it is clearly much greater than 
other treatment groups (36.9). By month 3 (figure 5.12E), more control + 
AAV.VEGF165b injected animals could not be imaged, meaning they could not be part of 
the analysis. However it appeared that both AAV.VEGF165b injected groups have a 
higher AF than other groups, although not significant. There was however a significant 
increase in AF in the diabetic AAV.Null group relative to control untreated groups. There 
was no change in AF in the control + Null groups, relative to both untreated groups. 
These data indicate that AAV.Null was also causing a detrimental effect on the ocular 
health. By month 4 (figure 5.12F) no AAV.VEGF165b injected animals could be imaged. 
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There was also no significant difference between the untreated groups and the AAV.Null 
groups.  
Figure 5.12.  Subretinal AAV.VEGF165b increases the AF area observed using SLO. 
Lewis rats were injected subretinally with AAV.Null (n=11,2x5µl of vector at 1x1012 
vp/ml) or titre-matched AAV.VEGF165b (n=12) or left untreated (n=10). Two weeks post-
subretinal injections, rats were either injected with saline (n=15, i.p) or STZ (n=18, 
50mg/kg, i.p). One-week post injections, blood glucose were tested and rats with a blood 
glucose ≥15mmol/l were deemed diabetic. Rats were then subject to month SLO 
assessments over 4 months, measuring retinal AF (A). At month 0 there is no difference 
between treatment groups. At month 1, AAV.VEGF165b injected groups have a 
significantly greater area of AF (B). At month 2, only 1 diabetic AAV.VEGF165b rat could 
not be imaged due to significant ocular dysfunction. At month 2, control AAV.VEGF165b 
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eyes were significantly more AF than all other groups (D). At month 3, only 1 control 
AAV.VEGF165b animal could be imaged. Diabetic AAV.Null eyes had a significantly 
greater AF than control untreated eyes (E). By month 4 no AAV.VEGF165b eyes could be 
imaged. There was no significant difference between untreated groups and AAV.Null 
groups (2-way ANOVA with Sidak's post hoc test, *p<0.05, **p<0.01).  
 
At the end of the study, rats were culled and eyes were enucleated, fixed and 
embedded in OCT. Sections were stained for CD45, a broad inflammatory marker and 
GFAP, a marker of neurodegeneration and glial stress (figure 5.13). I observed that there 
were very low levels of CD45 activation in the control (figure 5.13A) and diabetic 
untreated retinae (figure 5.13D). There is little CD45 activation in most retinae apart from 
the control and diabetic AAV.VEGF165b treated retinae (5.13C and 5.13F respectively. 
There appears to be a basal level of GFAP activation, as demonstrated in the control, 
healthy eyes (figure 5.13A). This increases with AAV.Null administration (figure 5.13B) 
and increases further upon AAV.VEGF165b administration. Interestingly the trend observed 
in ERG traces whereby diabetes appears to have a “protective effect” on ERG amplitude 
relative to control eyes when injected with virus, was mirrored in the immunofluorescence. 
The diabetic virus injected retinae express less CD45 and GFAP than the control virus 
injected retinae (figure 5.13G). However this difference was not significant. There is also a 
trend within both control and diabetic groups, whereby expression of these markers 
increases from control, to AAV.Null to AAV.VEGF165b. This reiterates that AAV.Null, 
although expressing nothing, induces retinal pathology. Furthermore, there is increasing 
evidence that AAV.VEGF165b causes retinal degeneration. 
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Figure 5.13. Subretinal gene therapy causes an increase in inflammatory and neuronal 
stress markers 
Lewis rats were injected subretinally with AAV.Null (n=11,2x5µl of vector at 1x1012 
vp/ml) or titre-matched AAV.VEGF165b (n=12) or left untreated (n=10). Two weeks post-
subretinal injections, rats were either injected with saline (n=15, i.p) or STZ (n=18, 
50mg/kg, i.p). One-week post injections, blood glucose were tested and rats with a blood 
glucose ≥15mmol/l were deemed diabetic. Rats were culled after 4 months and eyes were 
cryo-embedded, sectioned and stained for DAPI (blue), CD45 (green) and GFAP (red, 
scale: 50µm, x40 magnification). There was little expression of both markers in control 
untreated and diabetic eyes (A and D). Expression of both markers increased upon 
AAV.Null injection in control and diabetic eyes (B and E) and was greatest in 
AAV.VEGF165b injected eyes (C and F). This was quantified using Image (G). There was 
no significant difference in intensity relative to control groups (1-way ANOVA with 
Bonferroni post test).  
 
The immunofluorescence indicates that AAV.VEGF165b is detrimental to ocular 
health. This is particularly evident when looking at the structure of the retina. The 
typically stratified organisation, as observed in figure 5.13A, is not apparent in the 
AAV.VEGF165b injected eyes. I observed that there are no definitive layers in these 
retinae, which is likely to contribute to a reduction in ERG amplitude. During analysis, I 
also observed many AAV.VEGF165b injected retinae had structures growing through the 
middle of the eyes (figure 5.14A). When stained for the same markers, there was little 
expression in the new region of growth (figure 5.14B). However, as they appeared to 
resemble blood vessels, I stained them for occludin (figure 5.14C) and hypothesised that 
Co
ntr
ol 
+ U
ntr
ea
ted
Co
ntr
ol 
+ A
AV
.N
ull
Co
ntr
ol 
+ A
AV
.VE
GF
16
5b
Di
ab
eti
c +
 U
ntr
ea
ted
Di
ab
eti
c +
 A
AV
.N
ull
Di
ab
eti
c +
 A
AV
.VE
GF
16
5b
0.0
0.5
1.0
1.5
2.0
R
el
at
iv
e 
In
te
ns
ity
GFAP
CD45
(G) 
		 157	
these structures were likely to be vessels. This was further confirmed with CD31 staining 
(appendix 4). This region was also positive for HIF1α, particularly in the cells lining the 
proposed “lumen” of the new vasculature.  
 
Figure 5.14. Novel vascular structures are apparent in many AAV.VEGF165b injected 
eyes 
Lewis rats were injected subretinally with AAV.VEGF165b (n=12) and were culled 4 
months post-injection. Eyes were enucleated, cryo-embedded, sectioned and stained for 
(A) DAPI (blue), CD45 (green) and GFAP (red). However as these markers were weakly 
expressed, particularly in the novel structure across the eye (B), sequential sections were 
stained (C) for occludin (green) and GFAP (red). These occludin positive regions 
appeared to be blood vessels that were also (D) HIF positive (red). This indicates that this 
region is likely to be new blood vessels forming across the eye.  
  
100µm 
50µm 
DAPI CD45 GFAP x10 
DAPI Occludin GFAP x40 
DAPI HIF    x63 
100µm 100µm 100µm 
DAPI CD45 GFAP 
(A) 
(B) (C) (D) 
		 158	
5.3.5. AAV.VEGF165b is detrimental to ocular health in other eye diseases.  
 
The primary aim of AAV.VEGF165b was to assess its potential neuroprotectivity 
in diabetes-induced retinal degeneration. As it showed no effect in this model, I tested the 
virus in the mouse retina degeneration slow (RDS) mouse. This model results in a slow 
onset of degeneration of photoreceptors and I hypothesised that AAV.VEGF165b would 
prevent photoreceptor degeneration. To test this hypothesis, mice were injected 
subretinally at P10 with a single injection of 2µl AAV.VEGF165b (1x1012 vp/ml) in one 
eye, with the contralateral eye serving as an untreated control. Mice were then subject to 
monthly ERGs 2-weeks post-injection to assess changes in rate of onset of degeneration 
for 2 months. As this condition concerns photoreceptor degeneration, I only assessed 
changes in amplitude in response to photopic light stimuli. For the duration of the 
experiment I observed that for both A- and B-wave responses, AAV.VEGF165b injected 
eyes had consistently lower ERG amplitudes relative to control eyes. There was no 
significant difference in ERG A-wave amplitude between untreated eyes and 
AAV.VEGF165b injected eyes across all light intensities tested at month 0 (Figure 5.15A). 
When assessing the photopic B-wave amplitudes at month 0 (Figure 5.XB), there was a 
significant difference between both groups. At 0.1 cd.s/m2, AAV.VEGF165b injected eyes 
had a significantly lower amplitude (15.7±2.32µV) than control eyes (30.5±1.97µV). At 
month 1 there is no difference between both treatment groups when measuring A-wave 
amplitudes (figure 5.15C) as both group seems to express a decrease ERG amplitude 
relative to month 0. This is also true of B-wave responses at month 1 (figure 5.15D). 
However at month 2, there is a difference in A-wave response (figure 5.15E). At 0.1 
cd.s/m2 AAV.VEGF165b injected groups have a significantly lower ERG amplitude 
(0±0µV) relative to control eyes (1.68±0.24µV). This is also observed when stimulated 
with 31.6 cd.s/m2 light, AAV.VEGF165b injected groups have a significantly lower A-
wave amplitude (0±0.47µV) relative to control eyes (-2.4±0.45µV). B-wave responses at 
month 2 (figure 5.15F) were also less in the AAV.VEGF165b injected groups relative to 
control groups, but only reaching significance at 0.1 cd.s/m2 (0±0µV and 7.27±1.16µV 
respectively).  
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Figure. 5.15. Subretinal AAV.VEGF165b worsens photopic ERG amplitudes in RDS mice. 
RDS mice (n=5) were injected with subretinally with 2µl AAV.VEGF165b (1x1012 vp/ml) 
at P10, with the contralateral serving as an untreated control group. Two weeks post 
injection, mice were subject to month ERGs, measuring only photopic A- and B-wave 
responses evoked upon 6 different light stimuli (0.1, 1.0, 3.16, 10, 31.6 and 75.38 
cd.s/m2). At month 0, there was no difference between both groups’ A-wave responses 
across all intensities tested (A), however there was a significant difference at 0.1cd.s/m2 
evoked B-wave response (B). At month 1, there was no difference in ERG amplitude 
between both groups when assessing A- and B-wave response (C and D respectively). At 
month 2, AAV.VEGF165b groups had a significantly lower A-wave amplitude at 0.1 and 
31.6 cd.s/m2 (E) and had a significantly lower B-wave amplitude at 0.1 cd.s/m2 (F) 
(Student’s t-test, *p<0.05, **p<0.01, ***p<0.001). 
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Data from chapter 2 indicates that VEGF165b may be anti-angiogenic and so I 
hypothesised that AAV.VEGF165b may also be anti-angiogenic. I tested this hypothesis 
by injecting C57bl6j mice with either 2x2µl of AAV.VEGF165b or AAV.Null  (subretinal, 
1x1012 vp/ml) and comparing neovascular area upon laser-induced rupture of Bruch’s 
membrane, relative to untreated eyes (see Chapter 2: “Materials and Methods” for further 
details). I hypothesised that AAV.VEGF165b injected eyes would have a lower area of 
CNV relative to both AAV.Null and control groups. Two-weeks post subretinal injection, 
mice were subjected to lasering, followed by FFA using an SLO 3, 7 and 14-days post-
laser and lesion sizes were calculated using Image J, with n=number of burns. Any 
lesions that had merged, as shown in figure 5.16C, were discounted from analysis. Day 3 
post-laser (Figure 5.16A) showed that there was no change in relative lesion size in 
AAV.VEGF165b injected groups (figure 5.16B). On Day 7 (Figure 5.16B), there was no 
significant difference between treatment groups (Figure 5.16C), despite the apparent 
decrease in lesion size. On day 14 (figure 5.16E) there was a significant increase in 
relative lesion size in the AAV.Null injected groups (1.74±0.46) relative to control 
lesions (1±0.18). It appears that AAV.VEGF165b injected group had a lower lesion size 
(0.29±0), however this data is from 1 lesion only and therefore may be skewing the data. I 
observed that as time progressed, AAV.VEGF165b injected eyes appeared more swollen 
and increasingly difficult to image (figure 5.16G), as I had observed in Lewis rats (figure 
5.12), as a result the number of burns imaged decreased from 8 to 1 by day 14.  
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Figure 5.16. Subretinal AAV.VEGF165b does not significantly reduce lesion size in mice 
with CNV. 
Female C57bl6j mice (n=14) were injected subretinally with 2x2µl AAV.VEGF165b or 
AAV.Null (1x1012 vp/ml) or were left untreated. Two weeks post-injection, mice were 
subject to 3 laser burns using a 680nm laser to breach Bruch’s membrane. Mice were 
subject to FFA on day 3, 7 and 14-post laser. On day 3 (A) there was no significant 
difference in normalised lesion size (B) between groups (n=number of lesions). On day 7 
(C), there was no difference in normalised lesion size (D) between control and AAV.Null 
eyes. Only 2 lesions could be analysed in AAV.VEGF165b eyes, however there is a non-
significant reduction in lesion size relative to both control and AAV.Null eyes. On day 14 
(E), there was a significant increase in normalised lesion size (F) in AAV.Null injected 
eyes relative to control lesions. Only 1 lesion could be measure in AAV.VEGF165b eyes 
due to inability to image from poor ocular health and potential inflammation (G) (1-way 
ANOVA with Tukey’s post-test, **p<0.01).  
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 As I was unable to measure lesion sizes in all the groups using FFA and SLO, 
choroids were dissected, flat-mounted and stained for IB4 (figure 5.17A) and lesion size 
was calculated using Image J. However, many of the AAV.VEGF165b eyes were in such 
poor condition that many of the choroids were lost upon dissection. Having been unable 
to image using SLO and seeing the condition of the eyes, I hypothesised that the 
AAV.VEGF165b injected eyes would have a greater lesion size than both AAV.Null 
groups and control groups. I observed that there was no significant difference in 
normalised lesion size between treatment groups (figure 5.17B). There does appear to be 
a trend that indicates virus injection may exacerbate CNV. AAV.Null eyes have no 
change in normalised lesion size (1.69±0.26) relative to control eyes (1.0±0.42). 
AAV.VEGF165b injected eyes have an even greater normalised average lesion area 
(3.0±0.34) relative to AAV.Null eyes and control eyes.  
Figure 5.17. AAV.VEGF165b is not anti-angiogenic in mice with laser-induced CNV. 
Female C57bl6j mice (n=14) were injected subretinally with 2x2µl AAV.VEGF165b or 
AAV.Null (1x1012 vp/ml) or were left untreated. Two weeks post-injection, mice were 
subject to 3 laser burns using a 680nm laser to breach Bruch’s membrane. Mice were 
culled 2-weeks post laser and choroids were dissected and stained for IB4 (A). Relative 
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lesion size was calculated using Image J (B) and showed that there was no significant 
difference in lesion size between treatment groups (1-way ANOVA with Tukey’s post-
test).  
 
Figures 5.15, 5.16 and 5.17 all show that in alternative models of eye disease, 
AAV.VEGF165b does not improve visual function nor does it prevent CNV.  
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5.4. Discussion 
5.4.1. STZ-induced diabetes in Lewis rats is a poor model of diabetic retinopathy 
  
Despite being hyperglycaemic, diabetic Lewis rats showed no significant 
difference in A- and B-wave amplitude at 4-months post-induction of diabetes, relative to 
control rats (figure 5.3). There does appear to be a slight reduction in scotopic B-wave 
amplitude in the diabetic animals, however this is not significant (figure 5.3D). When 
these data are further dissected into A- and B-wave responses evoked from the minimum 
and maximum intensities tested over the 4-month period (figure 5.4), again there is no 
significant difference across photopic and scotopic intensities at any time point, 
indicating that there is no dysfunction at the level of photoreceptors, RPE, Muller glia and 
ON-bipolar cells. However these data did not tell us the state of the RGC layer. 
Unfortunately, I was unable to stain these sections with NeuN, as I did in flat-mounts in 
chapter 4, and therefore counted DAPI-positive cells in the RGC layer as way of 
assessing RGC layer dysfunction (figure 5.5). Despite this not being the preferred method 
of quantification, I observed that there was no decrease in RGC layer thickness in diabetic 
retinae, indicating that a hallmark of diabetic retinopathy is not present in this model. 
Overall, these data indicate that the model did not sufficiently produce any kind of retinal 
neurodegeneration induced by diabetes.  
The Kern group have written many reviews and have published data that this 
Lewis rats with STZ-induced diabetes do show differences in ERG amplitude as early as 
3 months post onset of hyperglycaemic (Engerman & Kern 1995; Kern et al. 2010; 
Robinson et al. 2012b). As a result, this aspect of my project was based upon the Kern 
groups’ findings. Despite keeping my protocol as identical to the Kern groups’ as 
possible, there was one difference – the Kern group administer subcutaneous insulin 2-3 
times per week upon onset of weight loss (Tim Kern, personal communication), whereas I 
implanted a subcutaneous insulin pellet on the same day as diabetes induction. I could not 
adhere to this method due to regulations set in place by the UCL BSU and ethics 
committee. This subtle difference in protocols is potentially why I observed no difference 
in ERG amplitude. Furthermore, STZ-diabetic rats that are treated with insulin show a 
reduction in the rate of IPL and GCL loss, compared to non-insulin treated diabetic rats, 
again confirming the hypothesis that poor glycaemic control attributes to 
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neurodegeneration in the retina (Barber et al., 1998). Interestingly in a review co-authored 
by Prof Kern (Kern & Barber 2008), it states that insulin is protective against RGC loss in 
animals (Barber et al. 1998; Barber et al. 2001). Insulin is also protective against diabetic 
retinopathy-induced RGC loss in humans (van Dijk et al. 2009). Insulin appears to be 
protective against apoptosis in culture by activating the PI3 kinase and Akt pathway and 
preventing activation of caspase 3 (Barber et al. 2001).  It is possible that the glycaemic 
control of my animals was not “poor enough”, and as a result I saw no pathology. This 
may be why the Kern group only administer insulin when needed as opposed to constant 
slow release. The constant exposure to insulin may have prevented any 
neurodegeneration in the retina in my study, however this was agreed upon method with 
the UCL ethics committee.  
I may have seen a difference in ERG amplitude had I used a different model of 
diabetes, for example it has been shown that Sprague-Dawleys with STZ-induced 
diabetes show RGC loss after 7.5 months of diabetes (Kern et al. 2000). However the 
PPL I was working under was only licenced for 4 months diabetes therefore I would not 
have been able to pursue this model. The Ins2Akita mouse spontaneously develops type 1 
diabetes, and histological analysis of the RGCs within 3 months of diabetes shows 
structural alterations such as axonal swelling and associated constriction. Also visible was 
enlarged cell bodies and increased dendritic branching and terminals in both medium ON-
RGCs and large ON-RGCs. Further histological analysis of the retinae of the Ins2Akita 
Thy1-YFP mice showed that within the first three months of diabetes, the peripheral 
retina loses RGCs first and the surviving RGCs (particularly ON-RGCs) are undergo 
dendritic remodelling and changes in axonal properties, before they too eventually die 
(Gastinger et al. 2008). However, to maintain consistency throughout this project, I used 
the STZ-model of type 1 diabetes.  
 5.4.2. VEGF165b gene therapy exacerbated retinal neurodegeneration 
 
This study has shown that the AAVVEGF165b virus I generated is not only 
ineffective in treating but worsens retinal neurovascular disease (figure 5.11), retinal 
neurodegeneration (figure 5.15) and choroidal neovascularisation (figure 5.16 and 5.17), 
areas where the recombinant protein has previously shown much potential. 
AAV.VEGF165b elicited detrimental effects to the neural retina, regardless of onset of 
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diabetes, as shown by figures 5.8-5.10. AAV.VEGF165b-injected eyes consistently had the 
lowest ERG amplitudes compared to any treatment group (figure 5.11). Furthermore, 
AAV.VEGF165b causes formation of vascularised internal structures (figure 5.14), which 
may attribute to the increase in atrophy and inability to image when assaying by SLO 
(figure 5.12). This may be due to AAV.VEGF165b eyes being hypoxic, resulting in 
increased HIF-mediated vessel growth across the retina. There was a moderate increase in 
CD45 expression in the AAV.VEGF165b injected eyes (figure 5.13) relative to control and 
null eyes and an increase in GFAP expression. This indicates that there is inflammation 
occurring in the AAV.VEGF165b-injected retinae, however a different inflammatory 
marker would need to be used to confirm this such as TNFα. There is also an apparent 
disorganisation of the structure of these retinae, however this may be a result of 
processing due to the eyes being in such bad condition upon excision. Together, these 
data suggest that injection of this AAV.VEGF165b virus may have triggered a response 
that results in increased infiltrating cells in the retinae, likely to be macrophages that 
accumulate and cause structural and functional damage to the eye. From personal 
observation, AAV.VEGF165b injected eyes were much bigger in size than contralateral 
untreated eyes and greater than AAV.Null eyes, again indicating possible ocular 
inflammation.  
 In the CNV+AAV.VEGF165b eyes, there is clear progressive worsening of SLO 
images, where only one eye could be images by 2 weeks (figure 5.16). However, the 
choroids appeared normal, despite the lesions, (figure 5.17). It is possible, that like I 
observed in the Lewis rats, there are many infiltrating cells in the retina and potential in 
the vitreous and this could be why imaging by SLO became progressively harder. 
Interestingly, the rate of onset of poor SLO imaging was much faster in the CNV mice 
(approximately 1 week, figure 5.16) than in the Lewis rats (approximately 3 months, 
figure 5.12). CNV does cause an increase in CD45 +ve  cell infiltration in the burned 
regions (Blackey and Ved et al., unpublished results), and therefore it is possible that 
CNV increased the rate of macrophage production already triggered by pre-injection of 
this AAV.VEGF165b virus.  
 AAVs are known for their low inflammatory profile (Vandendriessche et al. 
2007), which make them the preferential virus for use in patients. AAVs themselves do 
not cause synthesis of viral proteins but rather are reliant on the helper plasmid it’s 
packaged with. However the recombinant capsid is very similar to true viral capsids, and 
therefore any immune response to the vector is dependent on previous exposure to AAVs 
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and is likely to be directed towards the capsid (Vandendriessche et al. 2007). In humans, 
exposure to AAVs usually occurs at around 2-3 years of age (Mingozzi & High 2013), 
however as I have no knowledge to the exposure of rats to AAVs, if they have had a 
relative high exposure where they were bred, it may have triggered an immune response 
to my AAVs resulting in degeneration. I used an AAV2 capsid, one of the most prevalent 
serotypes, which has shown to evoke a T-cell response in muscle gene therapy (Brantly et 
al. 2009) and would in theory have the most anti-bodies produced against it, however in 
clinical trial data shows that AAV2 plasmids are well-tolerated in the eye with a minimal 
immune response (Bainbridge et al. 2008), likely due to the eye’s limited regenerative 
capacity. 
AAVs have shown to interact with toll-like receptor 9 in vitro and in mice, 
therefore interacting with the innate immune system and triggering a CD8+T cell 
response (Zhu et al. 2009). AAVs have also shown to trigger release of NFKB in the 
mouse liver (Jayandharan et al. 2011) which would cause the release of pro-inflammatory 
cytokines and chemokines potentially resulting in the dysfunction seen. Typically, 
activation of these immune pathways typically coincides with lack of transgene 
expression (Vandenberghe & Auricchio 2012) however I observed over expression of 
VEGF165b 2-weeks after AAV.VEGF165b injection (figure 5.2). It therefore seems likely 
that if it is an immune response, it is not directed at the AAV as there is not as diminished 
an ERG response in the AAV.Null eyes (Figure 5.11), nor was the SLO imaging as poor 
(figure 5.12) and there were less CD45+ cells and decreased GFAP (figure 5.13) relative 
to AAV.VEGF165b eyes. As immune-privileged regions such the eye and brain have 
relatively low neutralising antibodies to AAVs (Amado et al. 2010), its unlikely to be an 
adaptive immunity B-cell response that is driving the dysfunction. Again, if it were a 
response targeting the AAV, transgene expression would be supressed within hours 
(Mingozzi & High 2013), however there is still VEGF165b overexpression two-weeks 
post-injection.  
  
 It is possible that the dysfunction observed is indeed an immune response, but not 
to the viruses themselves but to contaminants in the vehicle that the viruses are made in. 
Endotoxin contamination of viruses may cause inflammation in the eye upon injection. 
Endotoxin-induced uveitis, a model of ocular inflammation (Csukas et al. 1990), uses 
endotoxin to induce ocular pathology. In Lewis rats, when injected at 100µg, there is 
macrophage recruitment in the eye (Rosenbaum et al. 1980). Any virus or plasmid with 
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an endotoxin concentration below 2.5EU/ml was deemed endotoxin negative. Whilst 
samples are rigorously endotoxin tested throughout the virus-making process, it is 
possible that samples were given a false negative after virus purification. It is also 
possible that a 10µl volume of virus that has ≤2.5EU/ml endotoxin could cause retinal 
degeneration. Endotoxin contamination is a highly likely candidate as similar 
degenerative and inflammatory effects have been observed in similar studies (Prof. 
Andrew Dick, personal communication). 
 The dysfunction may not be solely an immune response to what has been injected, 
but to the injection itself. Sub-retinal injections are designed to cause a temporary 
detachment of the retina, however there are occasions where the retina may not reattach 
quickly if at all. In such occasions, there has been increased photoreceptor apoptosis and 
increased TUNEL+ retinal neurones (Cook et al. 1995). There is also evidence of Muller 
cell remodelling, outer segment loss, reshaping of rod bipolar dendritic trees and changes 
in horizontal cell morphology, amongst other changes upon experimental subretinal 
detachment (Fisher & Lewis 2003). Upon reattachment, there is thinning of the retina and 
disorganisation of the retinal layers and where neurones innervate (Cook et al. 1995; 
Fisher & Lewis 2003). It is possible that the volume injected subretinally may have been 
too much, and as a result there was a disorganisation in the otherwise highly organised 
neural retina. This disorganisation showed a reduction in ERG amplitude that progressed 
over time that was worsened by an apoptosis-induced immune response that could not be 
overcome by the anti-inflammatory and neuroprotectivity of VEGF165b.  
 Interestingly, AAV.VEGF165b groups consistently appear to the most damaged 
eyes in all assays, relative to control and AAV.Null eyes. If the above hypotheses were 
true, then both AAV.VEGF165b and AAV.Null eyes should be affected equally, indicating 
that it may be a VEGF165b-mediated degeneration. At the time of writing this thesis, there 
was no literature published to suggest that overexpression of VEGF165b is deleterious, 
most papers show the contrary that either it is beneficial to the disease model used or that 
it has no effect. It could be that there is so much overexpression of VEGF165b that is 
causing geographic atrophy (GA) in the retina, as observed in many AMD patients treated 
with anti-VEGF therapy (Simo et al. 2014). RPE secreted VEGF is necessary for 
choriocapillaris maintenance (Saint-Geniez et al. 2009b), and mice incapable of 
producing VEGF120  and VEGF164 showed photoreceptor apoptosis, reduced ERG 
amplitude and loss of RPE. This was characterised as geographic atrophy (Saint-Geniez 
et al. 2009b) and highlighted the importance of the predominant pro-angiogenic isoforms. 
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It may be that the eyes’ transcriptional ability was at maximum capacity upon 
AAV.VEGF165b administration, and as a result failed to produce adequate amounts of 
VEGF164 and VEGF120 culminating in GA of the retina. This fits with SLO data in figure 
5.12, as the time progresses, the eyes become more autofluorescent, usually indicative of 
RPE loss. However, I was unable to obtain OCT images of AAV.VEGF165b eyes, 
especially at 4-months and OCT has been previously used to monitor GA (Fleckenstein et 
al. 2008), indicating much of the visual dysfunction may not be exclusively limited to the 
retina, but may also involve the anterior regions of the eye.  
 There are many different hypotheses to suggest why AAV.VEGF165b showed such 
dramatic worsening of the eye. It is likely to be a combination of these events. I 
hypothesise that upon subretinal injection, any endotoxin present elicited an inflammatory 
response in tandem with the subretinal detachment unable to correct itself appropriately. 
This was further exacerbated by over-production of AAV.VEGF165b, leaving little 
transcriptional capacity for other products that are essential for normal maintenance of the 
eye. Over time, the eye was unable to correct itself, and therefore worsened, resulting in a 
diminished A- and B-wave response and inability to image the eye in vivo. To test these 
hypotheses and improve upon this study, less volume of vector should be injected but at 
the same concentration, this would reduce the retinal detachment and therefore 
complications associated with it. Similarly, a parallel study would involve injecting a 
lower titre or a combination of both experiments and monitor over time how well these 
differing combinations are tolerated. This would give an indication of the ideal titre and 
ideal volume to inject in a study with a more appropriate model. It is possible that the 
subretinal injection itself is causing the greatest damage in the first instance; to remove 
this possibility a different promoter could be used. ShH10, a novel AAV similar to 
AAV6, targets Muller glia and can be injected intravitreally (Klimczak et al. 2009), thus 
removing the need for a subretinal injection. Considering Muller glia have been 
hypothesised to overproduce VEGF in models of diabetes (Wang et al. 2010), it may be 
also be a novel therapeutic target.  
Another possible experiment would be to repeat this study and compare it to eyes 
intravitreally injected with rhVEGF165b. Although this may increase the risk of 
endophthalmitis, this would give an indication of how well tolerated long term VEGF165b 
expression is in the eye. This would illuminate whether the dysfunction is virus-mediated, 
route of injection mediated (subretinal vs. intravitreal) or VEGF165b mediated.  
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Throughout this study, there was always a difference in degeneration between 
AAV.VEGF165b and AAV.Null. Whilst AAV.Null was designed to express nothing, 
perhaps a better negative control would be something that has transgene expression. This 
way one could adequately compare side effects more appropriately. AAV.hrGFP was 
discounted as a potential negative control due to its apparent atrophy (Appendix 4), 
however this may have been an adequate negative control, as it would help to 
differentiate between overexpression of VEGF165b-mediated dysfunction or general 
transgene induced dysfunction, if run in parallel with AAV.Null eyes. 
 This study can also be improved upon in future by using a much more rigorous 
endotoxin testing method, perhaps setting the upper limit lower than 2.5EU/ml. Using a 
different negative control in future would also help further studies. Unfortunately, do to 
lack of time and lack of resources; these ideas could not be further explored.  
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5.5. Concluding Remarks 
 Retinal gene therapy to treat blindness is a highly attractive concept considering 
the eye’s immune privilege and potential to reduce injection-induced adverse events. 
There is little published evidence of anti-angiogenic gene therapy being unsuccessful. 
However, considering the limited successes in this field, it is likely that there have been 
unsuccessful studies. One study showed that using AAV mediated delivery of cilliary 
neurotrophic factor (CNTF), previously shown to prevent retinal and photoreceptor 
degeneration, was in fact damaging to the eye and reduced B-wave amplitude 
(Schlichtenbrede et al. 2003). Whilst a different type of growth factor, it is still reporting 
abnormalities similar to those observed in this study, albeit to not as great an extent. It is 
likely that other groups have had similar ideas and have had limited success with anti-
angiogenic gene therapy for diabetic retinopathy, possibly due to a lack of an appropriate 
model or they observe a degenerative effect like this current study. This illustrates that 
although well researched, gene therapy to treat non-genetic retinal dysfunction is still in 
its infancy. AAV.VEGF165b was detrimental to the eye due to many different 
possibilities; however with some more refinement and a working model, this field study 
could show success in the future.  
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Chapter 6: Discussion 
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This study aimed to look at how the hallmark pathologies associated with diabetic 
retinopathy, pathological neovascularisation, oedema and retinal neurodegeneration, 
could be ameliorated by targeting the outer BRB with VEGF165b. This was investigated in 
vitro and in vivo using rhVEGF165b and AAV.VEGF165b, and has contributed to some of 
the hypotheses shown in figure 6.1 
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Figure 6.1. Proposed mechanisms involved in diabetic retinopathy in the inner and outer 
BRB. 
Increased glucose results in hypoxia in and around both RECs and RPE; as a result there 
is greater HIF1α transcription, resulting in greater VEGF165 transcription and translation. 
Hyperglycaemia also stimulates the production of ROS and as a result and increase in 
TNFα and NFKB, both of which also increase VEGF165 production and activation of the 
inflammatory pathway. VEGF165 binds to VEGFR2 and induces VEGFR2 dimerization 
and neuropilin stabilisation resulting in complete VEGFR2 phosphorylation. 
Phosphorylation results in activation of PLCγ and subsequent activation of typical PKC 
isoforms such as PKCα, β and δ. These PKC isoforms in turn phosphorylate tight 
junctions at the serine/threonine residue, resulting in their internalisation and degradation 
and subsequent increase in paracellular solute flux. In RPE, hypoxia stimulates de novo 
synthesis of DAG, resulting in atypical PKC activation resulting in further activation of 
TNFα and tight junction phosphorylation. In RECs it is likely that VEGFR2 
phosphorylation also results in transient changes in eNOS and NO resulting in vessel 
tortuosity. VEGFR2 phosphorylation also results in ERK phosphorylation and subsequent 
DLL4 activation, resulting in sprouting angiogenesis. VEGF165b, a competitive VEGFR2 
antagonist, binds to VEGFR2 and causes its dimerization without neuropilin involvement, 
resulting in partial, transient VEGFR2 phosphorylation. VEGF165b has been shown to 
prevent PKCε activation (S.Bestall, personal communication) and may also prevent 
activation of typical and atypical PKC isoforms, thus preventing tight junction 
phosphorylation. VEGF165b may prevent DLL4 activation in RECs and therefore 
potentially preventing VEGF165-induced angiogenesis. VEGF165b has been shown to 
prevent TNFα-mediated VEGF165 expression in RPE (Thichanpiang et al. 2014), 
therefore likely to prevent inflammation in RPE and potentially RECs. VEGF165b may 
prevent transient changes in NO expression or prevent its detection, resulting in reduced 
vascular tortuosity via an unknown mechanism. Red arrows = actions caused by 
VEGF165. Blue inhibition arrows = actions caused by VEGF165b. Green arrows = 
contributions from this thesis. 
6.1. Permeability and the outer BRB  
 
Breakdown of the BRB is responsible for fluid accumulation in the macula and 
exudate formation in the retina (A. J. Barber 2003). It is generally accepted that the BRB 
usually describes the tight junction complex formed between RECs, also known as the 
inner BRB, often leaving the outer BRB, formed by the RPE, overlooked. This is 
reflected in the literature with many papers using RECs when referring to the BRB in 
vitro. Of the groups that do use RPE, few of them use them intentionally as a model of 
the outer BRB, but rather the BRB in general. Many groups also use ARPE19 cells, an 
immortalised RPE line, likely due to their unlimited passage life and how easy they are to 
culture. However ARPE19s give an even less accurate representation of the BRB than 
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other primary RPE cells. I showed in chapter 3 that RPE extraction is a simple and 
reproducible protocol and moreover it can be used in a variety of assays.  
Whilst the notion that VEGF165 can induce BRB dysfunction and increase 
paracellular flux in vitro is not novel, there is limited published data in cultured 1˚hRPE.  
I have confirmed that VEGF165 can induce TJ dysfunction in RPE cells that can be 
verified by a variety of techniques in vitro (chapter 3). A previous study looking at TER 
in foetal RPE showed that VEGF165 treatment has no significant difference on TJ 
expression when using concentrations ranging from 50ng/ml to 300ng/ml (approximate 
1nM to 7.5nM) (Peng et al. 2010). They also observe no change in TJ expression at these 
concentrations. Whilst these data appear to directly contradict what I have observed in 
chapter 2, they are using hfRPE, which may be more resistant and more resilient against a 
VEGF165 challenge. Also, hfRPE are at a different developmental stage to 1˚RPE and 
therefore may display different characteristics in response to VEGF stimulation. 
 I have also shown novel data that VEGF165-induced permeability can be reversed 
by an isoform of VEGF, as shown by figure 6.1. These changes are consistent with 
published data looking at immortalised bovine RECs as a measure of inner BRB 
dysfunction (Deissler et al. 2012). Deissler and colleagues used the same concentration of 
VEGF165 (100ng/ml or 2.5nM) and observed in decrease in TER. TER was then increased 
with co-treatment with either bevacizumab or ranibizumab, with ranibizumab giving the 
greatest TER restoration, however to not as great an extent as I showed upon co-treatment 
with VEGF165b. Whilst there is the caveat of different cell lines (iBREC vs. RPE), 
different BRBs (inner vs. outer) and different assays (TER vs. TEER), this does support 
my hypothesis that the outer BRB is likely to be involved in DME.  
The literature concerning in vitro models of DME are in poor agreement. 
Experiments vary in length starting from 24 hours post glucose treatment (Pavan et al. 
2014) to days post glucose treatment (Chronopoulos et al. 2011), with varying notions of 
“low glucose” and “high glucose”. The majority of the literature suggests that 5mM 
glucose is sufficient to replicate normoglycaemia, whereas there is more disagreement 
surrounding what would truly represent hyperglycaemia, varying between 25mM glucose 
(Pavan et al. 2014; Qin et al. 2013) and 45mM glucose (Naggar et al. 2002) treatment. 
Based on these data I used 35mM glucose for 24 hours and showed novel data that acute 
high glucose treatment can indeed cause TJ loss and an increase in paracellular flux. 
Although I was unable to fully restore barrier properties using VEGF165b, this again 
supports my hypothesis that hyperglycaemia can induce outer BRB breakdown. I also 
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showed that there is increased VEGF expression in the conditioned media from these 
RPE, which is likely to be exacerbating PKC-mediated TJ loss. Published data has shown 
that 25mM glucose alone had no effect on different PKC isoform expression, however 
when co-treated with VEGF there was a significant increase in expression of different 
PKC isoforms, including atypical isoforms such as PKCζ (Young et al. 2005). This is of 
particular interest as I hypothesise that VEGF165b is acting to prevent hypoxia and 
hyperglycaemia induced TJ dysfunction either by preventing activation of atypical PKCs, 
such as PKCζ. Inhibition of PKCζ prevented glucose-induced VEGF secretion in RPE 
cells (Young et al. 2005). It is possible that 35mM glucose is sufficient to increase VEGF 
expression, PKC activation and subsequent TJ breakdown as opposed to the lack of 
change observed with 25mM glucose alone used by Young and colleagues (Young et al. 
2005).  
It is harder to distinguish between changes in inner and outer BRB in vivo 
particularly when assaying changes in permeability. Techniques such as the Evans’ blue 
dye perfusion technique limits how tissue can be used in ways other than measuring dye 
absorption. Xu and Le showed that by embedding eyes immediately after perfusion with 
FITC-dextran, it was possible to map out regions of dye leakage (Xu & Le 2011). They 
concluded that there was significant leakage from the RPE layer in models of diabetes, 
EIU and ischaemia-induced retinopathy relative to leakage from the inner BRB. Whilst I 
cannot definitively say that results from chapter 4 are indicative of outer BRB 
breakdown, results from Xu and Le’s paper support my hypothesis in that there is outer 
BRB involvement in vivo. Furthermore, they used FITC-dextran (10 kDa) whereas I used 
Evans’ blue (961 Da). Considering that Evans’ blue has a much lower MW than FITC-
dextran, its likely to leak from much smaller pores than FITC-dextran and is therefore 
more likely to give a better representation of BRB dysfunction. Therefore if significant 
dye leakage is shown from the RPE layer using FITC-dextran, the same is likely to be 
true of Evans’ blue.  
Many other groups have used the Evans’ blue dye perfusion technique to assay 
BRB dysfunction (Xu et al. 2001; Qaum et al. 2001; Abcouwer et al. 2010) however 
results from these experiments usually conclude in inner BRB dysfunction. Studies have 
shown that bevacizumab (Abcouwer et al. 2010) and atypical PKC inhibitors (Titchenell 
et al. 2012) reduce Evans’ blue leakage in the retina, however none to the same extent as I 
have shown using VEGF165b. Titchenell and colleagues targeted the inner BRB using 
atypical PKC inhibitors (Titchenell et al. 2012), however only saw a partial reduction in 
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Evans’ blue leakage. It has been shown that typical and atypical PKC isoforms are 
upregulated in hyperglycaemia (Young et al. 2005), and therefore targeting just one 
family may not be successful. As mentioned previously, VEGF165b could be acting as a 
VEGFR2 antagonist as well as a typical and atypical PKC inhibitor, thus preventing 
VEGF-induced TJ breakdown as shown by figure 6.1.  
Considering the RPE layer has TJs, like RECs, it is likely that in diabetic eyes 
both barriers will suffer similar levels of ischaemic insult. The RPE protects the rest of 
the inner retina from the choroidal circulation, which is greater than the retinal 
circulation. Disruption of the outer BRB may include choroidal vascular leakage into the 
retina, which could be more deleterious than leakage of the retinal circulation from the 
inner BRB. Therefore more research should be focused towards prevention of outer BRB 
and inner BRB dysfunction rather than just inner BRB dysfunction.  
6.2. Vascular remodelling and the outer BRB 
 
Although I have hypothesised that RPE / the outer BRB has a significantly greater 
involvement in DME than is acknowledged, I believe that the vascular remodelling I 
observed in vivo is a result of REC activation. However this does not mean that RPE are 
not involved. The RPE layer secretes VEGF (Saint-Geniez et al. 2009b), and it is possible 
that the RPE secretes even more VEGF in the hyperglycaemic eye, as shown in chapter 3 
in vitro, by many possible mechanisms induced by hypoxia (figure 6.1). As well outer 
BRB TJ breakdown, VEGF secreted by RPE could induce angiogenesis in neighbouring 
RECs that form microvessels, which may be in close proximity (figure 6.1). This may 
contribute to localised VEGFR2 activation and subsequent activation of DLL4, resulting 
in angiogenesis (figure 6.1). ARPE19s with a VEGF knock-down were co-cultured with 
normal RECs and showed that there was a reduction in REC proliferation relative to 
control groups (Ma et al. 2011). This indicates that VEGF secreted from the RPE layer 
may contribute to VEGF secreted by RECs and therefore may exacerbate the 
angiogenesis characteristic of PDR.  
AMD, another form of blindness induced by pathological angiogenesis and TJ 
breakdown, has been linked to loss of RPE function (Bird et al. 1995), it is possible that 
the same may be true of PDR and that the loss of RPE contributes to macular dysfunction 
and angiogenesis. VEGF165b has been shown to reduce CNV (Hua et al. 2010) and reduce 
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OIR-induced neovascularization (Magnussen et al. 2010) and now I have shown that it 
prevents STZ-induced vascular remodelling, likely due to preventing DLL4 activation 
and PKC activation, as well as other mechanisms shown by figure 6.1 and described 
previously. I am cautious to interpret VEGF165b preventing angiogenesis in the 8-weeks 
STZ model, as we have not proved that it is angiogenesis that was observed. However, as 
VEGF165b has prevented angiogenesis in many other models of retinopathy and CNV, it 
is likely that it is also anti-angiogenic in STZ-induced diabetic retinopathy. Until further 
studies are done, I cannot fully conclude that VEGF165b is anti-angiogenic in this 
particular model. I can however conclude that there was indeed vascular remodelling 
induced by the model that presented as increased vascular density and that VEGF165b 
successfully prevented this remodelling.  
Studies using small molecular inhibitors such as SRPIN340, an inhibitor of serine-
rich protein kinase 1 (SRPK1) a regulator of pro-angiogenic splicing, facilitates splicing 
in favour of anti-angiogenic isoforms of VEGF have shown a reduction in neovascular 
area in CNV when applied topically (M. V Gammons et al. 2013). Based on the data 
presented in this thesis, VEGF165b is a good candidate therapeutic, however its half-life is 
significantly shorter than the gold standard drugs. By promoting splicing in favour of 
VEGF165b, this small molecular inhibitor eye drop may be able to prevent or reduce the 
proliferative stage of PDR and may even prevent TJ breakdown, without the use of 
invasive intravitreal injections. Furthermore, SRPIN340 has also prevented the onset of 
peripheral neuropathy in the 8-week STZ rat model by promoting downregulation of pro-
angiogenic VEGF isoforms (Hulse et al. 2014b), illustrating that it could be a successful 
future area to investigate as a potential therapeutic for diabetic retinopathy.  
6.3. Eight weeks STZ-induced diabetes: a new model of diabetic retinopathy? 
 
 Throughout this thesis I have shown that 8 weeks STZ-induced diabetes with 
insulin supplementation presents some of the key features of diabetic retinopathy. I 
observed an increase in Evans’ blue leakage, indicative of increased vascular 
permeability. I also saw an increased vessel density, indicative of vascular remodelling 
and potential angiogenesis. Whilst this model may appear to recapitulate the vascular 
complications associated with DR, I cannot confirm neuronal complications with DR. 
Although I observed RGC shrinkage in this model, I did not see RGC loss. It is possible 
		 179	
that the shrinkage is preceding apoptosis and that insulin is eliciting an unwanted 
neuroprotective effect, which is why there was no RGC loss after two months. Barber and 
colleagues used the same model of diabetes and insulin supplementation and showed 
there was no difference in TUNEL staining between diabetes + insulin and control retinae 
(Barber et al. 1998). They also showed that diabetic rats without insulin supplementation 
showed increased TUNEL staining at month 1 relative to control and diabetes + insulin, 
and that these results were mirrored in human studies whereby patients on insulin had 
significantly less TUNEL staining relative to diabetic patients that were not insulin-
treated (Barber et al. 1998). Despite positive results shown in the absence of insulin 
supplementation I would not be able to repeat such an experiment as it would not be 
approved by most BSUs nor was it on the PPL.  
 Many other models of diabetic retinopathy are models of angiogenesis unrelated 
to diabetes such as OIR and CNV, however they present with clear neovascular areas. 
This thesis is one of the few studies that show vascular remodelling in response to 
hyperglycaemia in the retina. Again with further experiments such as confirmation of 
angiogenesis using Ki67 staining, this could potentially be a model for PDR. As most 
groups administer insulin ad hoc according to weight loss, usually many weeks after STZ 
has already been delivered, they may not see proliferation. Furthermore, most groups that 
use STZ do not use it as a model of PDR but rather a model of BRB breakdown and 
retinal neuronal dysfunction. As a result, potential changes in proliferation may be 
missed, as they are not being looked for, particularly when there are other models of 
vascular proliferation that may be faster and more definitive such as OIR.  
STZ has been used in models of DME extensively (Xu et al. 2001; A. J. Barber 
2003; Robinson et al. 2012b) and I have confirmed that it is a reproducible model at both 
1 and 8 weeks post induction of diabetes. As rats do not have a macula, we cannot mimic 
DME completely, however this does induce TJ loss and shows an increase in solute flux 
and therefore I believe it is as representative a model as possible. Perhaps future 
investigation into this model would involve regular FFA imaging on non-albino rats to 
monitor existence and progression of microaneurysms. This would then provide further 
confirmation that the model recapitulates DME.  
Unfortunately, I saw no difference in OCT thickness in diabetic Lewis rats 
indicating that either Lewis rats are not suitable for measuring changes in retinal 
thickness or that the changes in thickness are so small that they are not observed by OCT 
and thus unable to provide data on GCL thinning and thickening of the rest of the retina 
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from vessel leakage. A further study could involve repeating the 8-week STZ study and 
doing, for example, weekly OCT measurements in rats. OCT uses near-infra red light to 
penetrate the eye and if rats are injected with a dye with an near-infra red emission 
wavelength, such as Cy5, theoretically one could measure where there is dye leakage and 
compare within the different layers of the retina. This may result in a more definitive 
answer as to how involved the outer BRB is in the progression of DME.  
 
There are many caveats to the 8-week STZ-induced diabetes model of diabetic 
retinopathy, as previously described. However future studies into this model such as 
increasing the duration of diabetes to observe RGC loss and measuring visual dysfunction 
using ERG and perhaps a visual test such as the water maze test, would confirm loss of 
retinal neuronal function. Validation of the vascular changes would involve confirmation 
of angiogenesis using Ki67. Further, more long-term studies would involve measuring the 
progression of the disease by staining retinae for example every week and staining for: 
pericyte dropout using NG2, sprouting angiogenesis using a DLL4 antibody, a 
combination of IB4 and staining for collagen IV to measure area of non-perfusion. To 
confirm the permeability observed, further studies would involve FFA on pigmented rats 
to observe microaneurysms and staining of leaked red blood cells using a Ter119 
antibody.  
Although there are many necessary experiments needed to confirm that this is 
indeed a good model of DR, I have confidence in it as a successful model of DME. 
Considering the concurrent dysfunction I observed in the peripheral nervous system and 
the increased sensitivity to pain at this time point, it is evident that these rats were also 
experiencing peripheral diabetic neuropathy. As diabetic retinopathy and diabetic 
neuropathy in patients is often linked (Dyck et al. 1993; Dyck et al. 1999), we can infer 
that as the rats had neuropathy, any changes I observed in the eyes are likely to be a 
model of DR. Few other models present with neuropathy simultaneously with 
retinopathy, again further supporting that this may be a good model. Nevertheless, further 
tests are required to fully confirm this model as a reliable and reproducible model of DR.  
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6.4. Gene therapy and diabetic retinopathy 
 
 Anti-angiogenic gene therapy in the eye has been investigated by targeting many 
areas such as: endostatin (Balaggan et al. 2006), PEDF (Campochiaro et al. 2006), sFlt1 
(Bainbridge et al. 2002), erythropoietin (Xu et al. 2014) and many others, and have 
shown varying degrees of success. This was the first study that attempted RPE-targeted 
VEGF165b gene therapy to treat diabetic retinopathy and did not show a prevention of 
angiogenesis or increased neurone survival as I hypothesised. I observed a high level of 
inflammation in AAV.VEGF165b-injected eyes, which was unexpected. I am hesitant to 
believe that this is novel data. I believe that this is likely to have occurred to many other 
groups experimenting with similar constructs and their negative data has not been 
published.  
Vectors targeting sFlt1 appear to be the most successful anti-VEGF gene therapy 
in both targeting CNV (Bainbridge et al. 2002; Lai et al. 2009) and corneal 
neovascularisation (Dr. M. Basche, manuscript in preparation). A recent study in the 
brain shows that AAV.sFlt1 inhibits brain angiogenesis (Shen et al. 2015), however there 
have been few recent published studies on the use of AAV.sFlt1 in the eye.  
It is unfortunate that my endeavour with gene therapy was unsuccessful, however 
it did reveal potential pitfalls and areas that should be revisited for further studies, as 
mentioned previously, such as more rigorous endotoxin testing especially when working 
with upregulating cytokines. Also more dose-adjustment studies of AAV.VEGF165b are 
required if this study is to repeated again in future.  
6.5. Summary 
  
 Anti-angiogenic gene therapy to treat diabetic retinopathy has been the most 
successful form of treatment over the last decade. This thesis has shown that rhVEGF165b, 
when injected as a recombinant protein, is a suitable candidate for further drug 
development as it prevents vascular dysfunction in two the ways relevant to sufferers of 
DR: prevention of TJ breakdown and prevention of vascular remodelling. As an 
injectable recombinant protein, it falls short relative to aflibercept, bevacizumab and 
ranibizumab when comparing half-life and frequency of injection. VEGF165b would need 
to be injected far more frequently than the current gold standard drugs, and therefore is 
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not a suitable alternative. Despite this, I still believe that VEGF165b is a suitable candidate 
to be further investigated in treating DR as it aims to upregulate already existing isoforms 
as opposed to targeting whole genes and it appears to also be neuroprotective in the eye.  
 This thesis has also demonstrated that the outer BRB may have a greater 
involvement in diabetic retinopathy than is acknowledged. Although RPE seem to react to 
VEGF165 and glucose in vitro similarly to RECs, further studies are required to confirm 
my hypothesis of their greater involvement. Nevertheless, I believe that the RPE layer 
should be considered as a new target for future therapeutic intervention in treating 
diabetic retinopathy. 
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Appendix 1. Evans’ blue calculations 
 
a) Evans blue (EB) absorbance in wet weight (µg/g):  
 𝐸𝐵	𝑐𝑜𝑛𝑐	 𝜇𝑔𝑚𝑙 𝑋	𝑓𝑜𝑟𝑚𝑖𝑚𝑖𝑑𝑒	𝑣𝑜𝑙	(𝑚𝑙)𝑅𝑒𝑡𝑖𝑛𝑎	𝑤𝑒𝑡	𝑤𝑒𝑖𝑔ℎ𝑡	(𝑔)  
 
EB absorbance in dry weight (µg/g): same as (a), substituting wet weight for dry weight 
 
b) EB accumulation in tissue fluid (µg/ml):  𝐸𝐵	𝑐𝑜𝑛𝑐	 𝜇𝑔𝑚𝑙 𝑥	𝑓𝑜𝑟𝑚𝑎𝑚𝑖𝑑𝑒	𝑣𝑜𝑙(𝑚𝑙)𝑅𝑒𝑡𝑖𝑛𝑎	𝑤𝑒𝑡	𝑤𝑒𝑖𝑔ℎ𝑡	 𝑔 − 𝑑𝑟𝑦	𝑤𝑒𝑖𝑔ℎ𝑡	(𝑔) 
 
c) EB wet weight solute flux (µg/min/g): 𝐸𝐵	𝑤𝑒𝑡	𝑤𝑒𝑖𝑔ℎ𝑡	𝑎𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒	(𝜇𝑔𝑔 )𝑇𝑖𝑚𝑒	(min)  
 
d) EB dry weight permeability-surface area product (ml/min/g):  
𝐸𝐵	𝑑𝑟𝑦	𝑤𝑒𝑖𝑔ℎ𝑡	𝑠𝑜𝑙𝑢𝑡𝑒	𝑓𝑙𝑢𝑥	( 𝜇𝑔𝑚𝑖𝑛𝑔 )𝑇𝑖𝑚𝑒	𝑎𝑣𝑒𝑟𝑎𝑔𝑒𝑑	𝑃𝑙𝑎𝑠𝑚𝑎	𝐸𝐵	𝑐𝑜𝑛𝑐	 𝜇𝑔𝑚𝑙 𝑥	𝑡𝑜𝑡𝑎𝑙	𝑡𝑖𝑚𝑒	(ℎ𝑟) 
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Appendix 2. Plasmid Maps 
  
All plasmid maps were generated using Serial Cloner - 5 freeware.  
 
 Humanised Renilla reniformis GFP (hrGFP) plasmid under the CMV promoter. 
Used to generate all AAVs named “AAV.GFP” with AAV2/2 ITRs. 
 
 
Figure. 7.1. pd10.CMV.hrGFP plasmid map. 
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 Human VEGF165b gene under the CMV promoter. Used to generate all AAVs 
named “AAV.VEGF165b” with AAV2/2 ITRs. 
 
Figure. 7.2. pd10.CMV.VEGF165b plasmid map 
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Plasmid is a modified version of the pd10.RK.RPGR plasmid, but with no 
promoter. The RPGR gene is truncated and has no start codon. The AAV genomic 
construct is based on AAV2/2 ITRs. This plasmid generated all AAVs named 
“AAV.Null”.  
 
 
Figure. 7.3. pd10.Null plasmid map 
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Appendix 3. Plasmid and virus validation 
 
 7.3.1.AAV.VEGF165b 
 
 
 
 
 
Figure. 7.4. Verification and validation of AAV.VEGF165b 
VEGF165b plasmids (A) were first verified by plasmid digest (B). Following virus 
purification, the virus was validated by Sypro ruby SDS-PAGE (C) to assess the capsid 
(expected bands at 80, 65 and 59 kDa. Viruses were quantified using “dot blot” 
hybridisation, assaying against the CMV promoter.  
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 7.3.2. AAV.Null 
 
Figure. 7.5. Production and validation of AAV.Null 
The RKRPGR plasmid (A) underwent promoter excision, as described in chapter 2: 
“Materials and Methods”.  Plasmids were then verified using the BamH1 endonuclease 
(B). Upon satisfactory results, HEK293Ts were transfected with an RK-RPGR plasmid, 
Null vector plasmid, VEGF165b plasmid and a GFP plasmid and were assayed to quantify 
the absolute expression of RK RPGR of each plasmid. The Null vector showed an almost 
negligible expression of RK RPGR relative to RK RPGR transfected wells, indicating 
that the Null vector is no longer causing expression of RK RPGR. That same plasmid was 
used to produce AAV.Null, which underwent the Sypro ruby capsid verification (D). 
Following validation, viruses were quantified using a custom-made biotinylated HindIII 
probe (E).  
Un
tra
ns
fec
ted
RK
-R
PG
R
Nu
ll V
ec
tor
VE
GF
16
5b GF
P
0
500
1000
2500
3000
3500
4000
4500
5000
C
op
y 
nu
m
be
r /
 µ
g 
of
 c
D
N
A
BamH1 
4321 
3079 
M
W
M
 
 N
ul
l V
ec
to
r 
 U
nd
ig
es
te
d 
RK 
RPGR ORF Poly A 
Amp R 
RPGR ORF Poly A 
Amp R 
pD10 RK RPGR 
7913 nt 
“Null Vector” 
7390 nt 
Sp
e1
 
Hi
nd
III
 
Sypro Ruby 
5µl      1µl      
VP1 80 kDa 
VP2 65 kDa 
 
VP3 59 kDa 
 
 
AAV.Null 1012    1011   1010  109 
5µl        
1µl     
Biotinylated HindIII A
AV
.N
ul
l 
(A) 
(B) (C) 
(D) (E) 
		 226	
7.3.3.AAV.hrGFP 
 
Figure. 7.6. Production of AAV.hrGFP 
The GFP plasmid was verified by plasmid digest (A) and transfection of HEK293t cells 
(B). Cells were transfected for two days and imaged under bright field and under the 488 
channel. Plasmids were deemed satisfactory of a high population of cells were green. 
Following virus purification, capsid integrity (C) and viral copy number (D) was assayed 
using the Sypro ruby assay and the dot blot hybridisation assay respectively.  
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Appendix 4. Optimisation of vector volume using AAV.hrGFP.  
 
To assess the correct volume of vector to inject in Lewis rats, 3 volumes were 
tested for optimum transduction: 2 x 4µl (8µl), 2 x 5µl (10µl) and 2 x 6µl injections 
(12µl). Lewis rats (n=2 per group) were injected subretinally with AAV.hrGFP (1 x 1012 
vp/ml), for further details refer to chapter 2 “Materials and Methods”. Two weeks post 
injection, eyes were imaged using an HRA2 Spectralis (Heidelberg Engineering) and 
infrared and SLO images were taken to assess eye health and fluorescence respectively. 
Eyes injected with 2 x 4µl AAV.hrGFP showed poor transduction and eyes injected with 
2 x 6 µl AAV.hrGFP also showed poor transduction as well as retinal atrophy. Injections 
of 2 x 5µl AAV.hrGFP showed little retinal atrophy in infrared images and showed the 
best transduction out of all the volumes assayed, and was therefore the chosen volume for 
all vector dosing in rats.  
 
Figure. 7.7. Lewis rats injected with 12µl AAV.hrGFP show the greatest GFP expression 
and the lowest retinal atrophy. 
Lewis rats (n=6) were injected with either 2 x 4µl, 2 x 5µl or 2 x 6µl AAV.hrGFP 
subretinally (1 x 1012 vp/ml) and were imaged for retinal atrophy and GFP transduction 
using infrared and SLO imaging. Those injected with 2 x 4µl and 2 x 6µl showed poor 
GFP expression and retinal atrophy, therefore 2 x 5µl was chosen as the optimum volume 
for vector administration in rats.        
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